US20150259327A1 - Chemical Compounds - Google Patents

Chemical Compounds Download PDF

Info

Publication number
US20150259327A1
US20150259327A1 US14/722,275 US201514722275A US2015259327A1 US 20150259327 A1 US20150259327 A1 US 20150259327A1 US 201514722275 A US201514722275 A US 201514722275A US 2015259327 A1 US2015259327 A1 US 2015259327A1
Authority
US
United States
Prior art keywords
cyano
benzenesulfonamide
fluoropyridin
chloro
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/722,275
Inventor
Robert Ian Storer
Nigel Alan Swain
Robert McKenzie Owen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Priority to US14/722,275 priority Critical patent/US20150259327A1/en
Publication of US20150259327A1 publication Critical patent/US20150259327A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C07D241/22—Benzenesulfonamido pyrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes.
  • Uric acid is the final product of purine metabolism in humans. In humans, unlike many other animals, uric acid is not further broken down, but is predominantly (70%) excreted into the urine with the remaining 30% excreted in faeces. Hyperuricemia is defined as an excessive production or decreased excretion of uric acid and can occur as an overproduction or under excretion of serum uric acid (sUA), or a combination of the both. Renal under excretion of uric acid is the primary cause of hyperuricemia in about 90% of cases, while overproduction is the cause in less than 10%.
  • Increased sUA concentration above 6.8 mg/dL results in crystallisation of uric acid in the form of salts, such as monosodium urate, and to precipitation of these crystals in joints, on tendons and in the surrounding tissues. These crystals (known as tophi) trigger a local immune-mediated inflammatory reaction, leading to gout. The risk of gout increases with increased sUA levels.
  • salts such as monosodium urate
  • Gout is a painful condition that can present in a number of ways, although the most usual is a recurrent attack of acute inflammatory arthritis (a red, tender, hot, swollen joint) often occurring in big toes, heels, knees, wrists and fingers.
  • acute inflammatory arthritis a red, tender, hot, swollen joint
  • Gout is treated by agents to both decrease the cause and effects of uric acid crystal inflammation and pain.
  • the pain associated with gout is commonly treated with pain and anti-inflammatory drugs such as nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine and steroids.
  • Agents that decrease sUA levels may be used to treat the cause of gout. These include agents that: inhibit the enzymes that result in uric acid production, such as xanthine oxidase inhibitors (e.g. allopurinol, febuxostat or tisopurine), or purine nucleoside phosphorylase (PNP) inhibitors (e.g. ulodesine); metabolise uric acid, such as urate oxidases—also known as uricases (e.g.
  • xanthine oxidase inhibitors e.g. allopurinol, febuxostat or tisopurine
  • PNP purine nucleoside phosphorylase
  • metabolise uric acid such as urate oxidases—also known as
  • Uricosurics include agents that inhibit the transporters responsible for renal reabsorption of uric acid back into the blood, such as benziodarone, isobromindione, probenecid and sulphinpyrazone, and URAT-1 inhibitors (e.g. benzbromarone).
  • URAT-1 is also known as solute carrier family 22 (organic anion/cation transporter), member 12, and is encoded by the gene SLC22A12. Human genetic analysis has demonstrated that polymorphisms in the SLC22A12 gene are directly associated with changes in serum uric acid. Inhibitors of uric acid transport, such as URAT-1, are therefore effective in the treatment of gout.
  • URAT-1 inhibitors for the treatment of gout are known.
  • WO2011/159840 discloses phenylthioacetate URAT-1 inhibitors.
  • WO2008/118758, WO2009/012242, WO2010/079443, WO2012/004706, WO2012/004714 and WO2012/004743 disclose sulphonamides.
  • preferred compounds should have one or more of the following properties: be well absorbed from the gastrointestinal tract; be metabolically stable; have a good metabolic profile, in particular with respect to the toxicity or allergenicity of any metabolites formed; or possess favourable pharmacokinetic properties whilst still retaining their activity profile as URAT-1 inhibitors. They should be non-toxic and demonstrate few side-effects. Ideal drug candidates should exist in a physical form that is stable, non-hygroscopic and easily formulated.
  • R 1 is a ‘C-linked’ 6-membered heteroaryl containing one, two or three nitrogen atoms wherein said heteroaryl is optionally substituted by one, two or three, valency permitting, X 1 ;
  • each X 1 is independently selected from: F; Cl; CN; (C 1 -C 4 )alkyl optionally substituted by one, two or three F; and (C 1 -C 4 )alkyloxy optionally substituted by one two or three F;
  • R 2 , R 3 and R 5 are independently selected from: H; halogen; CN; (C 1 -C 4 )alkyl optionally substituted by one, two or three F; and (C 1 -C 4 )alkyloxy optionally substituted by one, two or three F;
  • R 4 is selected from: halogen; CN; (C 1 -C 4 )alkyl optionally substituted by one, two or three F; and (C 1 -C 4 )alkyloxy optionally substituted by one, two or three F;
  • R 6 is phenyl substituted by one, two or three X 2 ; or a ‘C-linked’ 6-membered heteroaryl containing one or two nitrogen atoms wherein said
  • R 1 is a ‘C-linked’ 6-membered heteroaryl containing one, two or three nitrogen atoms wherein said heteroaryl is optionally substituted by one, two or, valency permitting, three X 1 ; each X 1 is independently selected from: F; Cl; CN; (C 1 -C 4 )alkyl optionally substituted by one, two or three F; and (C 1 -C 4 )alkyloxy optionally substituted by one two or three F; one of R 2 , R 3 , R 4 and R 5 is either halogen or CN, and the remainder thereof are independently selected from: H; halogen; or CN; R 6 is phenyl substituted by one, two or three X 2 ; or a ‘C-linked’ 6-membered heteroaryl containing one or two nitrogen atoms wherein said heteroaryl is optionally substituted by one, two or three X 2 ; each X 2 is independently selected from: F; Cl;
  • Alkyl and alkoxy groups containing the requisite number of carbon atoms, can be unbranched or branched.
  • alkyl include methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl and t-butyl.
  • alkoxy include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, i-butoxy, sec-butoxy and t-butoxy.
  • cycloalkyl examples include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
  • Halo means fluoro, chloro, bromo or iodo.
  • C-linked used in the definitions of formula (I) means that the group in question is joined via a ring carbon.
  • C-linked 6-membered heteroaryl containing one, two or three nitrogen atoms include pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl.
  • references to compounds of the invention include compounds of formula (I) or pharmaceutically acceptable salts, solvates, or multi-component complexes thereof, or pharmaceutically acceptable solvates or multi-component complexes of pharmaceutically acceptable salts of compounds of formula (I), as discussed in more detail below.
  • Preferred compounds of the invention are compounds of formula (I) or pharmaceutically acceptable salts thereof.
  • Suitable acid addition salts are formed from acids which form non-toxic salts. Examples include the acetate, adipate, aspartate, benzoate, besylate, bicarbonate/carbonate, bisulphate/sulphate, borate, camsylate, citrate, cyclamate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hibenzate, hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate, maleate, malonate, mesylate, methylsulphate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, pyroglutamate, saccharate, ste
  • Suitable base salts are formed from bases which form non-toxic salts. Examples include the aluminium, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine and zinc salts.
  • Hemisalts of acids and bases may also be formed, for example, hemisulphate and hemicalcium salts.
  • salts include ones wherein the counterion is optically active, for example d-lactate or 1-lysine, or racemic, for example dl-tartrate or dl-arginine.
  • compositions of formula (I) may be prepared by one or more of three methods:
  • the resulting salt may precipitate out and be collected by filtration or may be recovered by evaporation of the solvent.
  • the degree of ionisation in the resulting salt may vary from completely ionised to almost non-ionised.
  • the compounds of formula (I) or pharmaceutically acceptable salts thereof may exist in both unsolvated and solvated forms.
  • solvate is used herein to describe a molecular complex comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable solvent molecules, for example, ethanol.
  • solvent molecules for example, ethanol.
  • hydrate is employed when said solvent is water.
  • Pharmaceutically acceptable solvates in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, e.g. D 2 O, d 6 -acetone and d 6 -DMSO.
  • Isolated site hydrates are ones in which the water molecules are isolated from direct contact with each other by intervening organic molecules.
  • channel hydrates the water molecules lie in lattice channels where they are next to other water molecules.
  • metal-ion coordinated hydrates the water molecules are bonded to the metal ion.
  • the complex When the solvent or water is tightly bound, the complex will have a well-defined stoichiometry independent of humidity. When, however, the solvent or water is weakly bound, as in channel solvates and hygroscopic compounds, the water/solvent content will be dependent on humidity and drying conditions. In such cases, non-stoichiometry will be the norm.
  • the compounds of the invention may exist in a continuum of solid states ranging from fully amorphous to fully crystalline.
  • amorphous refers to a state in which the material lacks long range order at the molecular level and, depending upon temperature, may exhibit the physical properties of a solid or a liquid. Typically such materials do not give distinctive X-ray diffraction patterns and, while exhibiting the properties of a solid, are more formally described as a liquid.
  • a change from solid to liquid properties occurs which is characterised by a change of state, typically second order (‘glass transition’).
  • crystalline refers to a solid phase in which the material has a regular ordered internal structure at the molecular level and gives a distinctive X-ray diffraction pattern with defined peaks. Such materials when heated sufficiently will also exhibit the properties of a liquid, but the change from solid to liquid is characterised by a phase change, typically first order (Melting point′).
  • multi-component complexes other than salts and solvates of compounds of formula (I) or pharmaceutically acceptable salts thereof wherein the drug and at least one other component are present in stoichiometric or non-stoichiometric amounts.
  • Complexes of this type include clathrates (drug-host inclusion complexes) and co-crystals. The latter are typically defined as crystalline complexes of neutral molecular constituents which are bound together through non-covalent interactions, but could also be a complex of a neutral molecule with a salt.
  • Co-crystals may be prepared by melt crystallisation, by recrystallisation from solvents, or by physically grinding the components together—see Chem Commun, 17, 1889-1896, by 0. Almarsson and M. J. Zaworotko (2004), incorporated herein by reference.
  • Chem Commun 17, 1889-1896
  • M. J. Zaworotko For a general review of multi-component complexes, see J Pharm Sci, 64 (8), 1269-1288, by Haleblian (August 1975), incorporated herein by reference.
  • the compounds of the invention may also exist in a mesomorphic state (mesophase or liquid crystal) when subjected to suitable conditions.
  • the mesomorphic state is intermediate between the true crystalline state and the true liquid state (either melt or solution).
  • Mesomorphism arising as the result of a change in temperature is described as ‘thermotropic’ and that resulting from the addition of a second component, such as water or another solvent, is described as lyotropic′.
  • the compounds of the invention may be administered as prodrugs.
  • prodrugs certain derivatives of compounds of formula (I) which may have little or no pharmacological activity themselves can, when administered into or onto the body, be converted into compounds of formula (I) having the desired activity, for example, by hydrolytic cleavage.
  • prodrugs Further information on the use of prodrugs may be found in ‘Pro-drugs as Novel Delivery Systems, Vol. 14, ACS Symposium Series (T Higuchi and W Stella) and ‘Bioreversible Carriers in Drug Design’, Pergamon Press, 1987 (ed. E B Roche, American Pharmaceutical Association).
  • Prodrugs can, for example, be produced by replacing appropriate functionalities present in a compound of formula (I) with certain moieties known to those skilled in the art as ‘pro-moieties’ as described, for example, in “Design of Prodrugs” by H Bundgaard (Elsevier, 1985).
  • prodrugs examples include phosphate prodrugs, such as dihydrogen or dialkyl (e.g. di-tert-butyl) phosphate prodrugs. Further examples of replacement groups in accordance with the foregoing examples and examples of other prodrug types may be found in the aforementioned references.
  • metabolites of compounds of formula (I) that is, compounds formed in vivo upon administration of the drug.
  • Some examples of metabolites in accordance with the invention include, where the compound of formula (I) contains a phenyl (Ph) moiety, a phenol derivative thereof (-Ph>-PhOH);
  • Compounds of the invention containing one or more asymmetric carbon atoms can exist as two or more stereoisomers. Included within the scope of the invention are all stereoisomers of the compounds of the invention and mixtures of one or more thereof.
  • the racemate (or a racemic precursor) may be reacted with a suitable optically active compound, for example, an alcohol, or, in the case where the compound of formula (I) contains an acidic or basic moiety, a base or acid such as 1-phenylethylamine or tartaric acid.
  • a suitable optically active compound for example, an alcohol, or, in the case where the compound of formula (I) contains an acidic or basic moiety, a base or acid such as 1-phenylethylamine or tartaric acid.
  • the resulting diastereomeric mixture may be separated by chromatography and/or fractional crystallization and one or both of the diastereoisomers converted to the corresponding pure enantiomer(s) by means well known to a skilled person.
  • Chiral compounds of the invention may be obtained in enantiomerically-enriched form using chromatography, typically HPLC, on an asymmetric resin with a mobile phase consisting of a hydrocarbon, typically heptane or hexane, containing from 0 to 50% by volume of isopropanol, typically from 2% to 20%, and from 0 to 5% by volume of an alkylamine, typically 0.1% diethylamine. Concentration of the eluate affords the enriched mixture.
  • chromatography typically HPLC
  • a mobile phase consisting of a hydrocarbon, typically heptane or hexane, containing from 0 to 50% by volume of isopropanol, typically from 2% to 20%, and from 0 to 5% by volume of an alkylamine, typically 0.1% diethylamine.
  • stereoisomers may be separated by conventional techniques known to those skilled in the art; see, for example, “Stereochemistry of Organic Compounds” by E. L. Eliel and S. H. Wilen (Wiley, New York, 1994.
  • the scope of the invention includes all crystal forms of the compounds of the invention, including racemates and racemic mixtures (conglomerates) thereof. Stereoisomeric conglomerates may also be separated by the conventional techniques described herein just above.
  • the scope of the invention includes all pharmaceutically acceptable isotopically-labelled compounds of the invention wherein one or more atoms are replaced by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number which predominates in nature.
  • isotopes suitable for inclusion in the compounds of the invention include isotopes of hydrogen, such as 2 H and 3 H, carbon, such as 11 C, 13 C and 14 C, chlorine, such as 36 Cl, fluorine, such as 18 F, iodine, such as 123 1 and 125 1, nitrogen, such as 13 N and 15 N, oxygen, such as 15 O, 17 O and 18 O, phosphorus, such as 32 P, and sulphur, such as 35 S.
  • Certain isotopically-labelled compounds of the invention are useful in drug and/or substrate tissue distribution studies.
  • the radioactive isotopes tritium, i.e. 3 H, and carbon-14, i.e. 14 C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.
  • Substitution with heavier isotopes such as deuterium, i.e. 2 H may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances.
  • Substitution with positron emitting isotopes, such as 11 C, 18 F, 15 O and 13 N can be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy.
  • PET Positron Emission Topography
  • Isotopically-labeled compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed.
  • intermediate compounds as hereinafter defined, all salts, solvates and complexes thereof and all solvates and complexes of salts thereof as defined hereinbefore for compounds of formula (I).
  • the invention includes all polymorphs of the aforementioned species and crystal habits thereof.
  • FIG. 1A represents a schematic showing organization of the URAT1(L)GFP construct (N to C terminal direction).
  • FIG. 1B represents a sequence alignment of the codon optimized URAT1(L)GFP construct with the wild type human URAT1 sequence deposited as NM — 144585.
  • Alignment row 1 is the sequence from accession NM — 144585.
  • Alignment row 2 is the sequence of the construct in the Gateway destination vector pLenti6.3V5/DEST (encoding URAT1(L)GFP) with the nucleotide alignment indicated with NM — 144585 above and the nucleotide numbering below.
  • Alignment row 3 is the amino acid translation with sequence annotation indicated in italics below.
  • the compounds of the invention may be prepared by any method known in the art for the preparation of compounds of analogous structure.
  • the compounds of the invention can be prepared by the procedures described by reference to the Schemes that follow, or by the specific methods described in the Examples, or by similar processes to either.
  • the skilled person will appreciate that it may be necessary or desirable at any stage in the synthesis of compounds of the invention to protect one or more sensitive groups, so as to prevent undesirable side reactions.
  • it may be necessary or desirable to protect amino or carboxylic acid groups.
  • the protecting groups used in the preparation of the compounds of the invention may be used in conventional manner. See, for example, those described in ‘Greene's Protective Groups in Organic Synthesis’ by Theodora W Greene and Peter G M Wuts, fourth edition, (John Wiley and Sons, 2006), in particular chapters 7 (“Protection for the Amino Group”) and 5 (“Protection for the Carboxyl Group”), incorporated herein by reference, which also describes methods for the removal of such groups.
  • R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as previously defined for a compound of formula (I) unless otherwise stated.
  • PG is a suitable amino protecting group, such as methoxymethyl or dimethoxybenzyl.
  • Hal is a suitable halogen, such as F or Cl. Where ratios of solvents are given, the ratios are by volume.
  • compounds of formula (I) may be prepared from compounds of formula (II) and (III), as illustrated by Scheme 1.
  • Compounds of formula (I) may be prepared from compounds of formula (II) according to reaction step (ii) by nucleophilic aromatic substitution reaction with compounds of formula (IV) under basic reaction conditions.
  • Convenient conditions are potassium carbonate in DMF or DMSO; cesium carbonate in DMSO; or potassium phosphate in DMSO; and at from room temperature to elevated temperature.
  • Typical conditions comprise potassium carbonate in DMSO at 80-100° C. for 18 hours.
  • Compounds of formula (II) may be prepared from compounds of formula (III) according to reaction step (i) by displacement of a sulfonyl chloride with compounds of formula (V) under basic reaction conditions.
  • Convenient conditions are pyridine in DCM; 1,4-diazabicyclo[2.2.2]octane in acetonitrile; N-methylmorpholine in THF; or an excess of compound of formula (V).
  • Preferred conditions comprise pyridine in DCM at room temperature.
  • compounds of formula (I) may be prepared from compounds of formulae (II) and (VIII), as illustrated by Scheme 2.
  • Compounds of formula (I) may be prepared from compound of formula (VI) according to process step (ii) according to the conditions described in Scheme 1 step (ii), followed by deprotection step (iii), typically mediated by an inorganic or organic acid.
  • Preferred conditions comprise potassium carbonate in DMSO at room temperature, followed by trifluoroacetic acid in DCM or HCl in 1,4-dioxane. It is also possible that deprotection step (iii) may occur under the conditions for effecting the nucleophilic aromatic substitution of step (ii).
  • Compounds of formula (VI) may be prepared from compounds of formula (II) according to process step (iv) by introduction of a suitable protecting group, such as methoxymethyl or dimethoxybenzyl, under basic reaction conditions or Mitsunobu reaction conditions.
  • a suitable protecting group such as methoxymethyl or dimethoxybenzyl
  • Typical conditions comprise diisopropylethylamine in DCM with chloromethoxymethane.
  • compounds of formula (VI) may be prepared from compounds of formula (III) according to process step (i) according to the conditions described in Scheme 1 step (i), or by using sodium or lithium hexamethyldisilazane in THF at from ⁇ 78° C. to room temperature.
  • Compounds of formula (VII) may be prepared from compounds of formula (VIII) according to reaction step (v) by a nucleophilic aromatic substitution reaction with compounds of formula (IX) under basic reaction conditions.
  • Preferred conditions comprise diisopropylethylamine in n-butanol at 100° C. or potassium carbonate in DMSO at 110° C.
  • compounds of formula (I) may be prepared from compounds of formula (XIII) as illustrated by Scheme 3.
  • Compounds of formula (X) may be prepared from compounds of formula (XI) according to process step (vii), an oxidation reaction in the presence of trichloroisocyanuric acid.
  • Preferred conditions comprise trichloroisocyanuric acid with benzyltrimethylammonium chloride and sodium carbonate in acetonitrile and water.
  • Compounds of formula (XII) may be prepared from compounds of formula (XIII) according to process step (vi), a cross-coupling reaction with benzylmercaptan in the presence of a suitable catalyst.
  • the catalyst is a palladium catalyst.
  • Preferred conditions comprise diisopropylethyamine with [1,1-bis(di-tert-butylphosphino)]ferrocene palladium (II) in toluene at 60° C.
  • a compound of formula (I) wherein R 2 , R 3 , R 4 or R 5 is CI, Br or I may be converted into the corresponding compound of formula (I) wherein the group in question is H, by dehalogenation in the presence of a suitable catalyst.
  • Typical conditions comprise zinc dust in acetic acid at room temperature, or triethylsilane with tetrakis(triphenylphosphine)palladium(0) in THF at reflux.
  • a compound of formula (I) wherein R 6 is 2- or 4-halo substituted ‘C-linked’ 6-membered heteroaryl containing one or two nitrogen atoms may be converted into the corresponding compound of formula (I) substituted by —NR 7 R 8 , by reaction with an appropriate amine.
  • halo is fluoro
  • typical conditions comprise heating the compound of formula (I) and the amine of formula HNR 7 R 8 in a solvent such as DMSO, in the presence of an inorganic base such as potassium carbonate, to a temperature of between 50-70° C.
  • R 7 and R 8 are both H, it may be necessary or desirable to employ an amino protecting group, such as dimethoxybenzyl, to introduce a protected amine; the protecting group is then removed under conventional conditions, such as in the presence of an organic acid.
  • Preferred conditions comprise dimethoxybenzylamine with potassium carbonate in THF at 70° C., followed by stirring in TFA at room temperature.
  • Compounds of the invention intended for pharmaceutical use may be administered as crystalline or amorphous products or may exist in a continuum of solid states ranging from fully amorphous to fully crystalline. They may be obtained, for example, as solid plugs, powders, or films by methods such as precipitation, crystallization, freeze drying, spray drying, or evaporative drying. Microwave or radio frequency drying may be used for this purpose.
  • excipient is used herein to describe any ingredient other than the compound(s) of the invention. The choice of excipient will to a large extent depend on factors such as the particular mode of administration, the effect of the excipient on solubility and stability, and the nature of the dosage form.
  • the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of the invention together with one or more pharmaceutically acceptable excipients.
  • compositions suitable for the delivery of compounds of the present invention and methods for their preparation will be readily apparent to those skilled in the art. Such compositions and methods for their preparation may be found, for example, in “Remington's Pharmaceutical Sciences”, 19th Edition (Mack Publishing Company, 1995).
  • Suitable modes of administration include oral, parenteral, topical, inhaled/intranasal, rectal/intravaginal, and ocular/aural administration.
  • Formulations suitable for the aforementioned modes of administration may be formulated to be immediate and/or modified release.
  • Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
  • the compounds of the invention may be administered orally.
  • Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, or buccal or sublingual administration may be employed by which the compound enters the blood stream directly from the mouth.
  • Formulations suitable for oral administration include solid formulations such as tablets, capsules containing particulates, liquids, or powders, lozenges (including liquid-filled), chews, multi- and nano-particulates, gels, solid solution, liposome, films, ovules, sprays, liquid formulations and buccal/mucoadhesive patches.
  • Liquid formulations include suspensions, solutions, syrups and elixirs. Such formulations may be employed as fillers in soft or hard capsules and typically comprise a carrier, for example, water, ethanol, polyethylene glycol, propylene glycol, methylcellulose, or a suitable oil, and one or more emulsifying agents and/or suspending agents. Liquid formulations may also be prepared by the reconstitution of a solid, for example, from a sachet.
  • the compounds of the invention may also be used in fast-dissolving, fast-disintegrating dosage forms such as those described in Expert Opinion in Therapeutic Patents, 11 (6), 981-986, by Liang and Chen (2001).
  • the drug may make up from 1 weight % to 80 weight % of the dosage form, more typically from 5 weight % to 60 weight % of the dosage form.
  • tablets generally contain a disintegrant.
  • disintegrants include sodium starch glycolate, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, croscarmellose sodium, crospovidone, polyvinylpyrrolidone, methyl cellulose, microcrystalline cellulose, lower alkyl-substituted hydroxypropyl cellulose, starch, pregelatinised starch and sodium alginate.
  • the disintegrant will comprise from 1 weight % to 25 weight %, preferably from 5 weight % to 20 weight % of the dosage form.
  • Binders are generally used to impart cohesive qualities to a tablet formulation. Suitable binders include microcrystalline cellulose, gelatin, sugars, polyethylene glycol, natural and synthetic gums, polyvinylpyrrolidone, pregelatinised starch, hydroxypropyl cellulose and hydroxypropyl methylcellulose. Tablets may also contain diluents, such as lactose (monohydrate, spray-dried monohydrate, anhydrous and the like), mannitol, xylitol, dextrose, sucrose, sorbitol, microcrystalline cellulose, starch and dibasic calcium phosphate dihydrate.
  • lactose monohydrate, spray-dried monohydrate, anhydrous and the like
  • mannitol xylitol
  • dextrose sucrose
  • sorbitol microcrystalline cellulose
  • starch dibasic calcium phosphate dihydrate
  • Tablets may also optionally comprise surface active agents, such as sodium lauryl sulfate and polysorbate 80, and glidants such as silicon dioxide and talc.
  • surface active agents such as sodium lauryl sulfate and polysorbate 80
  • glidants such as silicon dioxide and talc.
  • surface active agents may comprise from 0.2 weight % to 5 weight % of the tablet, and glidants may comprise from 0.2 weight % to 1 weight % of the tablet.
  • Tablets also generally contain lubricants such as magnesium stearate, calcium stearate, zinc stearate, sodium stearyl fumarate, and mixtures of magnesium stearate with sodium lauryl sulphate.
  • Lubricants generally comprise from 0.25 weight % to 10 weight %, preferably from 0.5 weight % to 3 weight % of the tablet.
  • Other possible ingredients include anti-oxidants, colourants, flavouring agents, preservatives and taste-masking agents.
  • Exemplary tablets contain up to about 80% drug, from about 10 weight % to about 90 weight % binder, from about 0 weight % to about 85 weight % diluent, from about 2 weight % to about 10 weight % disintegrant, and from about 0.25 weight % to about 10 weight % lubricant.
  • Tablet blends may be compressed directly or by roller to form tablets. Tablet blends or portions of blends may alternatively be wet-, dry-, or melt-granulated, melt congealed, or extruded before tabletting.
  • the final formulation may comprise one or more layers and may be coated or uncoated; it may even be encapsulated. The formulation of tablets is discussed in “Pharmaceutical Dosage Forms: Tablets”, Vol. 1, by H. Lieberman and L. Lachman (Marcel Dekker, New York, 1980).
  • Suitable modified release formulations for the purposes of the invention are described in U.S. Pat. No. 6,106,864. Details of other suitable release technologies such as high energy dispersions and osmotic and coated particles are to be found in “Pharmaceutical Technology On-line”, 25(2), 1-14, by Verma et al (2001). The use of chewing gum to achieve controlled release is described in WO 00/35298.
  • the compounds of the invention may also be administered directly into the blood stream, into muscle, or into an internal organ.
  • Suitable means for parenteral administration include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular and subcutaneous.
  • Suitable devices for parenteral administration include needle (including microneedle) injectors, needle-free injectors and infusion techniques.
  • Parenteral formulations are typically aqueous solutions which may contain excipients such as salts, carbohydrates and buffering agents (preferably to a pH of from 3 to 9), but, for some applications, they may be more suitably formulated as a sterile non-aqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as sterile, pyrogen-free water.
  • excipients such as salts, carbohydrates and buffering agents (preferably to a pH of from 3 to 9)
  • a suitable vehicle such as sterile, pyrogen-free water.
  • parenteral formulations under sterile conditions may readily be accomplished using standard pharmaceutical techniques well known to those skilled in the art.
  • solubility of compounds of formula (I) used in the preparation of parenteral solutions may be increased by the use of appropriate formulation techniques, such as the incorporation of solubility-enhancing agents.
  • Formulations for parenteral administration may be formulated to be immediate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
  • compounds of the invention may be formulated as a solid, semi-solid, or thixotropic liquid for administration as an implanted depot providing modified release of the active compound. Examples of such formulations include drug-coated stents and poly(dl-lactic-coglycolic)acid (PGLA) microspheres.
  • PGLA poly(dl-lactic-coglycolic)acid
  • the compounds of the invention may also be administered topically to the skin or mucosa, that is, dermally or transdermally.
  • Typical formulations for this purpose include gels, hydrogels, lotions, solutions, creams, ointments, dusting powders, dressings, foams, films, skin patches, wafers, implants, sponges, fibres, bandages and microemulsions. Liposomes may also be used.
  • Typical carriers include alcohol, water, mineral oil, liquid petrolatum, white petrolatum, glycerin, polyethylene glycol and propylene glycol. Penetration enhancers may be incorporated—see, for example, J Pharm Sci, 88 (10), 955-958, by Finnin and Morgan (October 1999).
  • topical administration include delivery by electroporation, iontophoresis, phonophoresis, sonophoresis and microneedle or needle-free (e.g. PowderjectTM, BiojectTM, etc.) injection.
  • the compounds of the invention can also be administered intranasally or by inhalation, typically in the form of a dry powder (either alone, as a mixture, for example, in a dry blend with lactose, or as a mixed component particle, for example, mixed with phospholipids, such as phosphatidylcholine) from a dry powder inhaler or as an aerosol spray from a pressurised container, pump, spray, atomiser (preferably an atomiser using electrohydrodynamics to produce a fine mist), or nebuliser, with or without the use of a suitable propellant, such as 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoropropane.
  • the powder may comprise a bioadhesive agent, for example, chitosan or cyclodextrin.
  • the pressurised container, pump, spray, atomizer, or nebuliser contains a solution or suspension of the compound(s) of the invention comprising, for example, ethanol, aqueous ethanol, or a suitable alternative agent for dispersing, solubilising, or extending release of the active, a propellant(s) as solvent and an optional surfactant, such as sorbitan trioleate, oleic acid, or an oligolactic acid.
  • a solution or suspension of the compound(s) of the invention comprising, for example, ethanol, aqueous ethanol, or a suitable alternative agent for dispersing, solubilising, or extending release of the active, a propellant(s) as solvent and an optional surfactant, such as sorbitan trioleate, oleic acid, or an oligolactic acid.
  • the drug product Prior to use in a dry powder or suspension formulation, the drug product is micronised to a size suitable for delivery by inhalation (typically less than 5 microns). This may be achieved by any appropriate comminuting method, such as spiral jet milling, fluid bed jet milling, supercritical fluid processing to form nanoparticles, high pressure homogenisation, or spray drying.
  • comminuting method such as spiral jet milling, fluid bed jet milling, supercritical fluid processing to form nanoparticles, high pressure homogenisation, or spray drying.
  • Capsules made, for example, from gelatin or hydroxypropylmethylcellulose
  • blisters and cartridges for use in an inhaler or insufflator may be formulated to contain a powder mix of the compound of the invention, a suitable powder base such as lactose or starch and a performance modifier such as 1-leucine, mannitol, or magnesium stearate.
  • the lactose may be anhydrous or in the form of the monohydrate, preferably the latter.
  • Other suitable excipients include dextran, glucose, maltose, sorbitol, xylitol, fructose, sucrose and trehalose.
  • a suitable solution formulation for use in an atomiser using electrohydrodynamics to produce a fine mist may contain from 1 ⁇ g to 20 mg of the compound of the invention per actuation and the actuation volume may vary from 1 ⁇ l to 100 ⁇ l.
  • a typical formulation may comprise a compound of formula (I), propylene glycol, sterile water, ethanol and sodium chloride.
  • Alternative solvents which may be used instead of propylene glycol include glycerol and polyethylene glycol.
  • Suitable flavours such as menthol and levomenthol, or sweeteners, such as saccharin or saccharin sodium, may be added to those formulations of the invention intended for inhaled/intranasal administration.
  • the dosage unit is determined by means of a valve which delivers a metered amount.
  • Units in accordance with the invention are typically arranged to administer a metered dose or “puff” containing from 1 ⁇ g to 100 mg of the compound of formula (I).
  • the overall daily dose will typically be in the range 1 ⁇ g to 200 mg which may be administered in a single dose or, more usually, as divided doses throughout the day.
  • the compounds of the invention may be administered rectally or vaginally, for example, in the form of a suppository, pessary, microbicide, vaginal ring or enema.
  • Cocoa butter is a traditional suppository base, but various alternatives may be used as appropriate.
  • the compounds of the invention may also be administered directly to the eye or ear, typically in the form of drops of a micronised suspension or solution in isotonic, pH-adjusted, sterile saline.
  • Other formulations suitable for ocular and aural administration include ointments, biodegradable (e.g. absorbable gel sponges, collagen) and non-biodegradable (e.g. silicone) implants, wafers, lenses and particulate or vesicular systems, such as niosomes or liposomes.
  • a polymer such as crossed-linked polyacrylic acid, polyvinylalcohol, hyaluronic acid, a cellulosic polymer, for example, hydroxypropylmethylcellulose, hydroxyethylcellulose, or methyl cellulose, or a heteropolysaccharide polymer, for example, gelan gum, may be incorporated together with a preservative, such as benzalkonium chloride.
  • a preservative such as benzalkonium chloride.
  • Such formulations may also be delivered by iontophoresis.
  • the compounds of the invention may be combined with soluble macromolecular entities, such as cyclodextrin and suitable derivatives thereof or polyethylene glycol-containing polymers, in order to improve their solubility, dissolution rate, taste-masking, bioavailability and/or stability for use in any of the aforementioned modes of administration.
  • soluble macromolecular entities such as cyclodextrin and suitable derivatives thereof or polyethylene glycol-containing polymers
  • Drug-cyclodextrin complexes are found to be generally useful for most dosage forms and administration routes. Both inclusion and non-inclusion complexes may be used.
  • the cyclodextrin may be used as an auxiliary additive, i.e. as a carrier, diluent, or solubiliser. Most commonly used for these purposes are alpha-, beta- and gamma-cyclodextrins, examples of which may be found in International Patent Applications Nos. WO 91/11172, WO 94/02518 and WO 98/55148.
  • the total daily dose of the compounds of the invention is typically in the range 1 mg to 10 g, such as 10 mg to 1 g, for example 25 mg to 500 mg depending, of course, on the mode of administration and efficacy.
  • oral administration may require a total daily dose of from 50 mg to 100 mg.
  • the total daily dose may be administered in single or divided doses and may, at the physician's discretion, fall outside of the typical range given herein. These dosages are based on an average human subject having a weight of about 60 kg to 70 kg. The physician will readily be able to determine doses for subjects whose weight falls outside this range, such as infants and the elderly.
  • the compounds of the invention are useful because they exhibit pharmacological activity in animals, i.e., URAT-1 inhibition. More particularly, the compounds of the invention are of use in the treatment of disorders for which a URAT-1 inhibitor is indicated.
  • the animal is a mammal, more preferably a human.
  • a compound of the invention for the treatment of a disorder for which a URAT-1 inhibitor is indicated.
  • a method of treating a disorder in an animal comprising administering to said animal a therapeutically effective amount of a compound of the invention.
  • disorders for which a URAT-1 inhibitor is indicated include diseases associated with high levels of uric acid in humans and other mammals including (but not limited to) hyperuricemia, asymptomatic hyperuricemia, gout (including juvenile forms), gouty arthritis, inflammatory arthritis, joint inflammation, deposition of urate crystals in the joint, tophaceous gout, chronic kidney disease, nephrolithiasis (kidney stones), Lesch-Nyhan syndrome and Kelley-Seegmiller syndrome.
  • diseases associated with high levels of uric acid in humans and other mammals including (but not limited to) hyperuricemia, asymptomatic hyperuricemia, gout (including juvenile forms), gouty arthritis, inflammatory arthritis, joint inflammation, deposition of urate crystals in the joint, tophaceous gout, chronic kidney disease, nephrolithiasis (kidney stones), Lesch-Nyhan syndrome and Kelley-Seegmiller syndrome.
  • Hyperuricemia may be defined by blood uric acid levels over 6.8 mg/dL. Guidelines for the management of hyperuricemia recommend that therapies aimed at lowering blood uric acid levels should be maintained until such blood uric acid levels are lowered to below 6.0 mg/dL, such as below 5.0 mg/dL.
  • asymptomatic hyperuricemia may nevertheless lead to the onset of diseases associated with high levels of uric acid.
  • the compounds of formula (I) may be used in the treatment of hyperuricemia where this is present together with one or more other diseases, such as kidney failure, type 2 diabetes, cardiovascular disease (e.g. hypertension, myocardial infarction, heart failure, coronary artery disease, cerebrovascular disease, atherosclerosis, angina, aneurism, hyperlipidemia and stroke), obesity, metabolic syndrome, myeloproliferative disorders, lymphoproliferative disorders and disorders associated with certain medications, such as a diuretic (e.g. a thiazide), an immunosuppressant (e.g. a cyclosporine therapy), a chemotherapeutic agent (e.g. cisplatin) or aspirin.
  • a diuretic e.g. a thiazide
  • an immunosuppressant e.g. a cyclosporine therapy
  • chemotherapeutic agent e.g. cisplatin
  • a URAT-1 inhibitor may be usefully combined with another pharmacologically active compound, or with two or more other pharmacologically active compounds, particularly in the treatment of a disease associated with elevated blood uric acid levels. Such combinations offer the possibility of significant advantages, including patient compliance, ease of dosing and synergistic activity.
  • the compound of the invention may be administered simultaneously, sequentially or separately in combination with the other therapeutic agent or agents.
  • the compounds of formula (I) may be administered in combination with one or more additional therapeutic agents.
  • Agents of interest include those that also lower blood uric acid levels.
  • Other agents of interest include those that reduce inflammation or pain.
  • the one or more additional therapeutic agents may be selected from any of the agents or types of agent that follow:
  • a compound of the invention together with one or more additional therapeutic agents which slow down the rate of metabolism of the compound of the invention, thereby leading to increased exposure in patients.
  • Increasing the exposure in such a manner is known as boosting.
  • This has the benefit of increasing the efficacy of the compound of the invention or reducing the dose required to achieve the same efficacy as an unboosted dose.
  • the metabolism of the compounds of the invention includes oxidative processes carried out by P450 (CYP450) enzymes, particularly CYP 3A4 and conjugation by UDP glucuronosyl transferase and sulphating enzymes.
  • agents that may be used to increase the exposure of a patient to a compound of the present invention are those that can act as inhibitors of at least one isoform of the cytochrome P450 (CYP450) enzymes.
  • the isoforms of CYP450 that may be beneficially inhibited include, but are not limited to, CYP1A2, CYP2D6, CYP2C9, CYP2C19 and CYP3A4.
  • Suitable agents that may be used to inhibit CYP 3A4 include ritonavir, saquinavir, ketoconazole, N-(3,4-difluorobenzyl)-N-methyl-2- ⁇ [(4-methoxypyridin-3-yl)amino]sulfonyl ⁇ benzamide and N-(1-(2-(5-(4-fluorobenzyl)-3-(pyridin-4-yl)-1H-pyrazol-1-yl)acetyl)piperidin-4-yl)methanesulfonamide.
  • kits suitable for coadministration of the compositions may conveniently be combined in the form of a kit suitable for coadministration of the compositions.
  • the kit of the invention comprises two or more separate pharmaceutical compositions, at least one of which contains a compound of the invention, and means for separately retaining said compositions, such as a container, divided bottle, or divided foil packet.
  • An example of such a kit is the familiar blister pack used for the packaging of tablets, capsules and the like.
  • the kit of the invention is particularly suitable for administering different dosage forms, for example, oral and parenteral, for administering the separate compositions at different dosage intervals, or for titrating the separate compositions against one another.
  • the kit typically comprises directions for administration and may be provided with a so-called memory aid.
  • the invention provides a pharmaceutical product (such as in the form of a kit) comprising a compound of the invention together with one or more additional therapeutically active agents as a combined preparation for simultaneous, separate or sequential use in the treatment of a disorder for which a URAT-1 inhibitor is indicated.
  • DIPEA is N-ethyldiisopropylamine, N,N-diisopropylethylamine;
  • DMAP is 4-dimethylaminopyridine
  • DMF is N,N-dimethylformamide
  • DMSO dimethyl sulphoxide
  • EDCl 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
  • EDTA is ethylenediaminetetraacetic acid
  • ELSD evaporative light scattering detection
  • Et 2 O diethyl ether
  • EtOAc is ethyl acetate
  • EtOH is ethanol
  • HPLC high-performance liquid chromatography
  • IPA is isopropanol
  • Ir 2 (OMe) 2 COD 2 is bis(1,5-cyclooctadiene)di-p-methoxydiiridium (I)
  • KOAc is potassium acetate
  • K 3 PO 4 is potassium phosphate tribasic
  • NMM is N-methylmorpholine
  • NMP is N-Methyl-2-pyrrolidone
  • Pd/C is palladium on carbon
  • Pd(PPh 3 ) 4 is palladium tetrakis
  • Pd(dppf) 2 Cl 2 is [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane
  • TBAF is tetra-n-butylammonium fluoride
  • TBME is tert-butyl methyl ether
  • TFA is trifluoroacetate
  • THF is tetrahydrofuran
  • THP is tetrahydropyran
  • TLC thin layer chromatography
  • UV is ultraviolet
  • WSCDI is 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride.
  • R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as previously defined for a compound of formula (I), unless otherwise stated, and PG (where present) is a suitable amino protecting group, such as methoxymethyl or dimethoxybenzyl.
  • the reaction mixture was diluted with water, or an aqueous solution of an inorganic acid such as saturated aqueous ammonium chloride or 2N HCl, or an aqueous solution of an inorganic base such as 1N NaOH; extracted into a solvent such as DCM or EtOAc; dried over a drying agent such as MgSO 4 or Na 2 SO 4 ; and concentrated in vacuo to afford a residue.
  • an inorganic acid such as saturated aqueous ammonium chloride or 2N HCl
  • an aqueous solution of an inorganic base such as 1N NaOH
  • solvent such as DCM or EtOAc
  • dried over a drying agent such as MgSO 4 or Na 2 SO 4
  • diethylamine salt 29 3-cyano-N-(5-fluoropyridin-2-yl)-4-[2-fluoro-3- 2-fluoro-3- m/z 456 (trifluoromethyl)phenoxy]benzenesulfonamide (trifluoromethyl)phenol [M + H] + diethylamine salt 30 4-(2-chloro-4-cyanophenoxy)-3-cyano-N-(5- 2-chloro-4- m/z 429 fluoropyridin-2-yl)benzenesulfonamide cyanophenol [M + H] + diethylamine salt 31 4-(2-chloro-4-fluorophenoxy)-3-cyano-N-(5- 2-chloro-4- m/z 422 fluoropyridin-2-yl)benzenesulfonamide fluorophenol [M + H] + 32 4-(2-chloro-3,5-difluorophenoxy)-3-cyano-N- 2-chloro-3
  • the title compound was prepared according to the method described for Example 101 using 4-aminopyridine.
  • the title compound was prepared according to the Method described for Example 101 using 3-methoxypyridine-2-amine.
  • the reaction mixture was diluted with dichloromethane and washed with 2 M HCl (100 mL).
  • the organic phase was dried with MgSO 4 , filtered, and evaporated to dryness under vacuum to leave a light brown solid.
  • the residue was dissolved in dichloromethane and purified using silica gel column chromatography eluting with 0% to 40% ethyl acetate in heptanes.
  • Mobile phase A 0.05% formic acid in water
  • Mobile phase B MeCN
  • Gradient From 98% A and 2% B to 90% A and 10% B in 1 min, further to 2% A and 98% B in 2.0 min and finally back to initial condition in 3 min
  • Flow rate 1.5 mL/min
  • Mobile phase A 0.1% formic acid in water
  • Mobile phase B MeCN
  • Mobile phase A 0.05% formic acid in water
  • Mobile phase B MeCN
  • Gradient From 98% A and 2% B to 90% A and 10% B in 1 min, further to 2% A and 98% B in 2.0 min and finally back to initial condition in 3 min
  • Flow rate 1.5 mL/min
  • the title compound was prepared according to the method described for Library Protocol 2 using 5-chloro-N-(2,4-dimethoxybenzyl)-2,4-difluoro-N-(pyrimidin-2-yl)benzenesulfonamide (WO2012004743) and 3-cyano-4-fluorophenol.
  • yl)benzenesulfonamide 240 4-(4-chloro-3- 4-chloro-3-(hydroxymethyl)phenol m/z 434 (hydroxymethyl)phenoxy)- and 3-cyano-N-(2,4- [M + H] + 3-cyano-N-(5-fluoropyridin- dimethoxybenzyl)-4-fluoro-N-(5- MV 5 2-yl)benzenesulfonamide fluoropyridin-2- PM B. yl)benzenesulfonamide (Prep 18).
  • Example 243 The method described by Example 243 was followed, but using dimethoxybenzylamine instead of azetidine and with heating to 70° C. followed by stirring the residue in TFA (12 mL) for 1 hour. The resulting mixture was concentrated in vacuo and purified using reverse phase column chromatography eluting from 5% to 80% MeCN (0.1% HCO 2 H) in water (0.1% HCO 2 H) to afford the title compound.
  • the crude product was purified by silica gel column chromatography eluting with 3:2 EtOAc:heptanes. The residue (76 mg, 0.13 mmol) was dissolved in DCM (2 mL) and treated with TFA (2 mL). The reaction was stirred at room temperature for 18 hours. MeOH (1 mL) was added and the reaction concentrated in vacuo. The crude product was purified by silica gel column chromatography eluting with 10-30% EtOAc in DCM to afford the title compound (25 mg, 44%) as a colourless solid (25 mg, 44%).
  • the title compound was prepared according to the method described for Preparation 2 using 5-aminopyrimidine.
  • N-(2,4-Dimethoxybenzyl)pyrimidin-4-amine (WO2012004743, 0.70 g, 2.86 mmol), 3-cyano-4-fluorobenzene-1-sulfonyl chloride (0.75 g, 3.43 mmol) and 1,4-diazabicyclo[2.2.2]octane (0.39 g, 3.43 mmol) in acetonitrile (15 mL) were stirred at room temperature for 18 hours.
  • the reaction mixture was diluted with dichloromethane (100 mL), washed with water (100 mL), the organic layer was dried over anhydrous magnesium sulphate and the filtrate was concentrated in vacuo.
  • the residue was purified by silica gel column chromatography eluting with 10% dichloromethane in ethyl acetate to afford the title compound as a yellow glass (0.69 g, 57%).
  • the title compound may be prepared according to the method described for Preparation 11 using 2,4,5-trifluorobenzenesulfonyl chloride and N-2,4-dimethoxybenzyl-5-fluoropyridin-2-amine (WO2012004743).
  • reaction mixture was stirred for 30 minutes at 0° C.
  • the reaction mixture was doubled in volume using ethyl acetate and washed twice with dilute sodium hydrogen carbonate solution (2 ⁇ 200 mL).
  • the organic layer was dried over MgSO 4 , filtered, and concentrated in vacuo.
  • the residue was purified using silica gel column chromatography eluting with 0% to 20% ethyl acetate in heptanes to afford the title compound as a yellow solid (2.1 g, 46%).
  • the title compound was prepared according to the method described for the preparation of 5-chloro-6-(2-methylpropoxy)-3-pyridinol (WO2012007869), using 2-ethoxy-3-chloro-5-hydroxypyridine.
  • the title compound was prepared according to the method described for Preparation 20 using 2,4-dimethoxybenzylamine and 2-fluoroisonicotinonitrile.
  • the title compound was prepared according to the method described for Preparation 20 using 2,4-dimethoxybenzylamine and 6-fluororonicotinonitrile.
  • the title compound was prepared according to the method described for Preparation 18 using 6-((2,4-dimethoxybenzyl)amino)nicotinonitrile (Preparation 37) and 3-cyano-4-fluorobenzene-1-sulfonyl chloride. The residue was purified by reverse phase chromatography eluting with 0-100% MeCN in water/0.1% formic acid.
  • the title compound was prepared according to the method described for Preparation at 120° C. for 68 hours using 5-bromo-3-fluoro-2-hydroxybenzonitrile (WO 2006022374) and 2-chloro-4-fluorobenzonitrile.
  • the title compound was prepared according to the method described for Preparation at reflux using 5-bromo-2-(4-cyano-3-chlorophenoxy)-3-fluorobenzonitrile (Preparation 41) and benzyl mercaptan.
  • the reaction was allowed to cool to room temperature and diluted with EtOAc (100 mL), water (50 mL) and saturated aqueous sodium hydrogen carbonate solution (100 mL).
  • the organic was separated and the aqueous was re-extracted with EtOAc (2 ⁇ 100 mL).
  • the combined organic layers were washed with brine (100 mL), dried over sodium sulfate, filtered and concentrated in vacuo.
  • the residue was absorbed onto silica and purified by silica gel column chromatography eluting with 10% EtOAc in heptanes to afford the title compound as a yellow solid (115 mg, 28%).
  • URAT1(L)GFP enhanced green fluorescent protein
  • the combined sequence was codon-optimised and custom synthesized.
  • the synthesized sequence was generated in pDONR221 Gateway entry vector (Invitrogen Life Technologies) prior to cloning in pLenti6.3/V5 Gateway destination vector (Invitrogen Life Technologies).
  • FIG. 1A A schematic of the URAT1(L)GFP construct is set forth in FIG. 1A .
  • FIG. 1B The nucleotide and amino acid sequence of the URAT1(L)GFP construct is set out in FIG. 1B , which also shows alignment of the nucleotide sequence with NM — 144585.
  • Lentiviral particles were generated according to ViraPower HiPerform expression system procedure (Invitrogen Life Technologies) and used to transduce CHO cells. Blasticidin selection enabled the generation of a stable clonal pool of cells, confirmed by expression of GFP and V5 epitope.
  • the clonal pools were sorted using fluorescence-activated cell sorting (FACS) on the basis of GFP expression with the gating set at the top 50% of expression into single cells which were subsequently expanded to generate clonal lines.
  • FACS fluorescence-activated cell sorting
  • One clone was identified with the best assay performance as determined by maximal separation between complete inhibition of uric acid transport (with 10 ⁇ M benzbromarone) and no inhibition (DMSO). This cell line was used for all screening activities and is referred to as CHO-URAT1(L)GFP#8 or CHO#8.
  • the potency of the compounds of formula (I) as inhibitors of the URAT-1 transporter was determined as follows.
  • CHO#8 cells were cultured in cell line maintenance flasks in medium consisting of Dulbecco's modified Eagle medium (DMEM) with high glucose and sodium pyruvate (4.5 g of glucose per litre, Invitrogen Life Technologies), supplemented with heat-inactivated foetal bovine serum (FBC, 10% v/v), 1 ⁇ NEAA (non-essential amino acids) and blasticidin (10 ⁇ g/ml). Cultures were grown in 175 cm 2 tissue culture flasks in a humidified incubator at approximately 37° C. in approximately 95% air/5% CO 2 . Near confluent CHO#8 cell cultures were harvested by trypsinisation, re-suspended in culture medium and the process was repeated once or twice weekly to provide sufficient cells for use.
  • DMEM Dulbecco's modified Eagle medium
  • FBC heat-inactivated foetal bovine serum
  • FBC heat-inactivated foetal bovine serum
  • 1 ⁇ NEAA non-essential amino acids
  • Assay ready flasks were generated by the same method, except the cells were not cultured in blasticidin.
  • Assay ready frozen cells were generated by freezing 40,000,000 cells in 1 ml of FBS (without blasticidin) containing 10% DMSO per vial. One vial was sufficient for 5 assay plates. Each vial was thawed rapidly to 37° C., washed and re-suspended in pre-warmed culture medium for seeding onto assay plates.
  • CHO#8 cells were seeded onto CytostarTM 96-well plates at a density of 5 ⁇ 10 5 cells per well. The cells were cultured for 1 day at approximately 37° C. in a humidified incubator containing approximately 5% CO 2 in air. After approximately 24 hours culture, cells were used for uptake experiments.
  • chloride-containing buffer 136.7 mM NaCl, 5.36 mM KCl, 0.952 mM CaCl 2 , 0.441 mM KH 2 PO 4 , 0.812 mM MgSO 4 , 5.6 mM D-glucose, 0.383 mM Na 2 HPO 4 .2H 2 O, 10 mM HEPES, pH 7.4 with NaOH.
  • the cells were pre-incubated with another 50 ⁇ L of chloride-containing buffer for one hour at approximately 37° C. in a humidified incubator containing approximately 5% CO 2 in air.
  • Assay compound plates were prepared by diluting the compounds of formula (I) with chloride-free buffer (125 mM Na-gluconate, 4.8 mM K-gluconate, 1.3 mM Ca-gluconate, 1.2 mM KH 2 PO 4 , 1.2 mM MgSO 4 , 5.6 mM D-glucose, 25 mM HEPES, pH 7.4 with NaOH) in 100% DMSO to a final concentration of 1% DMSO.
  • chloride-free buffer 125 mM Na-gluconate, 4.8 mM K-gluconate, 1.3 mM Ca-gluconate, 1.2 mM KH 2 PO 4 , 1.2 mM MgSO 4 , 5.6 mM D-glucose, 25 mM HEPES, pH 7.4 with NaOH
  • [ 14 C]-Uric Uric acid working stock was made by addition of radiolabeled compound to a final concentration of 120 nM in chloride-free buffer.
  • the final assay concentration of solvent (DMSO) was 0.25%; the final assay concentration of [ 14 C]-uric acid was 30 nM in chloride-free buffer and the final compound of formula (I) concentrations ranged from 0 to 10 ⁇ M.
  • the vehicle comparator was DMSO (i.e. no inhibition of uric acid transport) and the pharmacological blockade (i.e. 100% inhibition of uric acid transport) was defined by benzbromarone at 10 ⁇ M final assay concentration.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

The present invention relates to new sulfonamide URAT-1 inhibitor compounds of formula (I) or a pharmaceutically acceptable salt thereof:
Figure US20150259327A1-20150917-C00001
to compositions containing them, to processes for their preparation and to intermediates used in such processes, and to methods of treatment, wherein R1, R2, R3, R4, R5 and R6 are as defined in the description.

Description

  • This application is a Continuation Application under 35 U.S.C. §120 of U.S. patent application Ser. No. 14/254,988 filed on Apr. 17, 2014 which claims the benefit of U.S. Provisional Patent Application No. 61/917,532 filed on Dec. 18, 2013 and U.S. Provisional Patent Application No. 61/813,809 filed on Apr. 19, 2013, the disclosures of which are hereby incorporated by reference in its entirety.
    • FIELD OF THE INVENTION
  • The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes.
  • Uric acid is the final product of purine metabolism in humans. In humans, unlike many other animals, uric acid is not further broken down, but is predominantly (70%) excreted into the urine with the remaining 30% excreted in faeces. Hyperuricemia is defined as an excessive production or decreased excretion of uric acid and can occur as an overproduction or under excretion of serum uric acid (sUA), or a combination of the both. Renal under excretion of uric acid is the primary cause of hyperuricemia in about 90% of cases, while overproduction is the cause in less than 10%. Increased sUA concentration above 6.8 mg/dL results in crystallisation of uric acid in the form of salts, such as monosodium urate, and to precipitation of these crystals in joints, on tendons and in the surrounding tissues. These crystals (known as tophi) trigger a local immune-mediated inflammatory reaction, leading to gout. The risk of gout increases with increased sUA levels.
  • Gout is a painful condition that can present in a number of ways, although the most usual is a recurrent attack of acute inflammatory arthritis (a red, tender, hot, swollen joint) often occurring in big toes, heels, knees, wrists and fingers.
  • Gout is treated by agents to both decrease the cause and effects of uric acid crystal inflammation and pain.
  • The pain associated with gout is commonly treated with pain and anti-inflammatory drugs such as nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine and steroids. Agents that decrease sUA levels may be used to treat the cause of gout. These include agents that: inhibit the enzymes that result in uric acid production, such as xanthine oxidase inhibitors (e.g. allopurinol, febuxostat or tisopurine), or purine nucleoside phosphorylase (PNP) inhibitors (e.g. ulodesine); metabolise uric acid, such as urate oxidases—also known as uricases (e.g. pegloticase); or increase the excretion of uric acid in the urine (uricosurics), Uricosurics include agents that inhibit the transporters responsible for renal reabsorption of uric acid back into the blood, such as benziodarone, isobromindione, probenecid and sulphinpyrazone, and URAT-1 inhibitors (e.g. benzbromarone).
  • URAT-1 is also known as solute carrier family 22 (organic anion/cation transporter), member 12, and is encoded by the gene SLC22A12. Human genetic analysis has demonstrated that polymorphisms in the SLC22A12 gene are directly associated with changes in serum uric acid. Inhibitors of uric acid transport, such as URAT-1, are therefore effective in the treatment of gout.
  • There is a continuing need to provide new treatments for gout that are more effective and/or are better tolerated.
  • Certain URAT-1 inhibitors for the treatment of gout are known. WO2011/159840 discloses phenylthioacetate URAT-1 inhibitors. Additionally, WO2008/118758, WO2009/012242, WO2010/079443, WO2012/004706, WO2012/004714 and WO2012/004743 disclose sulphonamides.
  • There is, however, an ongoing need to provide new URAT-1 inhibitors that are good drug candidates.
  • Furthermore, preferred compounds should have one or more of the following properties: be well absorbed from the gastrointestinal tract; be metabolically stable; have a good metabolic profile, in particular with respect to the toxicity or allergenicity of any metabolites formed; or possess favourable pharmacokinetic properties whilst still retaining their activity profile as URAT-1 inhibitors. They should be non-toxic and demonstrate few side-effects. Ideal drug candidates should exist in a physical form that is stable, non-hygroscopic and easily formulated.
    • SUMMARY OF THE INVENTION
  • We have now found new sulphonamide URAT-1 inhibitors.
  • According to a first aspect of the invention there is provided a compound of formula (I)
  • Figure US20150259327A1-20150917-C00002
  • or a pharmaceutically acceptable salt thereof, wherein:
  • R1 is a ‘C-linked’ 6-membered heteroaryl containing one, two or three nitrogen atoms wherein said heteroaryl is optionally substituted by one, two or three, valency permitting, X1;
  • each X1 is independently selected from: F; Cl; CN; (C1-C4)alkyl optionally substituted by one, two or three F; and (C1-C4)alkyloxy optionally substituted by one two or three F;
    R2, R3 and R5 are independently selected from: H; halogen; CN; (C1-C4)alkyl optionally substituted by one, two or three F; and (C1-C4)alkyloxy optionally substituted by one, two or three F;
    R4 is selected from: halogen; CN; (C1-C4)alkyl optionally substituted by one, two or three F; and (C1-C4)alkyloxy optionally substituted by one, two or three F;
    R6 is phenyl substituted by one, two or three X2; or a ‘C-linked’ 6-membered heteroaryl containing one or two nitrogen atoms wherein said heteroaryl is optionally substituted by one, two or three X2;
    each X2 is independently selected from: F; Cl; CN; —S(C1-C4)alkyl; —NR7R8; (C1-C6)alkyloxy optionally substituted by one, two or three F; (C3-C6)cycloalkyloxy; (C1-C6)alkyl optionally substituted by one, two or three F; and (C1-C6)alkyl substituted by OH; and
    R7 and R8 are independently H or (C1-C4)alkyl or, together with the nitrogen atom to which they are attached, form a saturated 4- to 6-membered nitrogen containing monocycle.
  • Described below are a number of embodiments (E) of this first aspect of the invention, where for convenience E1 is identical thereto.
    • E1 A compound of formula (I) as defined above or a pharmaceutically acceptable salt thereof.
    • E2 A compound according to E1 wherein R1 is a ‘O-linked’ 6-membered heteroaryl containing one or two nitrogen atoms, wherein said heteroaryl is optionally substituted by one or two X1.
    • E3 A compound according to either E1 or E2 wherein R1 is a ‘O-linked’ 6-membered heteroaryl containing one or two nitrogen atoms, wherein said heteroaryl is optionally substituted by X1.
    • E4 A compound according to any of E1 to E3 wherein R1 is a ‘O-linked’ pyridinyl optionally substituted by X1.
    • E5 A compound according to any of E1 to E4 wherein R1 is a ‘O-linked’ pyridinyl substituted by X1.
    • E6 A compound according to any of E1 to E5 wherein X1 is F.
    • E7 A compound according to any of E1 to E3 wherein R1 is a ‘O-linked’ 6-membered heteroaryl containing one or two nitrogen atoms.
    • E8 A compound according to any of E1 to E7 wherein R4 is either halogen or CN, and R2, R3 and R5 are independently selected from: H; halogen; or CN.
    • E9 A compound according to any of E1 to E8 wherein R4 is CN; and each of R2, R3 and R5 are H.
    • E10 A compound according to any of E1 to E9 wherein R6 is phenyl substituted by one, two or three X2.
    • E11A compound according to E10 wherein R6 is phenyl substituted by two or three X2.
    • E12 A compound according to any of E1 to E9 wherein R6 is a ‘O-linked’ 6-membered heteroaryl containing one or two nitrogen atoms, wherein said heteroaryl is optionally substituted by one, two or three X2.
    • E13 A compound according to E12 wherein R6 is a ‘C-linked’ 6-membered heteroaryl containing one or two nitrogen atoms, wherein said heteroaryl is substituted by one or two X2.
    • E14 A compound according to any of E1 to E13 wherein each X2 is independently selected from: F; Cl; CN; —S(C1-C3)alkyl; (C1-C4)alkyloxy optionally substituted by one, two or three F; and (C1-C4)alkyl optionally substituted by one, two or three F.
    • E15 A compound according to any of E1 to E14 wherein each X2 is independently selected from: F; Cl; CN; (C1-C3)alkyloxy; and (C1-C3)alkyl.
    • E16 A compound according to any of E1 to E15 wherein each X2 is independently selected from: F; Cl; CN; methoxy; and methyl.
    • E17 A compound according to E1 selected from:
    • 3-cyano-4-(4-cyano-3,5-dimethylphenoxy)-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • 4-(3-chloro-4-cyanophenoxy)-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • 4-(3-chloro-4-cyanophenoxy)-3-cyano-N-(4-fluoropyridin-2-yl)benzenesulfonamide;
    • 4-(3-chloro-4-fluorophenoxy)-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • 3-cyano-N-(5-fluoropyridin-2-yl)-4-(2-methoxy-6-methylphenoxy)benzenesulfonamide;
    • 4-[(5-chloro-6-methoxypyridin-3-yl)oxy]-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • 4-(3-chloro-5-cyanophenoxy)-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • 4-(4-chloro-3-methoxyphenoxy)-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • 4-(4-cyano-3-fluorophenoxy)-2-fluoro-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • 4-[(5-chloropyridin-3-yl)oxy]-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • 3-cyano-4-(3-fluoro-4-methoxyphenoxy)-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • 3-cyano-4-(4-cyano-3-methylphenoxy)-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • 3-cyano-4-(4,5-difluoro-2-methoxyphenoxy)-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • 3-cyano-4-(3,4-difluorophenoxy)-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • 3-cyano-4-(4-fluoro-3-methylphenoxy)-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • 3-cyano-4-(4-cyano-2-fluorophenoxy)-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • 4-(4-chloro-2-fluorophenoxy)-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • 3-cyano-4-(2,6-dimethylphenoxy)-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • 4-(2-chloro-3,4-difluorophenoxy)-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • 3-cyano-N-(5-fluoropyridin-2-yl)-4-(2,3,4-trifluorophenoxyl)benzenesulfonamide;
    • 3-cyano-4-(4-cyano-3-fluorophenoxy)-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • 4-(3-chloro-4-methoxyphenoxy)-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • 3-cyano-N-(5-fluoropyridin-2-yl)-4-(5-methoxy-2-methylphenoxy)benzenesulfonamide;
    • 3-cyano-4-(2,3-dichloro-4-fluorophenoxy)-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • 3-cyano-4-(3-cyano-4-fluorophenoxy)-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • 4-(2-chloro-5-cyano-4-methylphenoxy)-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • 3-cyano-4-(4-cyano-3-methoxyphenoxy)-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • 3-cyano-4-(2,5-dichloro-4-fluorophenoxy)-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • 3-cyano-4-(2,4-difluorophenoxy)-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • 4-(2-chloro-6-methoxyphenoxy)-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • 3-cyano-4-(4-cyanophenoxy)-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • 3-cyano-4-(2-fluoro-6-methoxyphenoxy)-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • 3-cyano-N-(5-fluoropyridin-2-yl)-4-(4-methoxy-2-methylphenoxy)benzenesulfonamide;
    • 3-cyano-N-(5-fluoropyridin-2-yl)-4-(2-methoxyphenoxyl)benzenesulfonamide;
    • 3-cyano-4-(4-cyano-2,5-difluorophenoxy)-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • 4-(2-chloro-4-fluorophenoxy)-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • 4-(4-chloro-2-methoxyphenoxy)-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • 4-(4-chloro-3-methylphenoxy)-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • 4-(5-chloro-2-methylphenoxy)-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • 3-cyano-4-(2,4-dichlorophenoxy)-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • 3-cyano-4-(5-fluoro-2-methylphenoxy)-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • 4-(3-chlorophenoxy)-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • 4-(4-chlorophenoxy)-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • 3-cyano-4-(2,6-difluoro-3-methylphenoxy)-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • 4-(2-chloro-6-methylphenoxy)-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • 4-(3-chloro-5-fluorophenoxy)-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • 4-(4-chloro-3-cyanophenoxy)-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • 4-(4-chloro-3,5-dimethylphenoxy)-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • 3-cyano-4-(4-fluoro-2-methylphenoxy)-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • 4-(2-chloro-6-fluoro-3-methylphenoxy)-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide; or
    • 3-cyano-4-(3,4-dichlorophenoxy)-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • or a pharmaceutically acceptable salt thereof.
      E18 A compound of formula (I)
  • Figure US20150259327A1-20150917-C00003
  • or a pharmaceutically acceptable salt thereof, wherein:
    R1 is a ‘C-linked’ 6-membered heteroaryl containing one, two or three nitrogen atoms wherein said heteroaryl is optionally substituted by one, two or, valency permitting, three X1;
    each X1 is independently selected from: F; Cl; CN; (C1-C4)alkyl optionally substituted by one, two or three F; and (C1-C4)alkyloxy optionally substituted by one two or three F;
    one of R2, R3, R4 and R5 is either halogen or CN, and the remainder thereof are independently selected from: H; halogen; or CN;
    R6 is phenyl substituted by one, two or three X2; or a ‘C-linked’ 6-membered heteroaryl containing one or two nitrogen atoms wherein said heteroaryl is optionally substituted by one, two or three X2;
    each X2 is independently selected from: F; Cl; CN; —S(C1-C4)alkyl; —NR7R8; (C1-C6)alkyloxy optionally substituted by one, two or three F; (C3-C6)cycloalkyloxy; (C1-C6)alkyl optionally substituted by one, two or three F; and (C1-C6)alkyl substituted by OH; and
    each R7 and R8 is independently H or (C1-C4)alkyl or, together with the nitrogen atom to which they are attached, form a saturated 4- to 6-membered nitrogen containing monocycle.
    • E19 A compound according to E18 wherein R1 is a ‘C-linked’ 6-membered heteroaryl containing one or two nitrogen atoms, wherein said heteroaryl is optionally substituted by one or two X1.
    • E20 A compound according to either E18 or E19 wherein R1 is a ‘C-linked’ 6-membered heteroaryl containing one or two nitrogen atoms, wherein said heteroaryl is optionally substituted by X1.
    • E21 A compound according to any of E18 to E20 wherein R1 is a ‘C-linked’ pyridinyl optionally substituted by X1.
    • E22 A compound according to any of E18 to E21 wherein R1 is a ‘C-linked’ pyridinyl substituted by X1.
    • E23 A compound according to any of E18 to E22 wherein X1 is F.
    • E24 A compound according to any of E18 to E23 wherein R1 is a ‘C-linked’ 6-membered heteroaryl containing one or two nitrogen atoms.
    • E25 A compound according to any of E18 to E24 wherein R4 is either halogen or CN, and R2, R3 and R5 are independently selected from: H; halogen; or CN.
    • E26 A compound according to any of E18 to E25 wherein R4 is CN; and each of R2, R3 and R5 are H.
    • E27 A compound according to any of E18 to E26 wherein R6 is phenyl substituted by one, two or three X2.
    • E28 A compound according to E27 wherein R6 is phenyl substituted by two or three X2.
    • E29 A compound according to any of E18 to E26 wherein R6 is a ‘C-linked’ 6-membered heteroaryl containing one or two nitrogen atoms, wherein said heteroaryl is optionally substituted by one, two or three X2.
    • E30 A compound according to E29 wherein R6 is a ‘C-linked’ 6-membered heteroaryl containing one or two nitrogen atoms, wherein said heteroaryl is substituted by one or two X2.
    • E31 A compound according to any of E18 to E30 wherein each X2 is independently selected from: F; Cl; CN; —S(C1-C3)alkyl; (C1-C4)alkyloxy optionally substituted by one, two or three F; and (C1-C4)alkyl optionally substituted by one, two or three F.
    • E32 A compound according to any of E18 to E31 wherein each X2 is independently selected from: F; Cl; CN; (C1-C3)alkyloxy; and (C1-C3)alkyl.
    • E33 A compound according to any of E18 to E32 wherein each X2 is independently selected from: F: Cl; CN; methoxy; and methyl.
    • E34 A compound according to E1 which is:
    • 4-[3-chloro-4-(hydroxymethyl)phenoxy]-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • 4-{[5-chloro-6-(hydroxymethyl)pyridin-3-yl]oxy}-2-fluoro-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • 4-(3-chloro-4-cyanophenoxy)-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • 4-[(5-chloropyridin-3-yl)oxy]-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • 4-[(6-amino-5-chloropyridin-3-yl)oxy]-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • 3-cyano-4-(3,5-dichloro-4-cyanophenoxy)-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • 4-(3-chloro-4-cyanophenoxy)-3-cyano-N-(4-fluoropyridin-2-yl)benzenesulfonamide;
    • 4-(3-chloro-4-cyano-5-fluorophenoxy)-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • 4-(3-chloro-4-cyanophenoxy)-N-(5-chloropyridin-2-yl)-3-cyanobenzenesulfonamide; or
    • 3-cyano-4-(4-cyano-3,5-dimethylphenoxy)-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
    • or a pharmaceutically acceptable salt thereof.
  • Alkyl and alkoxy groups, containing the requisite number of carbon atoms, can be unbranched or branched. Examples of alkyl include methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl and t-butyl. Examples of alkoxy include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, i-butoxy, sec-butoxy and t-butoxy.
  • Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
  • Halo means fluoro, chloro, bromo or iodo.
  • The term ‘C-linked’ used in the definitions of formula (I) means that the group in question is joined via a ring carbon.
  • Specific examples of ‘C-linked’ 6-membered heteroaryl containing one, two or three nitrogen atoms include pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl.
  • Hereinafter, all references to compounds of the invention include compounds of formula (I) or pharmaceutically acceptable salts, solvates, or multi-component complexes thereof, or pharmaceutically acceptable solvates or multi-component complexes of pharmaceutically acceptable salts of compounds of formula (I), as discussed in more detail below.
  • Preferred compounds of the invention are compounds of formula (I) or pharmaceutically acceptable salts thereof.
  • Suitable acid addition salts are formed from acids which form non-toxic salts. Examples include the acetate, adipate, aspartate, benzoate, besylate, bicarbonate/carbonate, bisulphate/sulphate, borate, camsylate, citrate, cyclamate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hibenzate, hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate, maleate, malonate, mesylate, methylsulphate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, pyroglutamate, saccharate, stearate, succinate, tannate, tartrate, tosylate, trifluoroacetate and xinofoate salts.
  • Suitable base salts are formed from bases which form non-toxic salts. Examples include the aluminium, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine and zinc salts.
  • Hemisalts of acids and bases may also be formed, for example, hemisulphate and hemicalcium salts.
  • The skilled person will appreciate that the aforementioned salts include ones wherein the counterion is optically active, for example d-lactate or 1-lysine, or racemic, for example dl-tartrate or dl-arginine.
  • For a review on suitable salts, see “Handbook of Pharmaceutical Salts: Properties, Selection, and Use” by Stahl and Wermuth (Wiley-VCH, Weinheim, Germany, 2002).
  • Pharmaceutically acceptable salts of compounds of formula (I) may be prepared by one or more of three methods:
    • (i) by reacting the compound of formula (I) with the desired acid or base;
    • (ii) by removing an acid- or base-labile protecting group from a suitable precursor of the compound of formula (I) using the desired acid or base; or
    • (iii) by converting one salt of the compound of formula (I) to another by reaction with an appropriate acid or base or by means of a suitable ion exchange column.
  • All three reactions are typically carried out in solution. The resulting salt may precipitate out and be collected by filtration or may be recovered by evaporation of the solvent.
  • The degree of ionisation in the resulting salt may vary from completely ionised to almost non-ionised.
  • The compounds of formula (I) or pharmaceutically acceptable salts thereof may exist in both unsolvated and solvated forms. The term ‘solvate’ is used herein to describe a molecular complex comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable solvent molecules, for example, ethanol. The term ‘hydrate’ is employed when said solvent is water. Pharmaceutically acceptable solvates in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, e.g. D2O, d6-acetone and d6-DMSO.
  • A currently accepted classification system for organic hydrates is one that defines isolated site, channel, or metal-ion coordinated hydrates—see Polymorphism in Pharmaceutical Solids by K. R. Morris (Ed. H. G. Brittain, Marcel Dekker, 1995), incorporated herein by reference. Isolated site hydrates are ones in which the water molecules are isolated from direct contact with each other by intervening organic molecules. In channel hydrates, the water molecules lie in lattice channels where they are next to other water molecules. In metal-ion coordinated hydrates, the water molecules are bonded to the metal ion.
  • When the solvent or water is tightly bound, the complex will have a well-defined stoichiometry independent of humidity. When, however, the solvent or water is weakly bound, as in channel solvates and hygroscopic compounds, the water/solvent content will be dependent on humidity and drying conditions. In such cases, non-stoichiometry will be the norm.
  • The compounds of the invention may exist in a continuum of solid states ranging from fully amorphous to fully crystalline. The term ‘amorphous’ refers to a state in which the material lacks long range order at the molecular level and, depending upon temperature, may exhibit the physical properties of a solid or a liquid. Typically such materials do not give distinctive X-ray diffraction patterns and, while exhibiting the properties of a solid, are more formally described as a liquid. Upon heating, a change from solid to liquid properties occurs which is characterised by a change of state, typically second order (‘glass transition’). The term ‘crystalline’ refers to a solid phase in which the material has a regular ordered internal structure at the molecular level and gives a distinctive X-ray diffraction pattern with defined peaks. Such materials when heated sufficiently will also exhibit the properties of a liquid, but the change from solid to liquid is characterised by a phase change, typically first order (Melting point′).
  • Also included within the scope of the invention are multi-component complexes (other than salts and solvates) of compounds of formula (I) or pharmaceutically acceptable salts thereof wherein the drug and at least one other component are present in stoichiometric or non-stoichiometric amounts. Complexes of this type include clathrates (drug-host inclusion complexes) and co-crystals. The latter are typically defined as crystalline complexes of neutral molecular constituents which are bound together through non-covalent interactions, but could also be a complex of a neutral molecule with a salt. Co-crystals may be prepared by melt crystallisation, by recrystallisation from solvents, or by physically grinding the components together—see Chem Commun, 17, 1889-1896, by 0. Almarsson and M. J. Zaworotko (2004), incorporated herein by reference. For a general review of multi-component complexes, see J Pharm Sci, 64 (8), 1269-1288, by Haleblian (August 1975), incorporated herein by reference.
  • The compounds of the invention may also exist in a mesomorphic state (mesophase or liquid crystal) when subjected to suitable conditions. The mesomorphic state is intermediate between the true crystalline state and the true liquid state (either melt or solution). Mesomorphism arising as the result of a change in temperature is described as ‘thermotropic’ and that resulting from the addition of a second component, such as water or another solvent, is described as lyotropic′. Compounds that have the potential to form lyotropic mesophases are described as ‘amphiphilic’ and consist of molecules which possess an ionic (such as —COO−Na+, —COO−K+, or —SO3 −Na+) or non-ionic (such as —N−N+(CH3)3) polar head group. For more information, see Crystals and the Polarizing Microscope by N. H. Hartshorne and A. Stuart, 4th Edition (Edward Arnold, 1970), incorporated herein by reference.
  • The compounds of the invention may be administered as prodrugs. Thus certain derivatives of compounds of formula (I) which may have little or no pharmacological activity themselves can, when administered into or onto the body, be converted into compounds of formula (I) having the desired activity, for example, by hydrolytic cleavage. Such derivatives are referred to as ‘prodrugs’. Further information on the use of prodrugs may be found in ‘Pro-drugs as Novel Delivery Systems, Vol. 14, ACS Symposium Series (T Higuchi and W Stella) and ‘Bioreversible Carriers in Drug Design’, Pergamon Press, 1987 (ed. E B Roche, American Pharmaceutical Association).
  • Prodrugs can, for example, be produced by replacing appropriate functionalities present in a compound of formula (I) with certain moieties known to those skilled in the art as ‘pro-moieties’ as described, for example, in “Design of Prodrugs” by H Bundgaard (Elsevier, 1985).
  • Examples of prodrugs include phosphate prodrugs, such as dihydrogen or dialkyl (e.g. di-tert-butyl) phosphate prodrugs. Further examples of replacement groups in accordance with the foregoing examples and examples of other prodrug types may be found in the aforementioned references.
  • Also included within the scope of the invention are metabolites of compounds of formula (I), that is, compounds formed in vivo upon administration of the drug. Some examples of metabolites in accordance with the invention include, where the compound of formula (I) contains a phenyl (Ph) moiety, a phenol derivative thereof (-Ph>-PhOH);
  • Compounds of the invention containing one or more asymmetric carbon atoms can exist as two or more stereoisomers. Included within the scope of the invention are all stereoisomers of the compounds of the invention and mixtures of one or more thereof.
  • Conventional techniques for the preparation/isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography (HPLC).
  • Alternatively, the racemate (or a racemic precursor) may be reacted with a suitable optically active compound, for example, an alcohol, or, in the case where the compound of formula (I) contains an acidic or basic moiety, a base or acid such as 1-phenylethylamine or tartaric acid. The resulting diastereomeric mixture may be separated by chromatography and/or fractional crystallization and one or both of the diastereoisomers converted to the corresponding pure enantiomer(s) by means well known to a skilled person.
  • Chiral compounds of the invention (and chiral precursors thereof) may be obtained in enantiomerically-enriched form using chromatography, typically HPLC, on an asymmetric resin with a mobile phase consisting of a hydrocarbon, typically heptane or hexane, containing from 0 to 50% by volume of isopropanol, typically from 2% to 20%, and from 0 to 5% by volume of an alkylamine, typically 0.1% diethylamine. Concentration of the eluate affords the enriched mixture.
  • Mixtures of stereoisomers may be separated by conventional techniques known to those skilled in the art; see, for example, “Stereochemistry of Organic Compounds” by E. L. Eliel and S. H. Wilen (Wiley, New York, 1994.
  • The scope of the invention includes all crystal forms of the compounds of the invention, including racemates and racemic mixtures (conglomerates) thereof. Stereoisomeric conglomerates may also be separated by the conventional techniques described herein just above.
  • The scope of the invention includes all pharmaceutically acceptable isotopically-labelled compounds of the invention wherein one or more atoms are replaced by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number which predominates in nature.
  • Examples of isotopes suitable for inclusion in the compounds of the invention include isotopes of hydrogen, such as 2H and 3H, carbon, such as 11C, 13C and 14C, chlorine, such as 36Cl, fluorine, such as 18F, iodine, such as 1231 and 1251, nitrogen, such as 13N and 15N, oxygen, such as 15O, 17O and 18O, phosphorus, such as 32P, and sulphur, such as 35S.
  • Certain isotopically-labelled compounds of the invention, for example, those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies. The radioactive isotopes tritium, i.e. 3H, and carbon-14, i.e. 14C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection. Substitution with heavier isotopes such as deuterium, i.e. 2H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances. Substitution with positron emitting isotopes, such as 11C, 18F, 15O and 13N can be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy.
  • Isotopically-labeled compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed.
  • Also within the scope of the invention are intermediate compounds as hereinafter defined, all salts, solvates and complexes thereof and all solvates and complexes of salts thereof as defined hereinbefore for compounds of formula (I). The invention includes all polymorphs of the aforementioned species and crystal habits thereof.
  • When preparing a compound of formula (I) in accordance with the invention, a person skilled in the art may routinely select the form of intermediate which provides the best combination of features for this purpose. Such features include the melting point, solubility, processability and yield of the intermediate form and the resulting ease with which the product may be purified on isolation.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1A represents a schematic showing organization of the URAT1(L)GFP construct (N to C terminal direction).
  • FIG. 1B represents a sequence alignment of the codon optimized URAT1(L)GFP construct with the wild type human URAT1 sequence deposited as NM—144585.
    •
  • Alignment row 1 is the sequence from accession NM—144585.
  • Alignment row 2 is the sequence of the construct in the Gateway destination vector pLenti6.3V5/DEST (encoding URAT1(L)GFP) with the nucleotide alignment indicated with NM—144585 above and the nucleotide numbering below.
  • Alignment row 3 is the amino acid translation with sequence annotation indicated in italics below.
    • DETAILED DESCRIPTION
  • The compounds of the invention may be prepared by any method known in the art for the preparation of compounds of analogous structure. In particular, the compounds of the invention can be prepared by the procedures described by reference to the Schemes that follow, or by the specific methods described in the Examples, or by similar processes to either.
  • The skilled person will appreciate that the experimental conditions set forth in the schemes that follow are illustrative of suitable conditions for effecting the transformations shown, and that it may be necessary or desirable to vary the precise conditions employed for the preparation of compounds of formula (I). It will be further appreciated that it may be necessary or desirable to carry out the transformations in a different order from that described in the schemes, or to modify one or more of the transformations, to provide the desired compound of the invention.
  • In addition, the skilled person will appreciate that it may be necessary or desirable at any stage in the synthesis of compounds of the invention to protect one or more sensitive groups, so as to prevent undesirable side reactions. In particular, it may be necessary or desirable to protect amino or carboxylic acid groups. The protecting groups used in the preparation of the compounds of the invention may be used in conventional manner. See, for example, those described in ‘Greene's Protective Groups in Organic Synthesis’ by Theodora W Greene and Peter G M Wuts, fourth edition, (John Wiley and Sons, 2006), in particular chapters 7 (“Protection for the Amino Group”) and 5 (“Protection for the Carboxyl Group”), incorporated herein by reference, which also describes methods for the removal of such groups.
  • In the following general processes R1, R2, R3, R4, R5 and R6 are as previously defined for a compound of formula (I) unless otherwise stated. PG is a suitable amino protecting group, such as methoxymethyl or dimethoxybenzyl. Hal is a suitable halogen, such as F or Cl. Where ratios of solvents are given, the ratios are by volume.
  • According to a first process, compounds of formula (I) may be prepared from compounds of formula (II) and (III), as illustrated by Scheme 1.
  • Figure US20150259327A1-20150917-C00004
  • Compounds of formula (I) may be prepared from compounds of formula (II) according to reaction step (ii) by nucleophilic aromatic substitution reaction with compounds of formula (IV) under basic reaction conditions. Convenient conditions are potassium carbonate in DMF or DMSO; cesium carbonate in DMSO; or potassium phosphate in DMSO; and at from room temperature to elevated temperature. Typical conditions comprise potassium carbonate in DMSO at 80-100° C. for 18 hours.
  • Compounds of formula (II) may be prepared from compounds of formula (III) according to reaction step (i) by displacement of a sulfonyl chloride with compounds of formula (V) under basic reaction conditions. Convenient conditions are pyridine in DCM; 1,4-diazabicyclo[2.2.2]octane in acetonitrile; N-methylmorpholine in THF; or an excess of compound of formula (V). Preferred conditions comprise pyridine in DCM at room temperature.
  • According to a second process, compounds of formula (I) may be prepared from compounds of formulae (II) and (VIII), as illustrated by Scheme 2.
  • Compounds of formula (I) may be prepared from compound of formula (VI) according to process step (ii) according to the conditions described in Scheme 1 step (ii), followed by deprotection step (iii), typically mediated by an inorganic or organic acid. Preferred conditions comprise potassium carbonate in DMSO at room temperature, followed by trifluoroacetic acid in DCM or HCl in 1,4-dioxane. It is also possible that deprotection step (iii) may occur under the conditions for effecting the nucleophilic aromatic substitution of step (ii).
  • Figure US20150259327A1-20150917-C00005
  • Compounds of formula (VI) may be prepared from compounds of formula (II) according to process step (iv) by introduction of a suitable protecting group, such as methoxymethyl or dimethoxybenzyl, under basic reaction conditions or Mitsunobu reaction conditions. Typical conditions comprise diisopropylethylamine in DCM with chloromethoxymethane.
  • Alternatively, compounds of formula (VI) may be prepared from compounds of formula (III) according to process step (i) according to the conditions described in Scheme 1 step (i), or by using sodium or lithium hexamethyldisilazane in THF at from −78° C. to room temperature.
  • Compounds of formulae (II) and (III) may be prepared as described in Scheme 1.
  • Compounds of formula (VII) may be prepared from compounds of formula (VIII) according to reaction step (v) by a nucleophilic aromatic substitution reaction with compounds of formula (IX) under basic reaction conditions. Preferred conditions comprise diisopropylethylamine in n-butanol at 100° C. or potassium carbonate in DMSO at 110° C.
  • According to a third process, compounds of formula (I) may be prepared from compounds of formula (XIII) as illustrated by Scheme 3.
  • Figure US20150259327A1-20150917-C00006
  • Compounds of formula (I) may be prepared from compounds of formula (X) according to the conditions described in Scheme 2, step (i).
  • Compounds of formula (X) may be prepared from compounds of formula (XI) according to process step (vii), an oxidation reaction in the presence of trichloroisocyanuric acid. Preferred conditions comprise trichloroisocyanuric acid with benzyltrimethylammonium chloride and sodium carbonate in acetonitrile and water.
  • Compounds of formula (XI) may be prepared from compounds of formula (XII) according to process step (ii), a nucleophilic aromatic substitution reaction with compounds of formula (IV) as described in Scheme 1, step (i).
  • Compounds of formula (XII) may be prepared from compounds of formula (XIII) according to process step (vi), a cross-coupling reaction with benzylmercaptan in the presence of a suitable catalyst. Conveniently the catalyst is a palladium catalyst. Preferred conditions comprise diisopropylethyamine with [1,1-bis(di-tert-butylphosphino)]ferrocene palladium (II) in toluene at 60° C.
  • The skilled person will appreciate that a compound of formula (I) wherein R2, R3, R4 or R5 is CI, Br or I may be converted into the corresponding compound of formula (I) wherein the group in question is H, by dehalogenation in the presence of a suitable catalyst. Typical conditions comprise zinc dust in acetic acid at room temperature, or triethylsilane with tetrakis(triphenylphosphine)palladium(0) in THF at reflux.
  • The skilled person will further appreciate that a compound of formula (I) wherein R6 is 2- or 4-halo substituted ‘C-linked’ 6-membered heteroaryl containing one or two nitrogen atoms may be converted into the corresponding compound of formula (I) substituted by —NR7R8, by reaction with an appropriate amine. Where halo is fluoro, typical conditions comprise heating the compound of formula (I) and the amine of formula HNR7R8 in a solvent such as DMSO, in the presence of an inorganic base such as potassium carbonate, to a temperature of between 50-70° C.
  • The skilled person will further appreciate that in the aforementioned conversion, when R7 and R8 are both H, it may be necessary or desirable to employ an amino protecting group, such as dimethoxybenzyl, to introduce a protected amine; the protecting group is then removed under conventional conditions, such as in the presence of an organic acid. Preferred conditions comprise dimethoxybenzylamine with potassium carbonate in THF at 70° C., followed by stirring in TFA at room temperature.
  • Compounds of formula (III), (IV), (V), (VIII), (IX) and (XIII) are commercially available, known from the literature, easily prepared by methods well known to those skilled in the art, or can be made according to preparations described herein.
  • All new processes for preparing compounds of formula (I), and corresponding new intermediates employed in such processes, form further aspects of the present invention.
  • Compounds of the invention intended for pharmaceutical use may be administered as crystalline or amorphous products or may exist in a continuum of solid states ranging from fully amorphous to fully crystalline. They may be obtained, for example, as solid plugs, powders, or films by methods such as precipitation, crystallization, freeze drying, spray drying, or evaporative drying. Microwave or radio frequency drying may be used for this purpose.
  • They may be administered alone or in combination with one or more other compounds of the invention or in combination with one or more other drugs (or as any combination thereof). Generally, they will be administered as a formulation in association with one or more pharmaceutically acceptable excipients. The term ‘excipient’ is used herein to describe any ingredient other than the compound(s) of the invention. The choice of excipient will to a large extent depend on factors such as the particular mode of administration, the effect of the excipient on solubility and stability, and the nature of the dosage form.
  • In another aspect the invention provides a pharmaceutical composition comprising a compound of the invention together with one or more pharmaceutically acceptable excipients.
  • Pharmaceutical compositions suitable for the delivery of compounds of the present invention and methods for their preparation will be readily apparent to those skilled in the art. Such compositions and methods for their preparation may be found, for example, in “Remington's Pharmaceutical Sciences”, 19th Edition (Mack Publishing Company, 1995).
  • Suitable modes of administration include oral, parenteral, topical, inhaled/intranasal, rectal/intravaginal, and ocular/aural administration.
  • Formulations suitable for the aforementioned modes of administration may be formulated to be immediate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
  • The compounds of the invention may be administered orally. Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, or buccal or sublingual administration may be employed by which the compound enters the blood stream directly from the mouth. Formulations suitable for oral administration include solid formulations such as tablets, capsules containing particulates, liquids, or powders, lozenges (including liquid-filled), chews, multi- and nano-particulates, gels, solid solution, liposome, films, ovules, sprays, liquid formulations and buccal/mucoadhesive patches.
  • Liquid formulations include suspensions, solutions, syrups and elixirs. Such formulations may be employed as fillers in soft or hard capsules and typically comprise a carrier, for example, water, ethanol, polyethylene glycol, propylene glycol, methylcellulose, or a suitable oil, and one or more emulsifying agents and/or suspending agents. Liquid formulations may also be prepared by the reconstitution of a solid, for example, from a sachet.
  • The compounds of the invention may also be used in fast-dissolving, fast-disintegrating dosage forms such as those described in Expert Opinion in Therapeutic Patents, 11 (6), 981-986, by Liang and Chen (2001).
  • For tablet dosage forms, depending on dose, the drug may make up from 1 weight % to 80 weight % of the dosage form, more typically from 5 weight % to 60 weight % of the dosage form. In addition to the drug, tablets generally contain a disintegrant. Examples of disintegrants include sodium starch glycolate, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, croscarmellose sodium, crospovidone, polyvinylpyrrolidone, methyl cellulose, microcrystalline cellulose, lower alkyl-substituted hydroxypropyl cellulose, starch, pregelatinised starch and sodium alginate. Generally, the disintegrant will comprise from 1 weight % to 25 weight %, preferably from 5 weight % to 20 weight % of the dosage form.
  • Binders are generally used to impart cohesive qualities to a tablet formulation. Suitable binders include microcrystalline cellulose, gelatin, sugars, polyethylene glycol, natural and synthetic gums, polyvinylpyrrolidone, pregelatinised starch, hydroxypropyl cellulose and hydroxypropyl methylcellulose. Tablets may also contain diluents, such as lactose (monohydrate, spray-dried monohydrate, anhydrous and the like), mannitol, xylitol, dextrose, sucrose, sorbitol, microcrystalline cellulose, starch and dibasic calcium phosphate dihydrate.
  • Tablets may also optionally comprise surface active agents, such as sodium lauryl sulfate and polysorbate 80, and glidants such as silicon dioxide and talc. When present, surface active agents may comprise from 0.2 weight % to 5 weight % of the tablet, and glidants may comprise from 0.2 weight % to 1 weight % of the tablet.
  • Tablets also generally contain lubricants such as magnesium stearate, calcium stearate, zinc stearate, sodium stearyl fumarate, and mixtures of magnesium stearate with sodium lauryl sulphate. Lubricants generally comprise from 0.25 weight % to 10 weight %, preferably from 0.5 weight % to 3 weight % of the tablet. Other possible ingredients include anti-oxidants, colourants, flavouring agents, preservatives and taste-masking agents.
  • Exemplary tablets contain up to about 80% drug, from about 10 weight % to about 90 weight % binder, from about 0 weight % to about 85 weight % diluent, from about 2 weight % to about 10 weight % disintegrant, and from about 0.25 weight % to about 10 weight % lubricant. Tablet blends may be compressed directly or by roller to form tablets. Tablet blends or portions of blends may alternatively be wet-, dry-, or melt-granulated, melt congealed, or extruded before tabletting. The final formulation may comprise one or more layers and may be coated or uncoated; it may even be encapsulated. The formulation of tablets is discussed in “Pharmaceutical Dosage Forms: Tablets”, Vol. 1, by H. Lieberman and L. Lachman (Marcel Dekker, New York, 1980).
  • Suitable modified release formulations for the purposes of the invention are described in U.S. Pat. No. 6,106,864. Details of other suitable release technologies such as high energy dispersions and osmotic and coated particles are to be found in “Pharmaceutical Technology On-line”, 25(2), 1-14, by Verma et al (2001). The use of chewing gum to achieve controlled release is described in WO 00/35298.
  • The compounds of the invention may also be administered directly into the blood stream, into muscle, or into an internal organ. Suitable means for parenteral administration include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular and subcutaneous. Suitable devices for parenteral administration include needle (including microneedle) injectors, needle-free injectors and infusion techniques.
  • Parenteral formulations are typically aqueous solutions which may contain excipients such as salts, carbohydrates and buffering agents (preferably to a pH of from 3 to 9), but, for some applications, they may be more suitably formulated as a sterile non-aqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as sterile, pyrogen-free water.
  • The preparation of parenteral formulations under sterile conditions, for example, by lyophilisation, may readily be accomplished using standard pharmaceutical techniques well known to those skilled in the art.
  • The solubility of compounds of formula (I) used in the preparation of parenteral solutions may be increased by the use of appropriate formulation techniques, such as the incorporation of solubility-enhancing agents. Formulations for parenteral administration may be formulated to be immediate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release. Thus compounds of the invention may be formulated as a solid, semi-solid, or thixotropic liquid for administration as an implanted depot providing modified release of the active compound. Examples of such formulations include drug-coated stents and poly(dl-lactic-coglycolic)acid (PGLA) microspheres.
  • The compounds of the invention may also be administered topically to the skin or mucosa, that is, dermally or transdermally. Typical formulations for this purpose include gels, hydrogels, lotions, solutions, creams, ointments, dusting powders, dressings, foams, films, skin patches, wafers, implants, sponges, fibres, bandages and microemulsions. Liposomes may also be used. Typical carriers include alcohol, water, mineral oil, liquid petrolatum, white petrolatum, glycerin, polyethylene glycol and propylene glycol. Penetration enhancers may be incorporated—see, for example, J Pharm Sci, 88 (10), 955-958, by Finnin and Morgan (October 1999).
  • Other means of topical administration include delivery by electroporation, iontophoresis, phonophoresis, sonophoresis and microneedle or needle-free (e.g. Powderject™, Bioject™, etc.) injection.
  • The compounds of the invention can also be administered intranasally or by inhalation, typically in the form of a dry powder (either alone, as a mixture, for example, in a dry blend with lactose, or as a mixed component particle, for example, mixed with phospholipids, such as phosphatidylcholine) from a dry powder inhaler or as an aerosol spray from a pressurised container, pump, spray, atomiser (preferably an atomiser using electrohydrodynamics to produce a fine mist), or nebuliser, with or without the use of a suitable propellant, such as 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoropropane. For intranasal use, the powder may comprise a bioadhesive agent, for example, chitosan or cyclodextrin.
  • The pressurised container, pump, spray, atomizer, or nebuliser contains a solution or suspension of the compound(s) of the invention comprising, for example, ethanol, aqueous ethanol, or a suitable alternative agent for dispersing, solubilising, or extending release of the active, a propellant(s) as solvent and an optional surfactant, such as sorbitan trioleate, oleic acid, or an oligolactic acid.
  • Prior to use in a dry powder or suspension formulation, the drug product is micronised to a size suitable for delivery by inhalation (typically less than 5 microns). This may be achieved by any appropriate comminuting method, such as spiral jet milling, fluid bed jet milling, supercritical fluid processing to form nanoparticles, high pressure homogenisation, or spray drying.
  • Capsules (made, for example, from gelatin or hydroxypropylmethylcellulose), blisters and cartridges for use in an inhaler or insufflator may be formulated to contain a powder mix of the compound of the invention, a suitable powder base such as lactose or starch and a performance modifier such as 1-leucine, mannitol, or magnesium stearate. The lactose may be anhydrous or in the form of the monohydrate, preferably the latter. Other suitable excipients include dextran, glucose, maltose, sorbitol, xylitol, fructose, sucrose and trehalose.
  • A suitable solution formulation for use in an atomiser using electrohydrodynamics to produce a fine mist may contain from 1 μg to 20 mg of the compound of the invention per actuation and the actuation volume may vary from 1 μl to 100 μl. A typical formulation may comprise a compound of formula (I), propylene glycol, sterile water, ethanol and sodium chloride. Alternative solvents which may be used instead of propylene glycol include glycerol and polyethylene glycol.
  • Suitable flavours, such as menthol and levomenthol, or sweeteners, such as saccharin or saccharin sodium, may be added to those formulations of the invention intended for inhaled/intranasal administration.
  • In the case of dry powder inhalers and aerosols, the dosage unit is determined by means of a valve which delivers a metered amount. Units in accordance with the invention are typically arranged to administer a metered dose or “puff” containing from 1 μg to 100 mg of the compound of formula (I). The overall daily dose will typically be in the range 1 μg to 200 mg which may be administered in a single dose or, more usually, as divided doses throughout the day.
  • The compounds of the invention may be administered rectally or vaginally, for example, in the form of a suppository, pessary, microbicide, vaginal ring or enema. Cocoa butter is a traditional suppository base, but various alternatives may be used as appropriate.
  • The compounds of the invention may also be administered directly to the eye or ear, typically in the form of drops of a micronised suspension or solution in isotonic, pH-adjusted, sterile saline. Other formulations suitable for ocular and aural administration include ointments, biodegradable (e.g. absorbable gel sponges, collagen) and non-biodegradable (e.g. silicone) implants, wafers, lenses and particulate or vesicular systems, such as niosomes or liposomes. A polymer such as crossed-linked polyacrylic acid, polyvinylalcohol, hyaluronic acid, a cellulosic polymer, for example, hydroxypropylmethylcellulose, hydroxyethylcellulose, or methyl cellulose, or a heteropolysaccharide polymer, for example, gelan gum, may be incorporated together with a preservative, such as benzalkonium chloride. Such formulations may also be delivered by iontophoresis.
  • The compounds of the invention may be combined with soluble macromolecular entities, such as cyclodextrin and suitable derivatives thereof or polyethylene glycol-containing polymers, in order to improve their solubility, dissolution rate, taste-masking, bioavailability and/or stability for use in any of the aforementioned modes of administration.
  • Drug-cyclodextrin complexes, for example, are found to be generally useful for most dosage forms and administration routes. Both inclusion and non-inclusion complexes may be used. As an alternative to direct complexation with the drug, the cyclodextrin may be used as an auxiliary additive, i.e. as a carrier, diluent, or solubiliser. Most commonly used for these purposes are alpha-, beta- and gamma-cyclodextrins, examples of which may be found in International Patent Applications Nos. WO 91/11172, WO 94/02518 and WO 98/55148.
  • For administration to human patients, the total daily dose of the compounds of the invention is typically in the range 1 mg to 10 g, such as 10 mg to 1 g, for example 25 mg to 500 mg depending, of course, on the mode of administration and efficacy. For example, oral administration may require a total daily dose of from 50 mg to 100 mg. The total daily dose may be administered in single or divided doses and may, at the physician's discretion, fall outside of the typical range given herein. These dosages are based on an average human subject having a weight of about 60 kg to 70 kg. The physician will readily be able to determine doses for subjects whose weight falls outside this range, such as infants and the elderly.
  • As noted above, the compounds of the invention are useful because they exhibit pharmacological activity in animals, i.e., URAT-1 inhibition. More particularly, the compounds of the invention are of use in the treatment of disorders for which a URAT-1 inhibitor is indicated. Preferably the animal is a mammal, more preferably a human.
  • In a further aspect of the invention there is provided a compound of the invention for use as a medicament.
  • In a further aspect of the invention there is provided a compound of the invention for the treatment of a disorder for which a URAT-1 inhibitor is indicated.
  • In a further aspect of the invention there is provided use of a compound of the invention for the preparation of a medicament for the treatment of a disorder for which a URAT-1 inhibitor is indicated.
  • In a further aspect of the invention there is provided a method of treating a disorder in an animal (preferably a mammal, more preferably a human) for which a URAT-1 inhibitor is indicated, comprising administering to said animal a therapeutically effective amount of a compound of the invention.
  • Disorders for which a URAT-1 inhibitor is indicated include diseases associated with high levels of uric acid in humans and other mammals including (but not limited to) hyperuricemia, asymptomatic hyperuricemia, gout (including juvenile forms), gouty arthritis, inflammatory arthritis, joint inflammation, deposition of urate crystals in the joint, tophaceous gout, chronic kidney disease, nephrolithiasis (kidney stones), Lesch-Nyhan syndrome and Kelley-Seegmiller syndrome.
  • Hyperuricemia may be defined by blood uric acid levels over 6.8 mg/dL. Guidelines for the management of hyperuricemia recommend that therapies aimed at lowering blood uric acid levels should be maintained until such blood uric acid levels are lowered to below 6.0 mg/dL, such as below 5.0 mg/dL.
  • The skilled person will appreciate that while by definition without symptoms, asymptomatic hyperuricemia may nevertheless lead to the onset of diseases associated with high levels of uric acid.
  • The skilled person will also appreciate that the compounds of formula (I) may be used in the treatment of hyperuricemia where this is present together with one or more other diseases, such as kidney failure, type 2 diabetes, cardiovascular disease (e.g. hypertension, myocardial infarction, heart failure, coronary artery disease, cerebrovascular disease, atherosclerosis, angina, aneurism, hyperlipidemia and stroke), obesity, metabolic syndrome, myeloproliferative disorders, lymphoproliferative disorders and disorders associated with certain medications, such as a diuretic (e.g. a thiazide), an immunosuppressant (e.g. a cyclosporine therapy), a chemotherapeutic agent (e.g. cisplatin) or aspirin.
  • The skilled person will also appreciate that the compounds of formula (I) may be used in the treatment of hyperuricemia where this is present following organ transplant.
  • A URAT-1 inhibitor may be usefully combined with another pharmacologically active compound, or with two or more other pharmacologically active compounds, particularly in the treatment of a disease associated with elevated blood uric acid levels. Such combinations offer the possibility of significant advantages, including patient compliance, ease of dosing and synergistic activity.
  • In the combinations that follow the compound of the invention may be administered simultaneously, sequentially or separately in combination with the other therapeutic agent or agents.
  • The compounds of formula (I) may be administered in combination with one or more additional therapeutic agents. Agents of interest include those that also lower blood uric acid levels. Other agents of interest include those that reduce inflammation or pain. The one or more additional therapeutic agents may be selected from any of the agents or types of agent that follow:
      • a xanthine oxidase inhibitor (e.g. allopurinol, febuxostat or tisopurine);
      • a purine nucleoside phosphorylase (PNP) inhibitor (e.g. ulodesine);
      • a uricase (e.g. pegloticase or rasburicase);
      • a uricosuric, such as an agent that inhibits one or more transporters responsible for reabsorption of uric acid back into the blood at renal or intestinal sites, for example another URAT1 inhibitor (e.g. benzbromarone, PN2107 or RDEA3170); a glucose transporter (GLUT) inhibitor, such as a GLUTS inhibitor; an organic anion transporter (OAT) inhibitor, such as an OAT4 inhibitor or an OAT10 inhibitor; or an agent which inhibits one or more of the above transporters, such as benziodarone; isobromindione, probenecid, sulphinpyrazone, arhalofenate, tranilast, lesinurad or KUX-1151;
      • an agent that otherwise exerts blood uric acid lowering effects, such as amlodipine, atorvastatin, fenofibrate or indomethacin;
      • an anti-inflammatory drug such as an NSAID (e.g. celecoxib), colchicine, a steroid, an interleukin 1 inhibitor (e.g. rilonacept) or an agent that modulates inflammosome signaling cascades (e.g. an IRAK4 inhibitor); or
      • an agent that reduces pain, such as an ion channel modulator (e.g. an inhibitor of Nav1.7, TRPV1 or TRPM2).
  • There is also included within the scope the present invention combinations of a compound of the invention together with one or more additional therapeutic agents which slow down the rate of metabolism of the compound of the invention, thereby leading to increased exposure in patients. Increasing the exposure in such a manner is known as boosting. This has the benefit of increasing the efficacy of the compound of the invention or reducing the dose required to achieve the same efficacy as an unboosted dose. The metabolism of the compounds of the invention includes oxidative processes carried out by P450 (CYP450) enzymes, particularly CYP 3A4 and conjugation by UDP glucuronosyl transferase and sulphating enzymes. Thus, among the agents that may be used to increase the exposure of a patient to a compound of the present invention are those that can act as inhibitors of at least one isoform of the cytochrome P450 (CYP450) enzymes. The isoforms of CYP450 that may be beneficially inhibited include, but are not limited to, CYP1A2, CYP2D6, CYP2C9, CYP2C19 and CYP3A4. Suitable agents that may be used to inhibit CYP 3A4 include ritonavir, saquinavir, ketoconazole, N-(3,4-difluorobenzyl)-N-methyl-2-{[(4-methoxypyridin-3-yl)amino]sulfonyl}benzamide and N-(1-(2-(5-(4-fluorobenzyl)-3-(pyridin-4-yl)-1H-pyrazol-1-yl)acetyl)piperidin-4-yl)methanesulfonamide.
  • It is within the scope of the invention that two or more pharmaceutical compositions, at least one of which contains a compound of the invention, may conveniently be combined in the form of a kit suitable for coadministration of the compositions. Thus the kit of the invention comprises two or more separate pharmaceutical compositions, at least one of which contains a compound of the invention, and means for separately retaining said compositions, such as a container, divided bottle, or divided foil packet. An example of such a kit is the familiar blister pack used for the packaging of tablets, capsules and the like. The kit of the invention is particularly suitable for administering different dosage forms, for example, oral and parenteral, for administering the separate compositions at different dosage intervals, or for titrating the separate compositions against one another. To assist compliance, the kit typically comprises directions for administration and may be provided with a so-called memory aid.
  • In another aspect the invention provides a pharmaceutical product (such as in the form of a kit) comprising a compound of the invention together with one or more additional therapeutically active agents as a combined preparation for simultaneous, separate or sequential use in the treatment of a disorder for which a URAT-1 inhibitor is indicated.
  • It is to be appreciated that all references herein to treatment include curative, palliative and prophylactic treatment.
  • The invention is further illustrated by the non-limiting Examples and Preparations that follow (for the avoidance of doubt, those compounds marked as Reference Examples do not fall within formula (I)).
  • In these non-limiting Examples and Preparations, and in the aforementioned Schemes, the following abbreviations, definitions and analytical procedures may be referred to:
  • AcOH is acetic acid;
    nBuOH is n-butanol
    Cu(acac)2 is copper (II) acetylacetonate;
    Cu(OAc)2 is copper (II) acetate;
    DABCO is 1,4-diazabicyclo[2,2,2]octane
    DAD is diode array detector;
    DCM is dichloromethane; methylene chloride;
    DEA is diethylamine
    DIP-CI is chlorodiisopinocampheylborane;
    • DIPEA is N-ethyldiisopropylamine, N,N-diisopropylethylamine;
  • DMAP is 4-dimethylaminopyridine;
    • DMF is N,N-dimethylformamide;
  • DMSO is dimethyl sulphoxide;
    EDCl is 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride;
    EDTA is ethylenediaminetetraacetic acid;
    ELSD is evaporative light scattering detection;
    Et2O is diethyl ether;
    EtOAc is ethyl acetate;
    EtOH is ethanol;
    HPLC is high-performance liquid chromatography
    IPA is isopropanol;
    Ir2(OMe)2COD2 is bis(1,5-cyclooctadiene)di-p-methoxydiiridium (I);
    KOAc is potassium acetate;
    K3PO4 is potassium phosphate tribasic;
    LCMS is liquid chromatography mass spectrometry (Rt=retention time)
    Me is methyl
    MeOH is methanol;
    MS is mass spectrometry
    • NMM is N-methylmorpholine
  • NMP is N-Methyl-2-pyrrolidone;
    Pd/C is palladium on carbon;
    Pd(PPh3)4 is palladium tetrakis;
    Pd(dppf)2Cl2 is [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane;
    TBAF is tetra-n-butylammonium fluoride
    TBME is tert-butyl methyl ether;
    TFA is trifluoroacetate;
    THF is tetrahydrofuran;
    THP is tetrahydropyran;
    TLC is thin layer chromatography;
    UV is ultraviolet; and
    WSCDI is 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride.
  • 1H and 19F Nuclear magnetic resonance (NMR) spectra were in all cases consistent with the proposed structures. Characteristic chemical shifts (δ) are given in parts-per-million downfield from tetramethylsilane (for 1H-NMR) and upfield from trichloro-fluoro-methane (for 19F NMR) using conventional abbreviations for designation of major peaks: e.g. s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad. The following abbreviations have been used for common solvents: CDCl3, deuterochloroform; d6-DMSO, deuterodimethylsulphoxide; and CD3OD, deuteromethanol.
  • Mass spectra, MS (m/z), were recorded using either electrospray ionisation (ESI) or atmospheric pressure chemical ionisation (APCI). Where relevant and unless otherwise stated the m/z data provided are for isotopes 19F, 35Cl, 79Br and 127I.
  • LCMS conditions:
    • System 1
  • A: 0.1% formic acid in water
    B: 0.1% formic acid in acetonitrile
    Column: C18 phase Phenomenex 20×4.0 mm with 3 micron particle size
    Gradient: 98-2% or 98-10% A over 1.5 min, 0.3 min hold, 0.2 re-equilibration, 1.8
    mL/min flow rate
    UV: 210 nm-450 nm DAD
    • Temperature: 75° C. System 2
  • A: 0.1% formic acid in water
    B: 0.1% formic acid in acetonitrile
    Using either:
    Column: Agilent Extend C18 phase 50×3 mm with 3 micron particle size
    Gradient: 95-0% A over 3.5 min, 1 min hold, 0.4 min re-equilibration, 1.2 mL/min flow rate
  • Or
  • Column: C18 phase Waters Sunfire 50×4.6 mm with 5 micron particle size
    Gradient: 95-5% A over 3 min, 1 min hold, 2 min re-equilibration, 1 mL/min flow rate
    UV: 210 nm-450 nm DAD
    • Temperature: 50° C. System 3
  • A: 10 mM Ammonium Acetate in water (basic Buffer)
    • B: Acetonitrile
  • Column: Xbridge C18 4.6×50 mm with 5 micron particle size
    Gradient: from 90% [Buffer] and 10% [MeCN] to 70% [Buffer] and 30% [MeCN] in 1.5 min, further to 10% [buffer] and 90% [MeCN] in 3.0 min, held for 4 min and back to initial condition in 5 min),
    1.2 mL/minflow rate
    • UV: 220 nm Temperature: 25° C. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS Example 1 4-(3-chloro-4-cyanophenoxy)-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide
  • Figure US20150259327A1-20150917-C00007
  • 3-Cyano-4-fluoro-N-(5-fluoropyridin-2-yl)benzenesulfonamide (Preparation 2, 10.5 g, 35.6 mmol) was added to a solution of 2-chloro-4-hydroxybenzonitrile (8.19 g, 53.3 mmol) and potassium carbonate (14.74 g, 106.7 mmol) in dimethylsulfoxide (100 mL) at room temperature. The resulting mixture was stirred at 80° C. for 44 hours. On cooling, the reaction mixture was poured into saturated aqueous sodium hydrogen carbonate solution (200 mL) and ethyl acetate (1000 mL) was added. The aqueous layer was separated and the organic layer was washed with saturated aqueous sodium hydrogen carbonate solution (3×200 mL), water (2×200 mL) and brine (2×200 mL). The organic layer was dried over sodium sulphate, filtered and concentrated in vacuo. The residue was purified by reverse phase column chromatography eluting with acetonitrile (containing 0.1% HCO2H): water (containing 0.1% HCO2H) from 0 to 100% to afford the title compound as a white solid (6.982 g, 46%).
  • 1H NMR (400 MHz, DMSO-d6): δ ppm 7.09 (dd, 1H), 7.28 (d, 1H), 7.44 (dd, 1H), 7.68 (td, 1H), 7.81 (d, 1H), 8.09-8.15 (m, 2H), 8.19 (d, 1H), 8.41 (d, 1H), 11.30 (br s, 1H).
  • 19 F NMR (400 MHz, DMSO-d6): δ ppm −134 MS m/z 427 [M−H]−
    • General Method:
  • Figure US20150259327A1-20150917-C00008
  • Wherein R1, R2, R3, R4, R5 and R6 are as previously defined for a compound of formula (I), unless otherwise stated, and PG (where present) is a suitable amino protecting group, such as methoxymethyl or dimethoxybenzyl.
    • a) To a solution of a compound of formula (IV) was added an inorganic base (as specifically described in the Method Variations below), followed by a compound of formula (II). The reaction mixture was: cooled, kept at room temperature or heated, as required.
  • The reaction mixture was diluted with water, or an aqueous solution of an inorganic acid such as saturated aqueous ammonium chloride or 2N HCl, or an aqueous solution of an inorganic base such as 1N NaOH; extracted into a solvent such as DCM or EtOAc; dried over a drying agent such as MgSO4 or Na2SO4; and concentrated in vacuo to afford a residue. Alternatively, the reaction was concentrated in vacuo directly. The residue was purified as necessary.
    • b) Where required, the residue was deprotected using an acid such as TFA or HCl in dioxane/DCM, to afford the compound of formula (I).
    Method Variations (MV):
    • Method 1: a) Unprotected compound (II), K2CO3 in DMSO at 80-100° C. for 48 hours.
    • Method 2: a) Unprotected compound (II), K2CO3 in DMF at 90° C. for 24 hours.
    • Method 3: a) Methoxymethyl protected compound (II), K2CO3 in DMSO at 80-100° C. for 24 hours. Deprotection occurs under the conditions for effecting the nucleophilic aromatic substitution.
    • Method 4: a) Methoxymethyl protected compound (II), K2CO3 or Cs2CO3 in DMSO at from room temperature to 100° C. for 18 hours.
      • b) Followed by deprotection with 4M HCl in dioxane or TFA at room temperature for 18 hours.
    • Method 5: a) Dimethoxybenzyl protected compound (II), K2CO3 in DMSO at from room temperature to 60° C. for 18 hours.
      • b) Followed by deprotection with 4M HCl in dioxane or TFA at room temperature for 18 hours.
    • Method 6: a) Unprotected compound (II), Cs2Co3 in DMSO at 80-100° C. for 48 hours.
    • Method 7: a) Dimethoxybenzyl protected compound (II), K3PO4 in DMSO at 80° C. for 18 hours.
      • b) Followed by deprotection with 4M HCl in dioxane at room temperature for 18 hours.
    Purification Methods (PM): Purification Method A: Preparative HPLC
  • For compounds of the Examples prepared as singletons (i.e. other than via the Library Protocols described hereinafter), one of two preparative HPLC methods was used, as shown below:
    • Acidic Conditions
  • Column Gemini NX C18, 5 um 21.2 × 100 mm
    Temperature Ambient
    Detection ELSD-MS
    Mobile Phase A 0.1% formic acid in water
    Mobile Phase B 0.1% formic acid in acetonitrile
    Gradient initial 0% B, 1 mins- 5% B; 7 mins - 98% B;
    9 mins - 98% B; 9.1 mins - 5% B; 10 mins - 5% B
    Flow rate 18 mL/min
    Injection volume 1000 uL
    • Basic Conditions
  • Column Gemini NX C18, 5 um 21.2 × 100 mm
    Temperature Ambient
    Detection ELSD-MS
    Mobile Phase A 0.1% diethylamine in water
    Mobile Phase B 0.1% diethylamine in acetonitrile
    Gradient initial 0% B, 1 mins- 5% B; 7 mins - 98% B;
    9 mins - 98% B; 9.1 mins - 5% B; 10 mins - 5% B
    Flowrate 18 mL/min
    Injection volume 1000 uL

    Purification Method B: Silica gel column chromatography eluting with:
    • i) 95:5 DCM:EtOAc;
  • ii) 12-75% EtOAc in heptanes;
    iii) 1:1 TBME:Heptanes; or
    • iv) 0-1% MeOH in DCM.
  • Purification Method C: Reverse phase column chromatography using:
    • Column: Phenomenex Luna C18 5u 110A 21.2×150 mm
  • Detection @ 254 nm, threshold 25 mV
    Solvent system:
      • A: 0.05% formic acid in water, B: 0.05% formic acid in acetonitrile, 0 min 95% A, 2.25 min 95% A, 17.5 min 95% B, 22.5 min 95% B;
      • Between 5-60% MeCN in water; or
      • −85% A to 100% B over 25 minutes, where mobile phase A is water:MeCN:TFA 7800:200:8 and mobile phase B is MeCN:water:TFA 7200:800:8.
        Purification Method D: Trituration with MeOH and/or DCM or EtOAc.
        Purification Method E: Reverse phase silica gel column chromatography eluting with (0.1% formic acid in MeCN): (0.1% formic acid in water) from 0-100%.
  • Unless stated otherwise, the compounds of the Examples in the table below were prepared from 3-cyano-4-fluoro-N-(5-fluoropyridin-2-yl)benzenesulfonamide (Preparation 2) and the appropriate phenol according to Method Variation 1 (MV1), and then purified according to Purification Method A (PM A).
  • MS Data
    Ex Name Phenol (MV, PM)
    2 3-cyano-4-(3-ethylphenoxy)-N-(5- 3-ethylphenol m/z 396
    fluoropyridin-2-yl)benzenesulfonamide [M − H]−
    formate salt
    3 3-cyano-4-(2,3-dichlorophenoxy)-N-(5- 2,3-dichlorophenol m/z 438
    fluoropyridin-2-yl)benzenesulfonamide [M + H]+
    formate salt
    4 3-cyano-N-(5-fluoropyridin-2-yl)-4-[2-fluoro-5- 2-fluoro-5- m/z 456
    (trifluoromethyl)phenoxy]benzenesulfonamide trifluoromethyl- [M + H]+
    phenol
    5 4-(4-chloro-2-methylphenoxy)-3-cyano-N-(5- 4-chloro-2- m/z 416
    fluoropyridin-2-yl)benzenesulfonamide methylphenol [M − H]−
    formate salt
    6 3-cyano-4-[4-cyano-3- 4-cyano-3- m/z 463
    (trifluoromethyl)phenoxy]-N-(5-fluoropyridin-2- trifluoromethyl [M + H]+
    yl)benzenesulfonamide formate salt phenol
    7 3-cyano-4-(2,4-difluorophenoxy)-N-(5- 2,4-difluorophenol m/z 406
    fluoropyridin-2-yl)benzenesulfonamide [M + H]+
    formate salt
    8 3-cyano-4-(3-fluoro-5-methoxyphenoxy)-N-(5- 3-fluoro-5- m/z 418
    fluoropyridin-2-yl)benzenesulfonamide methoxyphenol [M + H]+
    formate salt
    9 4-(2-chlorophenoxy)-3-cyano-N-(5- 2-chlorophenol m/z 404
    fluoropyridin-2-yl)benzenesulfonamide [M + H]+
    formate salt
    10 3-cyano-4-(4-cyanophenoxy)-N-(5- 4-cyanophenol m/z 395
    fluoropyridin-2-yl)benzenesulfonamide [M + H]+
    diethylamine salt
    11 3-cyano-4-(3,5-difluorophenoxy)-N-(5- 3,5-difluorophenol m/z 406
    fluoropyridin-2-yl)benzenesulfonamide [M + H]+
    formate salt
    12 3-cyano-4-(4-cyano-2-fluorophenoxy)-N-(5- 4-cyano-2- m/z 825
    fluoropyridin-2-yl)benzenesulfonamide fluorophenol [2M + H]+
    diethylamine salt
    13 3-cyano-4-(2,4-dichlorophenoxy)-N-(5- 2,4-dichlorophenol m/z 875
    fluoropyridin-2-yl)benzenesulfonamide [2M + H]+
    diethylamine salt
    14 3-cyano-4-(3-cyanophenoxy)-N-(5- 3-cyanophenol m/z 395
    fluoropyridin-2-yl)benzenesulfonamide [M + H]+
    formate salt
    15 4-(3-chloro-5-methylphenoxy)-3-cyano-N-(5- 3-chloro-5- m/z 418
    fluoropyridin-2-yl)benzenesulfonamide methylphenol [M + H]+
    diethylamine salt
    16 3-cyano-4-(2,3-difluorophenoxy)-N-(5- 2,3-difluorophenol m/z 406
    fluoropyridin-2-yl)benzenesulfonamide [M + H]+
    formate salt
    17 3-cyano-4-(2-cyanophenoxy)-N-(5- 2-cyanophenol m/z 789
    fluoropyridin-2-yl)benzenesulfonamide [2M + H]+
    formate salt
    18 3-cyano-N-(5-fluoropyridin-2-yl)-4-[3- 3- m/z 454
    (trifluoromethoxy)phenoxy]benzenesulfonamide (trifluoromethoxy)phenol [M + H]+
    formate salt
    19 3-cyano-4-(3-cyano-4-fluorophenoxy)-N-(5- 3-cyano-4- m/z 413
    fluoropyridin-2-yl)benzenesulfonamide fluorophenol [M + H]+
    formate salt
    20 4-(4-chlorophenoxy)-3-cyano-N-(5- 4-chlorophenol m/z 404
    fluoropyridin-2-yl)benzenesulfonamide [M + H]+
    formate salt
    21 3-cyano-4-(5-fluoro-2-methylphenoxy)-N-(5- 5-fluoro-2- m/z 402
    fluoropyridin-2-yl)benzenesulfonamide methylphenol [M + H]+
    formate salt
    22 4-(3-chloro-4-methylphenoxy)-3-cyano-N-(5- 3-chloro-4- m/z 418
    fluoropyridin-2-yl)benzenesulfonamide methylphenol [M + H]+
    diethylamine salt
    23 3-cyano-N-(5-fluoropyridin-2-yl)-4-[3- 3-(trifluoromethyl)phenol m/z 438
    (trifluoromethyl)phenoxy]benzenesulfonamide [M + H]+
    formate salt
    24 4-(3-chloro-2-fluorophenoxy)-3-cyano-N-(5- 3-chloro-2- m/z 422
    fluoropyridin-2-yl)benzenesulfonamide fluorophenol [M + H]+
    formate salt
    25 4-(3-chlorophenoxy)-3-cyano-N-(5- 3-chlorophenol m/z 404
    fluoropyridin-2-yl)benzenesulfonamide [M + H]+
    diethylamine salt
    26 4-(2-chloro-5-cyano-4-methylphenoxy)-3- 2-chloro-5-cyano- m/z 443
    cyano-N-(5-fluoropyridin-2- 4-methylphenol [M + H]+
    yl)benzenesulfonamide
    formate salt
    27 3-cyano-N-(5-fluoropyridin-2-yl)-4-[2- 2- m/z 454
    (trifluoromethoxy)phenoxy]benzenesulfonamide (trifluoromethoxy)phenol [M + H]+
    diethylamine salt
    28 4-(3-chloro-5-fluorophenoxy)-3-cyano-N-(5- 3-chloro-5- m/z 422
    fluoropyridin-2-yl)benzenesulfonamide fluorophenol [M + H]+.
    diethylamine salt
    29 3-cyano-N-(5-fluoropyridin-2-yl)-4-[2-fluoro-3- 2-fluoro-3- m/z 456
    (trifluoromethyl)phenoxy]benzenesulfonamide (trifluoromethyl)phenol [M + H]+
    diethylamine salt
    30 4-(2-chloro-4-cyanophenoxy)-3-cyano-N-(5- 2-chloro-4- m/z 429
    fluoropyridin-2-yl)benzenesulfonamide cyanophenol [M + H]+
    diethylamine salt
    31 4-(2-chloro-4-fluorophenoxy)-3-cyano-N-(5- 2-chloro-4- m/z 422
    fluoropyridin-2-yl)benzenesulfonamide fluorophenol [M + H]+
    32 4-(2-chloro-3,5-difluorophenoxy)-3-cyano-N- 2-chloro-3,5- m/z 440
    (5-fluoropyridin-2-yl)benzenesulfonamide difluorophenol [M + H]+
    formate salt
    33 3-cyano-4-(2-fluoro-5-methylphenoxy)-N-(5- 2-fluoro-5- m/z 803
    fluoropyridin-2-yl)benzenesulfonamide methylphenol [2M + H]+
    formate salt
    34 4-(4-chloro-3-methylphenoxy)-3-cyano-N-(5- 4-chloro-3- m/z 418
    fluoropyridin-2-yl)benzenesulfonamide methylphenol [M + H]+
    formate salt
    35 3-cyano-N-(5-fluoropyridin-2-yl)-4-[4- 4- m/z 454
    (trifluoromethoxy)phenoxy]benzenesulfonamide (trifluoromethoxy)phenol [M + H]+
    formate salt
    36 3-cyano-4-(2-cyano-4-fluorophenoxy)-N-(5- 2-cyano-4- m/z 413
    fluoropyridin-2-yl)benzenesulfonamide fluorophenol [M + H]+
    diethylamine salt
    37 4-(2-chloro-5-methylphenoxy)-3-cyano-N-(5- 2-chloro-5- m/z 835
    fluoropyridin-2-yl)benzenesulfonamide methylphenol [2M + H]+
    formate salt
    38 3-cyano-4-(2,3-dichloro-4-fluorophenoxy)-N- 2,3-dichloro-4- m/z 456
    (5-fluoropyridin-2-yl)benzenesulfonamide fluorophenol [M + H]+
    formate salt
    39 4-(5-chloro-2-methylphenoxy)-3-cyano-N-(5- 5-chloro-2- m/z 418
    fluoropyridin-2-yl)benzenesulfonamide methylphenol [M + H]+
    formate salt
    40 3-cyano-N-(5-fluoropyridin-2-yl)-4-[3-fluoro-5- 3-fluoro-5- m/z 456
    (trifluoromethyl)phenoxy]benzenesulfonamide (trifluoromethyl)phenol [M + H]+
    formate salt
    41 3-cyano-4-(2-fluorophenoxy)-N-(5- 2-fluorophenol m/z 388
    fluoropyridin-2-yl)benzenesulfonamide [M + H]+
    formate salt
    42 4-(2-chloro-4-methylphenoxy)-3-cyano-N-(5- 2-chloro-4- m/z 418
    fluoropyridin-2-yl)benzenesulfonamide methylphenol [M + H]+
    formate salt
    43 3-cyano-4-(4-cyano-3-fluorophenoxy)-N-(5- 4-cyano-3- m/z 413
    fluoropyridin-2-yl)benzenesulfonamide fluorophenol [M + H]+
    diethylamine salt
    44 4-(2-chloro-5-methoxyphenoxy)-3-cyano-N- 2-chloro-5- m/z 434
    (5-fluoropyridin-2-yl)benzenesulfonamide methoxyphenol [M + H]+
    diethylamine salt
    45 4-(4-chloro-2-cyanophenoxy)-3-cyano-N-(5- 4-chloro-2- m/z 429
    fluoropyridin-2-yl)benzenesulfonamide cyanophenol [M + H]+
    formate salt
    46 3-cyano-4-(2-ethylphenoxy)-N-(5- 2-ethylphenol m/z 398
    fluoropyridin-2-yl)benzenesulfonamide [M + H]+
    diethylamine salt
    47 4-(4-chloro-2-fluorophenoxy)-3-cyano-N-(5- 4-chloro-2- m/z 422
    fluoropyridin-2-yl)benzenesulfonamide fluorophenol [M + H]+
    formate salt
    48 3-cyano-N-(5-fluoropyridin-2-yl)-4-[4-fluoro-3- 4-fluoro-3- m/z 456
    (trifluoromethyl)phenoxy]benzenesulfonamide (trifluoromethyl)phenol [M + H]+
    49 3-cyano-N-(5-fluoropyridin-2-yl)-4-[2-(propan- 2-(propan-2- m/z 412
    2-yl)phenoxy]benzenesulfonamide formate yl)phenol [M + H]+
    salt
    50 3-cyano-4-(4-ethylphenoxy)-N-(5- 4-ethylphenol m/z 398
    fluoropyridin-2-yl)benzenesulfonamide [M + H]+
    diethylamine salt
    51 3-cyano-N-(5-fluoropyridin-2-yl)-4-[2- 2-(trifluoromethyl)phenol m/z 438
    (trifluoromethyl)phenoxy]benzenesulfonamide [M + H]+
    formate salt
    52 3-cyano-4-(3-fluorophenoxy)-N-(5- 3-fluorophenol m/z 388
    fluoropyridin-2-yl)benzenesulfonamide [M + H]+
    formate salt
    53 3-cyano-4-(2,5-difluorophenoxy)-N-(5- 2,5-difluorophenol m/z 406
    fluoropyridin-2-yl)benzenesulfonamide [M + H]+
    formate salt
    54 3-cyano-N-(5-fluoropyridin-2-yl)-4-[4- 4-(trifluoromethyl)phenol m/z 438
    (trifluoromethyl)phenoxy]benzenesulfonamide [M + H]+
    formate salt
    55 4-(4-chloro-3-fluorophenoxy)-3-cyano-N-(5- 4-chloro-3- m/z 422
    fluoropyridin-2-yl)benzenesulfonamide fluorophenol [M + H]+
    56 3-cyano-4-(2-ethyl-4-fluorophenoxy)-N-(5- 2-ethyl-4- m/z 416
    fluoropyridin-2-yl)benzenesulfonamide fluorophenol [M + H]+PM B
    57 3-cyano-N-(5-fluoropyridin-2-yl)-4-[3-(propan- 3-(propan-2- m/z 412
    2-yl)phenoxy]benzenesulfonamide yl)phenol [M + H]+
    MV 2
    PM B
    58 4-(4-chloro-2-iodophenoxy)-3-cyano-N-(5- 4-chloro-2- m/z 530
    fluoropyridin-2-yl)benzenesulfonamide iodophenol [M + H]+
    (Reference Example) MV 2
    PM B
    59 3-cyano-4-(3-cyano-4-methylphenoxy)-N-(5- 3-cyano-4- m/z 409
    fluoropyridin-2-yl)benzenesulfonamide methylphenol [M + H]+
    PM B
    60 4-(4-chloro-3-cyanophenoxy)-3-cyano-N-(5- 4-chloro-3- m/z 429
    fluoropyridin-2-yl)benzenesulfonamide cyanophenol [M + H]+
    PM B
    61 3-cyano-4-(4-cyano-3-methylphenoxy)-N-(5- 4-cyano-3- m/z 407
    fluoropyridin-2-yl)benzenesulfonamide methylphenol [M − H]−
    PM B
    62 4-(3-chloro-5-cyanophenoxy)-3-cyano-N-(5- 3-chloro-5- m/z 429
    fluoropyridin-2-yl)benzenesulfonamide cyanophenol [M + H]+
    MV 6
    63 4-(2-chloro-5-cyanophenoxy)-3-cyano-N-(5- 2-chloro-5- m/z 429
    fluoropyridin-2-yl)benzenesulfonamide cyanophenol [M + H]+
    MV 6
    64 4-(2-chloro-3-cyanophenoxy)-3-cyano-N-(5- 2-chloro-3- m/z 427
    fluoropyridin-2-yl)benzenesulfonamide cyanophenol [M − H]−
    65 4-(5-chloro-2-cyanophenoxy)-3-cyano-N-(5- 5-chloro-2- m/z 427
    fluoropyridin-2-yl)benzenesulfonamide cyanophenol [M − H]−
    66 3-cyano-4-(3-cyano-4-methoxyphenoxy)-N- 3-cyano-4- m/z 423
    (5-fluoropyridin-2-yl)benzenesulfonamide methoxyphenol [M − H]−
    67 3-cyano-4-[4-cyano-2- 4-cyano-2- m/z 459
    (difluoromethoxy)phenoxy]-N-(5-fluoropyridin- (difluoromethoxy)phenol [M − H]−
    2-yl)benzenesulfonamide
    68 4-[(5-chloro-6-cyanopyridin-3-yl)oxy]-3-cyano- 5-chloro-6-cyanopyridin- m/z 430
    N-(5-fluoropyridin-2-yl)benzenesulfonamide 3-yl)ol [M + H]+
    (WO2011009943) PM B
    69 3-cyano-4-(5-cyano-2-fluorophenoxy)-N-(5- 5-cyano-2- m/z 413
    fluoropyridin-2-yl)benzenesulfonamide fluorophenol [M + H]+
    70 4-[(5-chloro-6-methoxypyridin-3-yl)oxy]-3- 5-chloro-6- m/z 433
    cyano-N-(5-fluoropyridin-2- methoxypyridin-3- [M − H]−
    yl)benzenesulfonamide yl)ol MV 5
    (from 3-cyano-N-(2,4-dimethoxybenzyl)-4- PM C
    fluoro-N-(5-fluoropyridin-2-
    yl)benzenesulfonamide)
    71 4-(4-chloro-3-methoxyphenoxy)-3-cyano-N- 4-chloro-3- m/z 434
    (5-fluoropyridin-2-yl)benzenesulfonamide methoxyphenol [M + H]+
    (from 3-cyano-N-(2,4-dimethoxybenzyl)-4- MV 5
    fluoro-N-(5-fluoropyridin-2-
    yl)benzenesulfonamide)
    72 3-cyano-4-(4-cyano-2,5-difluorophenoxy)-N- 4-cyano-2,5- m/z 431
    (5-fluoropyridin-2-yl)benzenesulfonamide difluorophenol [M + H]+
    (from 3-cyano-N-(2,4-dimethoxybenzyl)-4- MV 5
    fluoro-N-(5-fluoropyridin-2- PM B
    yl)benzenesulfonamide)
    73 4-(2-chloro-6-cyanophenoxy)-3-cyano-N-(5- 2-chloro-6- m/z 429
    fluoropyridin-2-yl)benzenesulfonamide cyanophenol [M + H]+
    (from 3-cyano-N-(2,4-dimethoxybenzyl)-4- MV 5
    fluoro-N-(5-fluoropyridin-2- PM B
    yl)benzenesulfonamide)
    74 4-[4-chloro-2-(difluoromethoxy)phenoxy]-3- 4-chloro-2- m/z 470
    cyano-N-(5-fluoropyridin-2- (difluoromethoxy)phenol [M + H]+
    yl)benzenesulfonamide MV 5
    (from 3-cyano-N-(2,4-dimethoxybenzyl)-4-
    fluoro-N-(5-fluoropyridin-2-
    yl)benzenesulfonamide)
    75 3-cyano-4-(3-cyano-2-fluorophenoxy)-N-(5- 3-cyano-2- m/z 413
    fluoropyridin-2-yl)benzenesulfonamide fluorophenol [M + H]+
    PM B
    76 3-cyano-4-(4-cyano-3-methoxyphenoxy)-N- 4-cyano-3- m/z 423
    (5-fluoropyridin-2-yl)benzenesulfonamide methoxyphenol [M − H]−
    77 3-cyano-4-(3,4-difluorophenoxy)-N-(5- 3,4-difluorophenol m/z 404
    fluoropyridin-2-yl)benzenesulfonamide [M − H]−
    PM B
    78 4-(3-chloro-4-fluorophenoxy)-3-cyano-N-(5- 3-chloro-4- m/z 422
    fluoropyridin-2-yl)benzenesulfonamide fluorophenol [M + H]+
    PM B
    79 3-cyano-4-(4-cyano-3,5-dimethylphenoxy)-N- 4-cyano-3,5- m/z 421
    (5-fluoropyridin-2-yl)benzenesulfonamide dimethylphenol [M − H]−
    PM D
  • The compounds of the Examples in the table below were prepared from appropriate compounds of formulae (II) and (IV) according to the specified Method Variation (MV) and, as necessary, purified according to the specified Purification Method (PM).
  • MS Data
    Ex Name Phenol & Sulfonamide (MV, PM)
    80 4-(4-chloro-2-iodophenoxy)- 4-chloro-2-iodophenol and 3-cyano- m/z 512
    3-cyano-N-(pyridin-2- 4-fluoro-N-(pyridin-2- [M + H]+
    yl)benzenesulfonamide yl)benzenesulfonamide MV 2
    (Reference Example)
    81 3-chloro-4-(4-chloro-2- 4-chloro-2-methoxyphenol and 3- m/z 424
    methoxyphenoxy)-N- chloro-4-fluoro-N-(methoxymethyl)- [M − H]−
    (pyridazin-3- N-(pyridazin-3- MV 3
    yl)benzenesulfonamide yl)benzenesulfonamide PM A
    (WO2012004743)
    82 4-{4-chloro-2-[D3- 4-chloro-2-D3-methoxyphenol and 3- m/z 420
    methyloxy]phenoxy}-3- cyano-4-fluoro-N-(methoxymethyl)- [M + H]+
    cyano-N-(pyridazin-3- N-(pyridazin-3- MV 4
    yl)benzenesulfonamide yl)benzenesulfonamide PM A
    83 5-chloro-4-[4-chloro-2- 4-chloro-2-(difluoromethoxy)phenol m/z 480
    (difluoromethoxy)phenoxy]- and 5-chloro-N-(2,4- [M + H]+
    2-fluoro-N-(pyrimidin-2- dimethoxybenzyl)-2,4-difluoro-N- MV 5
    yl)benzenesulfonamide (pyrimidin-2-yl)benzenesulfonamide PM C
    (WO2012004743)
    84 3-chloro-4-[4-chloro-2- 4-chloro-2-(difluoromethoxy)phenol m/z 462
    (difluoromethoxy)phenoxy]- and 3-chloro-4-fluoro-N- [M + H]+
    N-(pyridazin-3- (methoxymethyl)-N-(pyrimidin-2- MV 4
    yl)benzenesulfonamide yl)benzenesulfonamide PM C
    (WO2012004743)
    85 5-chloro-4-[4-chloro-2- 4-chloro-2-(difluoromethoxy)phenol m/z 480
    (difluoromethoxy)phenoxy]- and 5-chloro-2,4-difluoro-N- [M + H]+
    2-fluoro-N-(pyridazin-3- (methoxymethyl)-N-(pyrimidin-2- MV 4
    yl)benzenesulfonamide yl)benzenesulfonamide PM B
    (WO2010079443)
    86 4-[4-chloro-2- 4-chloro-2-(difluoromethoxy)phenol m/z 453
    (difluoromethoxy)phenoxy]- and 3-cyano-4-fluoro-N- [M + H]+
    3-cyano-N-(pyridazin-3- (methoxymethyl)-N-(pyridazin-3- MV 4
    yl)benzenesulfonamide yl)benzenesulfonamide PM C
    87 4-(3-chloro-4- 3-chloro-4-cyanophenol and 5- m/z 410
    cyanophenoxy)-3-cyano-N- chloro-N-(2,4-dimethoxybenzyl)-2,4- [M − H]−
    (pyrimidin-4- difluoro-N-(pyrimidin-4- MV 5
    yl)benzenesulfonamide yl)benzenesulfonamide PM D
    88 3-cyano-4-(4-cyano-3- 4-cyano-3-fluorophenol and 3- m/z 394
    fluorophenoxy)-N-(pyridazin- cyano-N-(2,4-dimethoxybenzyl)-4- [M − H]−
    3-yl)benzenesulfonamide fluoro-N-(pyridazin-3- MV 5
    yl)benzenesulfonamide PM A
    89 4-(3-chloro-4- 3-chloro-4-cyanophenol and 3- m/z 411
    cyanophenoxy)-3-cyano-N- cyano-4-fluoro-N-(pyridin-2- [M + H]+
    (pyridin-2- yl)benzenesulfonamide MV 1
    yl)benzenesulfonamide PM D
    90 4-(3-chloro-4- 3-chloro-4-cyanophenol and 3- m/z 412
    cyanophenoxy)-3-cyano-N- cyano-N-(2,4-dimethoxybenzyl)-4- [M + H]+
    (pyrimidin-2- fluoro-N-(pyrimidin-2- MV 7
    yl)benzenesulfonamide yl)benzenesulfonamide PM A
    91 4-(3-chloro-4- 3-chloro-4-cyanophenol and m/z 428
    cyanophenoxy)-3-cyano-N- 3-cyano-N-(2,4-dimethoxybenzyl)-4- [M − H]−
    (5-fluoropyrimidin-2- fluoro-N-(5-fluoropyrimidin-2- MV 5
    yl)benzenesulfonamide yl)benzenesulfonamide PM C.
    92 4-(3-chloro-4- 3-chloro-4-cyanophenol and 3- m/z 411
    cyanophenoxy)-3-cyano-N- cyano-4-fluoro-N-(pyridin-3- [M + H]+
    (pyridin-3- yl)benzenesulfonamide MV 1
    yl)benzenesulfonamide PM A
    93 4-(3-chloro-4- 3-chloro-4-cyanophenol and m/z 412
    cyanophenoxy)-3-cyano-N- 3-cyano-4-fluoro-N-(pyrazin-2- [M + H]+
    (pyrazin-2- yl)benzenesulfonamide MV 1
    yl)benzenesulfonamide PM A,
    followed
    by PM B
    94 4-(3-chloro-4- 3-chloro-4-cyanophenol and m/z 412
    cyanophenoxy)-3-cyano-N- 3-chloro-4-fluoro-N-(pyridazin-4- [M + H]+
    (pyridazin-4- yl)benzenesulfonamide MV 1
    yl)benzenesulfonamide PM A
    95 4-(4-cyano-3- 4-cyano-3-fluorophenol and N-2,4- m/z 422
    fluorophenoxy)-2,5-difluoro- dimethoxybenzyl-2,4,5-trifluoro-N- [M − H]−
    N-(5-fluoropyridin-2- (5-fluoropyridin-2-
    yl)benzenesulfonamide yl)benzenesulfonamide
    96 4-(3-chloro-4- 3-chloro-4-cyanophenol and 3- m/z 410
    cyanophenoxy)-3-cyano-N- cyano-4-fluoro-N-(pyrimidin-5- [M − H]−
    (pyrimidin-5- yl)benzenesulfonamide MV 5
    yl)benzenesulfonamide PM C
    97 4-(4-cyano-3- 4-cyano-3-fluorophenol and N-3,4- m/z 406
    fluorophenoxy)-3-fluoro-N- dimethoxybenzyl-3,4-di-fluoro-N-(5- [M + H]+
    (5-fluoropyridin-2- fluoropyridin-2- MV 5
    yl)benzenesulfonamide yl)benzenesulfonamide PM C
    98 4-(3-chloro-4- 3-chloro-4-cyanophenol and 3- m/z 412
    cyanophenoxy)-3-cyano-N- cyano-N-(2,4-dimethoxybenzyl)-4- [M + H]+
    (pyridazin-3- fluoro-N-(pyridazin-3-
    yl)benzenesulfonamide yl)benzenesulfonamide.
    • Example 99 4-(4-cyano-3-fluorophenoxy)-2-fluoro-N-(5-fluoropyridin-2-yl)benzenesulfonamide
  • Figure US20150259327A1-20150917-C00009
  • To a solution of 5-bromo-4-(4-cyano-3-fluorophenoxy)-N-(2,4-dimethoxybenzyl)-2-fluoro-N-(5-fluoropyridin-2-yl)benzenesulfonamide (Preparation 1, 220 mg, 0.35 mmol) in THF (8 mL), AcOH (10 mL) and water (2.5 mL) was added zinc dust (800 mg, 12.2 mmol). The reaction mixture was left to stir at room temperature for 70 hours. To the reaction mixture was added EtOAc (25 mL) and the mixture filtered through celite and washed with EtOAc (50 mL). The filtrate was retained and to this was added saturated aqueous NaHCO3 (80 mL). The organic layer was retained, dried over MgSO4, and the solvent removed in vacuo. The residue was purified using reverse phase column chromatography eluting with acetonitrile and water (acidic). The residue was dissolved in DCM and treated with TFA (0.3 mL) and stirred at room temperature for 1 hour. The reaction was concentrated in vacuo azeotroping with MeOH. The residue was purified using preparative HPLC to afford the title compound as a colourless powder (16 mg, 26%).
  • MS m/z 404 [M−H]−
    • Example 100 4-(3-chloro-4-cyanophenoxy)-3-cyano-N-(pyridin-4-yl)benzenesulfonamide
  • Figure US20150259327A1-20150917-C00010
  • The title compound was prepared according to the method described for Example 101 using 4-aminopyridine.
  • MS m/z 411 [M+H]+
    • Example 101 4-(3-chloro-4-cyanophenoxy)-3-cyano-N-(3-methylpyridin-2-yl)benzenesulfonamide
  • Figure US20150259327A1-20150917-C00011
  • To a solution of 4-(3-chloro-4-cyanophenoxy)-3-cyanobenzene-1-sulfonyl chloride (Preparation 21, 240 mg, 0.65 mmol) in dry dichloromethane (3 ml) was added 3-methylpyridin-2-amine (176 mg, 1.63 mmol). The reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was evaporated to dryness under vacuum to leave a brown gum (150 mg). The crude material was dissolved in dimethylsulfoxide and purified by preparative HPLC to afford the title compound as a colourless solid (44 mg, 16%).
  • 1H NMR (400 MHz, DMSO-d6): δ ppm 2.17 (s, 3H), 6.81 (t, 1H), 7.39 (d, 1H), 7.42 (d, 1H), 7.63 (s, 1H), 7.71 (d, 1H), 7.90 (d, 1H), 8.01 (d, 1H), 8.22 (d, 1H), 8.40 (s, 1H).
  • MS m/z 425 [M+H]+
    • Example 102 4-(3-chloro-4-cyanophenoxy)-3-cyano-N-(3-methoxypyridin-2-yl)benzenesulfonamide
  • Figure US20150259327A1-20150917-C00012
  • The title compound was prepared according to the Method described for Example 101 using 3-methoxypyridine-2-amine. The reaction mixture was diluted with dichloromethane and washed with 2 M HCl (100 mL). The organic phase was dried with MgSO4, filtered, and evaporated to dryness under vacuum to leave a light brown solid. The residue was dissolved in dichloromethane and purified using silica gel column chromatography eluting with 0% to 40% ethyl acetate in heptanes.
  • MS m/z 441 [M+H]+
    • Example 103 4-(3-chloro-4-cyanophenoxy)-3-cyano-N-(3-fluoropyridin-2-yl)benzenesulfonamide
  • Figure US20150259327A1-20150917-C00013
  • The title compound was prepared according to the Method described for Example 101 using 3-fluoropyridine-2-amine.
  • MS m/z 429 [M+H]+
    • Example 104 4-(3-chloro-4-cyanophenoxy)-3-cyano-N-(4-fluoropyridin-2-yl)benzenesulfonamide
  • Figure US20150259327A1-20150917-C00014
  • The title compound was prepared according to the Method described for Example 101 using 3-fluoropyridine-2-amine in pyridine.
  • MS m/z 429 [M+H]+
    • Library Protocol 1
  • Figure US20150259327A1-20150917-C00015
  • To a 0.2M solution of 3-cyano-4-fluoro-N-(5-fluoropyridin-2-yl)benzenesulfonamide in DMSO (Preparation 2, 500 uL, 100 umol) was added a 0.2M solution in DMSO of the appropriate phenol/hydroxypyridine (compound of formula (IV), 500 uL, 100 umol) followed by anhydrous K3PO4 (64 mg, 300 umol) and the reaction mixtures were stirred at 80° C. for 18 hours. The reaction mixtures were cooled and purified using one of the two preparative HPLC described below to afford the desired compounds of formula (Ia).
    • Preparative HPLC Method 1:
  • Mobile phase A: 10 mM ammonium acetate in water; Mobile phase B: MeCN
    • Column: Gemini NX C18 (20×100 mm, 5u)
  • Gradient: Initial 10% B; 2 mins 40% B; 10 mins 70% B, 11-12 mins 95% B, 13-15 mins 10% B
    Flow rate: 20 mL/min.
    • Preparative HPLC Method 2:
  • Mobile phase A: 10 mM ammonium acetate in water; Mobile phase B: MeCN
    • Column: Xbridge C18 (19×50 mm, 5u)
  • Gradient: Initial 10% B; 2 mins 20% B; 7 mins 80% B, 7.5-8.5 mins 95% B, 9-10 mins 10% B,
    Flow rate: 20 mL/min
    • LCMS Conditions:
  • Mobile phase A: 0.05% formic acid in water; Mobile phase B: MeCN
    Column: RESTEK C18 2.1×30 mm×3p
    Gradient: From 98% A and 2% B to 90% A and 10% B in 1 min, further to 2% A and 98% B in 2.0 min and finally back to initial condition in 3 min
    Flow rate: 1.5 mL/min
  • The compounds of the Examples in the table below were prepared from 3-cyano-4-fluoro-N-(5-fluoropyridin-2-yl)benzenesulfonamide in DMSO (Preparation 2) and the appropriate phenol or hydroxypyridine according to Library protocol 1.
  • Ex Name R6OH MS Data
    105 3-cyano-N-(5-fluoropyridin-2-yl)-4-[3-methyl- 3-methyl-5- m/z 426
    5-(propan-2-yl)phenoxy]benzenesulfonamide (propan-2- [M + H]+
    yl)phenol
    106 4-(5-chloro-2-methoxyphenoxy)-3-cyano-N- 5-chloro-2- m/z 434
    (5-fluoropyridin-2-yl)benzenesulfonamide methoxyphenol [M + H]+
    107 3-cyano-4-(2,5-dichloro-4-fluorophenoxy)-N- 2,5-dichloro-4- m/z 456
    (5-fluoropyridin-2-yl)benzenesulfonamide fluorophenol [M + H]+
    108 4-(2-chloro-6-fluoro-3-methylphenoxy)-3- 2-chloro-6-fluoro- m/z 436
    cyano-N-(5-fluoropyridin-2- 3-methylphenol [M + H]+
    yl)benzenesulfonamide
    109 3-cyano-4-(2,4-dichloro-5-methylphenoxy)-N- 2,4-dichloro-5- m/z 452
    (5-fluoropyridin-2-yl)benzenesulfonamide methylphenol [M + H]+
    110 4-(4-chloro-2-ethoxyphenoxy)-3-cyano-N-(5- 4-chloro-2- m/z 448
    fluoropyridin-2-yl)benzenesulfonamide ethoxyphenol [M + H]+
    111 3-cyano-4-(2-fluoro-6-methoxyphenoxy)-N-(5- 2-fluoro-6- m/z 418
    fluoropyridin-2-yl)benzenesulfonamide methoxyphenol [M + H]+
    112 4-(2-chloro-4-fluoro-3-methoxyphenoxy)-3- 2-chloro-4-fluoro- m/z 452
    cyano-N-(5-fluoropyridin-2- 3-methoxyphenol [M + H]+
    yl)benzenesulfonamide
    113 3-cyano-4-[3-(diethylamino)phenoxy]-N-(5- 3-(diethylamino)phenol m/z 441
    fluoropyridin-2-yl)benzenesulfonamide [M + H]+
    114 4-(2-chloro-6-methoxyphenoxy)-3-cyano-N- 2-chloro-6- m/z 434
    (5-fluoropyridin-2-yl)benzenesulfonamide methoxyphenol [M + H]+
    115 3-cyano-N-(5-fluoropyridin-2-yl)-4-(2- 2-methoxy-6- m/z 414
    methoxy-6- methylphenol [M + H]+
    methylphenoxy)benzenesulfonamide
    116 4-(3-chloro-4-ethoxyphenoxy)-3-cyano-N-(5- 3-chloro-4- m/z 448
    fluoropyridin-2-yl)benzenesulfonamide ethoxyphenol [M + H]+
    117 4-{[5-chloro-6-(propan-2-yl)pyridin-3-yl]oxy}-3- 5-chloro-6- m/z 447
    cyano-N-(5-fluoropyridin-2- (propan-2- [M + H]+
    yl)benzenesulfonamide yl)pyridin-3-yl]ol
    (WO20120010183)
    118 3-cyano-4-(3-cyclopropylphenoxy)-N-(5- 3- m/z 410
    fluoropyridin-2-yl)benzenesulfonamide cyclopropylphenol [M + H]+
    (Reference Example)
    119 3-cyano-4-(2,6-difluoro-3-methylphenoxy)-N- 2,6-difluoro-3- m/z 420
    (5-fluoropyridin-2-yl)benzenesulfonamide methylphenol M + H]+
    120 3-cyano-4-(5-fluoro-2-methoxyphenoxy)-N-(5- 5-fluoro-2- m/z 418
    fluoropyridin-2-yl)benzenesulfonamide methoxyphenol [M + H]+
    121 3-cyano-N-(5-fluoropyridin-2-yl)-4-{[6-(2- 6-(2- m/z 441
    methylpropoxy)pyridin-3- methylpropoxy)pyridin- [M − H]−
    yl]oxy}benzenesulfonamide 3-yl]ol
    122 3-cyano-4-(3,4-dichlorophenoxy)-N-(5- 3,4-dichlorophenol m/z 436
    fluoropyridin-2-yl)benzenesulfonamide [M − H]−
    123 4-(2-chloro-6-methylphenoxy)-3-cyano-N-(5- 2-chloro-6- m/z 418
    fluoropyridin-2-yl)benzenesulfonamide methylphenol [M + H]+
    124 3-cyano-4-(2,6-difluorophenoxy)-N-(5- 2,6-difluorophenol m/z 406
    fluoropyridin-2-yl)benzenesulfonamide [M + H]+
    125 4-[(5-chloro-6-ethoxypyridin-3-yl)oxy]-3- 5-chloro-6- m/z 449
    cyano-N-(5-fluoropyridin-2- ethoxypyridin-3- [M + H]+
    yl)benzenesulfonamide yl)ol.
    126 3-cyano-N-(5-fluoropyridin-2-yl)-4-[4-(propan- 4-(propan-2- m/z 412
    2-yl)phenoxy]benzenesulfonamide yl)phenol [M + H]+
    127 4-(4-tert-butyl-2-chlorophenoxy)-3-cyano-N- 4-tert-butyl-2- m/z 460
    (5-fluoropyridin-2-yl)benzenesulfonamide chlorophenol [M + H]+
    128 3-cyano-4-(2,3-difluoro-4-methylphenoxy)-N- 2,3-difluoro-4- m/z 420
    (5-fluoropyridin-2-yl)benzenesulfonamide methylphenol [M + H]+
    129 4-(3-tert-butylphenoxy)-3-cyano-N-(5- 3-tert-butylphenol m/z 426
    fluoropyridin-2-yl)benzenesulfonamide [M + H]+
    130 3-cyano-N-(5-fluoropyridin-2-yl)-4-(2,4,5- 2,4,5- m/z 424
    trifluorophenoxy)benzenesulfonamide trifluorophenol [M + H]+
    131 3-cyano-4-[3-(dimethylamino)phenoxy]-N-(5- 3-(dimethylamino)phenol m/z 413
    fluoropyridin-2-yl)benzenesulfonamide [M + H]+
    132 3-cyano-4-(3-fluoro-4-methoxyphenoxy)-N-(5- 3-fluoro-4- m/z 418
    fluoropyridin-2-yl)benzenesulfonamide methoxyphenol [M + H]+
    133 4-[4-chloro-5-methyl-2-(propan-2-yl)phenoxy]- 4-chloro-5-methyl- m/z 460
    3-cyano-N-(5-fluoropyridin-2- 2-(propan-2- [M + H]+
    yl)benzenesulfonamide yl)phenol
    134 3-cyano-N-(5-fluoropyridin-2-yl)-4-(2,3,6- 2,3,6- m/z 424
    trifluorophenoxy)benzenesulfonamide trifluorophenol [M + H]+
    135 3-cyano-4-(3-ethoxyphenoxy)-N-(5- 3-ethoxyphenol m/z 414
    fluoropyridin-2-yl)benzenesulfonamide [M + H]+
    136 4-(2-chloro-4,5-dimethylphenoxy)-3-cyano-N- 2-chloro-4,5- m/z 432
    (5-fluoropyridin-2-yl)benzenesulfonamide dimethylphenol [M + H]+
    137 4-(4-tert-butylphenoxy)-3-cyano-N-(5- 4-tert-butylphenol m/z 426
    fluoropyridin-2-yl)benzenesulfonamide [M + H]+
    138 3-cyano-4-(2-ethoxy-4-methylphenoxy)-N-(5- 2-ethoxy-4- m/z 428
    fluoropyridin-2-yl)benzenesulfonamide methylphenol [M + H]+
    139 3-cyano-N-(5-fluoropyridin-2-yl)-4-[3-methyl- 3-methyl-4- m/z 426
    4-(propan-2-yl)phenoxy]benzenesulfonamide (propan-2- [M + H]+
    yl)phenol
    140 3-cyano-N-(5-fluoropyridin-2-yl)-4-(2- 2-methoxy-4- m/z 414
    methoxy-4- methylphenol [M + H]+
    methylphenoxy)benzenesulfonamide
    141 3-cyano-4-(4-fluoro-3-methylphenoxy)-N-(5- 4-fluoro-3- m/z 402
    fluoropyridin-2-yl)benzenesulfonamide methylphenol [M + H]+
    142 3-cyano-N-(5-fluoropyridin-2-yl)-4-(2- 2-methoxyphenol m/z 400
    methoxyphenoxy)benzenesulfonamide [M + H]+
    143 4-(4-chloro-2-methoxyphenoxy)-3-cyano-N- 4-chloro-2- m/z 434
    (5-fluoropyridin-2-yl)benzenesulfonamide methoxyphenol [M + H]+
    144 3-cyano-4-(4,5-difluoro-2-methoxyphenoxy)- 4,5-difluoro-2- m/z 436
    N-(5-fluoropyridin-2-yl)benzenesulfonamide methoxyphenol [M + H]+
    145 3-cyano-4-(4-fluoro-2-methylphenoxy)-N-(5- 4-fluoro-2- m/z 402
    fluoropyridin-2-yl)benzenesulfonamide methylphenol [M + H]+
    146 3-cyano-N-(5-fluoropyridin-2-yl)-4-[2- 2-(methylsulfanyl)phenol m/z 416
    (methylsulfanyl)phenoxy]benzenesulfonamide [M + H]+
    147 4-(2-chloro-4-fluoro-3-methylphenoxy)-3- 2-chloro-4-fluoro- m/z 436
    cyano-N-(5-fluoropyridin-2- 3-methylphenol [M + H]+
    yl)benzenesulfonamide
    148 4-(3-chloro-4-methoxyphenoxy)-3-cyano-N- 3-chloro-4- m/z 434
    (5-fluoropyridin-2-yl)benzenesulfonamide methoxyphenol [M + H]+
    149 4-(4-chloro-3,5-dimethylphenoxy)-3-cyano-N- 4-chloro-3,5- m/z 432
    (5-fluoropyridin-2-yl)benzenesulfonamide dimethylphenol [M + H]+
    150 3-cyano-4-(3,5-dimethylphenoxy)-N-(5- 3,5-dimethylphenol m/z 398
    fluoropyridin-2-yl)benzenesulfonamide [M + H]+
    151 3-cyano-4-(2-ethoxyphenoxy)-N-(5- 2-ethoxyphenol m/z 414
    fluoropyridin-2-yl)benzenesulfonamide [M + H]+
    152 3-cyano-4-(2,6-dimethylphenoxy)-N-(5- 2,6-dimethylphenol m/z 398
    fluoropyridin-2-yl)benzenesulfonamide [M + H]+
    153 3-cyano-4-(4-ethoxyphenoxy)-N-(5- 4-ethoxyphenol m/z 414
    fluoropyridin-2-yl)benzenesulfonamide [M + H]+
    154 3-cyano-4-[(2-ethoxypyridin-3-yl)oxy]-N-(5- 2-ethoxypyridin-3- m/z 415
    fluoropyridin-2-yl)benzenesulfonamide yl)ol [M + H]+
    155 3-cyano-N-(5-fluoropyridin-2-yl)-4-(2- 2-methoxy-5- m/z 414
    methoxy-5- methylphenol [M + H]+
    methylphenoxy)benzenesulfonamide
    156 3-cyano-4-[5-fluoro-2-(propan-2- 5-fluoro-2-(propan- m/z 446
    yloxy)phenoxy]-N-(5-fluoropyridin-2- 2-yloxy)phenol [M + H]+
    yl)benzenesulfonamide
    157 3-cyano-N-(5-fluoropyridin-2-yl)-4-(2,3,4- 2,3,4- m/z 424
    trifluorophenoxy)benzenesulfonamide trifluorophenol [M + H]+
    158 3-cyano-4-(2,5-dimethylphenoxy)-N-(5- 2,5-dimethylphenol m/z 398
    fluoropyridin-2-yl)benzenesulfonamide [M + H]+
    159 4-(5-chloro-2,3-dimethylphenoxy)-3-cyano-N- 5-chloro-2,3- m/z 432
    (5-fluoropyridin-2-yl)benzenesulfonamide dimethylphenol [M + H]+
    160 3-cyano-4-(4-fluoro-2-methoxyphenoxy)-N-(5- 4-fluoro-2- m/z 418
    fluoropyridin-2-yl)benzenesulfonamide methoxyphenol [M + H]+
    161 4-(3-tert-butyl-4-cyanophenoxy)-3-cyano-N- 3-tert-butyl-4- m/z 451
    (5-fluoropyridin-2-yl)benzenesulfonamide cyanophenol [M + H]+
    162 4-(3-chloro-5-methoxyphenoxy)-3-cyano-N- 3-chloro-5- m/z 434
    (5-fluoropyridin-2-yl)benzenesulfonamide methoxyphenol [M + H]+
    163 4-(4-bromophenoxy)-3-cyano-N-(5- 4-bromophenol m/z 448
    fluoropyridin-2-yl)benzenesulfonamide [M + H]+
    (Reference Example)
    164 4-[4-chloro-3-(propan-2-yl)phenoxy]-3-cyano- 4-chloro-3- m/z 446
    N-(5-fluoropyridin-2-yl)benzenesulfonamide (propan-2- [M + H]+
    yl)phenol
    165 3-cyano-4-(4-fluoro-3-methoxy-2- 4-fluoro-3- m/z 432
    methylphenoxy)-N-(5-fluoropyridin-2- methoxy-2- [M + H]+
    yl)benzenesulfonamide methylphenol
    166 3-cyano-4-(2-fluoro-5-methoxyphenoxy)-N-(5- 2-fluoro-5- m/z 418
    fluoropyridin-2-yl)benzenesulfonamide methoxyphenol [M + H]+
    167 4-(2-chloro-3,4-difluorophenoxy)-3-cyano-N- 2-chloro-3,4- m/z 440
    (5-fluoropyridin-2-yl)benzenesulfonamide difluorophenol [M + H]+
    168 4-(2-chloro-4-methoxyphenoxy)-3-cyano-N- 2-chloro-4- m/z 434
    (5-fluoropyridin-2-yl)benzenesulfonamide methoxyphenol [M + H]+
    169 4-(3-chloro-2,6-dimethylphenoxy)-3-cyano-N- 3-chloro-2,6- m/z 432
    (5-fluoropyridin-2-yl)benzenesulfonamide dimethylphenol [M + H]+
    170 3-cyano-4-(2,5-dichlorophenoxy)-N-(5- 2,5-dichlorophenol m/z 436
    fluoropyridin-2-yl)benzenesulfonamide [M − H]−
    171 4-(3-chloro-4,5-dimethylphenoxy)-3-cyano-N- 3-chloro-4,5- m/z 432
    (5-fluoropyridin-2-yl)benzenesulfonamide dimethylphenol [M + H]+
    172 3-cyano-4-(4-fluoro-2,3-dimethylphenoxy)-N- 4-fluoro-2,3- m/z 416
    (5-fluoropyridin-2-yl)benzenesulfonamide dimethylphenol [M + H]+
    173 3-cyano-4-(4-fluoro-2-methoxy-3- 4-fluoro-2- m/z 432
    methylphenoxy)-N-(5-fluoropyridin-2- methoxy-3- [M + H]+
    yl)benzenesulfonamide methylphenol
    174 3-cyano-N-(5-fluoropyridin-2-yl)-4-[2-methyl- 2-methyl-5- m/z 426
    5-(propan-2-yl)phenoxy]benzenesulfonamide (propan-2- [M + H]+
    yl)phenol
    175 4-(3-chloro-2,4-dimethylphenoxy)-3-cyano-N- 3-chloro-2,4- m/z 432
    (5-fluoropyridin-2-yl)benzenesulfonamide dimethylphenol [M + H]+
    176 4-(2-chloro-5-fluorophenoxy)-3-cyano-N-(5- 2-chloro-5- m/z 420
    fluoropyridin-2-yl)benzenesulfonamide fluorophenol [M − H]−
    177 4-(2-chloro-4,5-difluorophenoxy)-3-cyano-N- 2-chloro-4,5- m/z 438
    (5-fluoropyridin-2-yl)benzenesulfonamide difluorophenol [M − H]−
    178 4-(2-chloro-3,4-dimethylphenoxy)-3-cyano-N- 2-chloro-3,4- m/z 432
    (5-fluoropyridin-2-yl)benzenesulfonamide dimethylphenol [M + H]+
    • Library Protocol 2
  • Figure US20150259327A1-20150917-C00016
  • To a 0.2M solution of 3-cyano-4-fluoro-N-(5-fluoropyridin-2-yl)benzenesulfonamide in DMSO (Preparation 2, 500 uL, 100 umol) was added a 0.2M solution in DMSO of the appropriate phenol/hydroxypyridine (compound of formula (IV), 500 uL, 100 umol) followed by anhydrous K3PO4 (64 mg, 300 umol) and the reaction mixtures were stirred at 80° C. for 18 hours. The reaction mixtures were cooled and purified using one of the two preparative HPLC described below to afford the desired compounds of formula (Ia).
    • Preparative HPLC Method 1:
  • Mobile phase A: 10 mM ammonium acetate in water; Mobile phase B: MeCN
    • Column: Gemini NX C18 (20×100 mm, 5u)
  • Gradient: Initial 10% B; 2 mins 40% B; 10 mins 70% B, 11-12 mins 95% B, 13-15 mins 10% B
    Flow rate: 20 mL/min.
    • Preparative HPLC Method 2:
  • Mobile phase A: 0.1% formic acid in water; Mobile phase B: MeCN
    • Column: Zorbax SB C18 921×250 mm, 7u)
  • Gradient: Initial 10% B; 3 mins 20% B; 18 mins 80% B, 19-20 mins 95% B, 22-25 mins 10% B,
    Flow rate: 20 mL/min
    • LCMS Conditions 1:
  • Mobile phase A: 0.05% formic acid in water; Mobile phase B: MeCN
    Column: RESTEK C18 2.1×30 mm×3p
    Gradient: From 98% A and 2% B to 90% A and 10% B in 1 min, further to 2% A and 98% B in 2.0 min and finally back to initial condition in 3 min
    Flow rate: 1.5 mL/min
    • LCMS Conditions 2:
  • Mobile phase A: 10 mM ammonium acetate in water; Mobile phase B: MeCN
    • Column: Zorbax Extend C18 (50×4.6 mm, 5u)
  • Gradient: From 95% A and 5% B to 85% A and 15% B in 1.5 min, further to 10% A and 90% B in 3-4 min and finally back to initial condition in 5 min
    Flow rate: 1.5 mL/min
  • The compounds of the Examples in the table below were prepared from 3-cyano-4-fluoro-N-(5-fluoropyridin-2-yl)benzenesulfonamide in DMSO (Preparation 2) and the appropriate phenol or hydroxypyridine according to Library protocol 2.
  • Ex Name R6OH Data
    179 4-(3-chloro-2-cyanophenoxy)-3-cyano-N-(5- 3-chloro-2- m/z 429
    fluoropyridin-2-yl)benzenesulfonamide cyanophenol [M + H]+
    180 4-[(5-chloro-6-cyclopropylpyridin-3-yl)oxy]-3- 5-chloro-6- m/z 445
    cyano-N-(5-fluoropyridin-2- cyclopropylpyridin- [M + H]+
    yl)benzenesulfonamide 3-yl)ol
    (Reference Example) (WO2012007869)
    181 3-cyano-N-(5-fluoropyridin-2-yl)-4-(3- 3-methoxy-2- m/z 414
    methoxy-2- methylphenol [M + H]+
    methylphenoxy)benzenesulfonamide
    182 3-cyano-N-(5-fluoropyridin-2-yl)-4-(3- 3-methoxy-5- m/z 414
    methoxy-5- methylphenol [M + H]+
    methylphenoxy)benzenesulfonamide
    183 3-cyano-4-(4-fluorophenoxy)-N-(5- 4-fluorophenol m/z 388
    fluoropyridin-2-yl)benzenesulfonamide [M + H]+
    184 3-cyano-N-(5-fluoropyridin-2-yl)-4-[(2- 2-methylpyridin-3- m/z 385
    methylpyridin-3-yl)oxy]benzenesulfonamide yl)ol [M + H]+
    185 3-cyano-N-(5-fluoropyridin-2-yl)-4-(3- 3-methylphenol m/z 384
    methylphenoxy)benzenesulfonamide [M + H]+
    186 3-cyano-N-(5-fluoropyridin-2-yl)-4-(2- 2-methylphenol m/z 384
    methylphenoxy)benzenesulfonamide [M + H]+
    187 3-cyano-N-(5-fluoropyridin-2-yl)-4-(pyridin-2- 2-hydroxypyridine m/z 371
    yloxy)benzenesulfonamide [M + H]+
    188 3-cyano-N-(5-fluoropyridin-2-yl)-4-(4- 4-methoxyphenol m/z 400
    methoxyphenoxy)benzenesulfonamide [M + H]+
    189 4-(2-bromophenoxy)-3-cyano-N-(5- 2-bromophenol m/z 449
    fluoropyridin-2-yl)benzenesulfonamide [M + H]+
    (Reference Example)
    190 3-cyano-N-(5-fluoropyridin-2-yl)-4-[(4- (4-methoxypyridin- m/z 401
    methoxypyridin-3-yl)oxy]benzenesulfonamide 3-yl)ol [M + H]+
    191 3-cyano-N-(5-fluoropyridin-2-yl)-4-(4- 4-methylphenol m/z 384
    methylphenoxy)benzenesulfonamide [M + H]+
    192 3-cyano-4-[(2-ethyl-6-methylpyridin-3-yl)oxy]- (2-ethyl-6-methyl m/z 413
    N-(5-fluoropyridin-2-yl)benzenesulfonamide pyridin-3-yl)ol [M + H]+
    193 3-cyano-N-(5-fluoropyridin-2-yl)-4-[(6- (6-methylpyridin-3- m/z 385
    methylpyridin-3-yl)oxy]benzenesulfonamide yl)ol [M + H]+
    194 3-cyano-N-(5-fluoropyridin-2-yl)-4-(pyridin-3- 3-hydroxypyridine m/z 371
    yloxy)benzenesulfonamide [M + H]+
    195 3-cyano-N-(5-fluoropyridin-2-yl)-4-(3,4,5- 3,4,5- m/z 424
    trifluorophenoxy)benzenesulfonamide trifluorophenol [M + H]+
    196 3-cyano-N-(5-fluoropyridin-2-yl)-4-{[6- 6-(trifluoromethyl)pyridin- m/z 439
    (trifluoromethyl)pyridin-3- 3-yl]ol [M + H]+
    yl]oxy}benzenesulfonamide
    197 3-cyano-4-(5-cyano-2-methoxyphenoxy)-N- 5-cyano-2- m/z 425
    (5-fluoropyridin-2-yl)benzenesulfonamide methoxyphenol [M + H]+
    198 3-cyano-N-(5-fluoropyridin-2-yl)-4-[(4- (4-methylpyridin-3- m/z 385
    methylpyridin-3-yl)oxy]benzenesulfonamide yl)ol [M + H]+
    199 3-cyano-N-(5-fluoropyridin-2-yl)-4-[(6- (6-methoxypyridin- m/z 401
    methoxypyridin-3-yl)oxy]benzenesulfonamide 3-yl)ol [M + H]+
    200 3-cyano-N-(5-fluoropyridin-2-yl)-4-(5- 5-methoxy-2- m/z 414
    methoxy-2- methylphenol [M + H]+
    methylphenoxy)benzenesulfonamide
    201 3-cyano-N-(5-fluoropyridin-2-yl)-4-(4- 4-methoxy-2- m/z 414
    methoxy-2- methylphenol [M + H]+
    methylphenoxy)benzenesulfonamide
    202 4-[(5-chloropyridin-3-yl)oxy]-3-cyano-N-(5- 5-chloro-3- m/z 405
    fluoropyridin-2-yl)benzenesulfonamide hydroxypyridine [M + H]+
    203 3-cyano-4-(4-cyano-3-cyclopropylphenoxy)- 4-cyano-3- m/z 435
    N-(5-fluoropyridin-2-yl)benzenesulfonamide cyclopropylphenol [M + H]+
    (Reference Example)
    204 3-cyano-4-(4-cyano-2-methoxyphenoxy)-N- 4-cyano-2- m/z 425
    (5-fluoropyridin-2-yl)benzenesulfonamide methoxyphenol [M + H]+
    205 3-cyano-4-[(6-cyanopyridin-3-yl)oxy]-N-(5- 3-hydroxy-6- m/z 396
    fluoropyridin-2-yl)benzenesulfonamide cyanopyridine [M + H]+
    206 3-cyano-4-[(5-cyanopyridin-3-yl)oxy]-N-(5- 3-hydroxy-5- m/z 396
    fluoropyridin-2-yl)benzenesulfonamide cyanipyridine [M + H]+
    207 3-cyano-N-(5-fluoropyridin-2-yl)-4-[2-(propan- 2-(propan-2- m/z 428
    2-yloxy)phenoxy]benzenesulfonamide yloxy)phenol [M + H]+
    208 3-cyano-N-(5-fluoropyridin-2-yl)-4-(3- 3-methoxyphenol m/z 400
    methoxyphenoxy)benzenesulfonamide [M + H]+
    • Library Protocol 3
  • Figure US20150259327A1-20150917-C00017
  • To a 0.2M solution in DMSO of the appropriate sulphonamide (compound of formula (Via), 500 uL, 100 umol) was added a 0.2M solution in DMSO of the appropriate phenol/hydroxypyridine (compound of formula (IV), 500 uL, 100 umol) followed by anhydrous K3PO4 (64 mg, 300 umol) and the reaction mixtures were stirred at 80° C. for 18 hours. The reaction mixtures were concentrated in vacuo and treated with 4M HCl in dioxane (1 mL). The reaction mixtures were concentrated in vacuo and purified using preparative HPLC as described below to afford the desired compounds of formula (I).
    • Preparative HPLC Method:
  • Mobile phase A: 10 mM ammonium acetate in water; Mobile phase B: MeCN
    • Column: Sunfire C18 (19×150 mm, 5u)
  • Gradient: Initial 10% B; 2 mins 30% B; 10 mins 60% B, 12-13 mins 95% B, 14-15 mins 10% B
    Flow rate: 16 mL/min.
  • The compounds of the Examples in the table below were prepared from the appropriate sulphonamide of formula (Via) and the appropriate phenol of formula (IV) according to Library Protocol 3.
  • Ex Name Phenol & sulfonamide Data
    209 3-cyano-4-(3-cyano-4- 3-cyano-4-fluorophenol and 3-cyano-N- m/z 396
    fluorophenoxy)-N- (2,4-dimethoxybenzyl)-4-fluoro-N- [M + H]+
    (pyrimidin-2- (pyrimidin-2-yl)benzenesulfonamide.
    yl)benzenesulfonamide
    210 5-chloro-4-(3,4- 3,4-difluorophenol and 5-chloro-N-(2,4- m/z 416
    difluorophenoxy)-2- dimethoxybenzyl)-2,4-difluoro-N- [M + H]+
    fluoro-N-(pyrimidin-2- (pyrimidin-2-yl)benzenesulfonamide
    yl)benzenesulfonamide (WO2012004743)
    211 3-cyano-4-(3,4- 3,4-difluorophenol and 3-cyano-N-(2,4- m/z 389
    difluorophenoxy)-N- dimethoxybenzyl)-4-fluoro-N-(pyrimidin- [M + H]+
    (pyrimidin-2- 2-yl)benzenesulfonamide.
    yl)benzenesulfonamide
    212 5-chloro-4-(3,4- 3,4-difluorophenol and 5-chloro-N-(2,4- m/z 434
    difluorophenoxy)-2- dimethoxybenzyl)-2,4-difluoro-N-(5- [M + H]+
    fluoro-N-(5- fluoropyrimidin-2-
    fluoropyrimidin-2- yl)benzenesulfonamide
    yl)benzenesulfonamide (WO2012004706)
    213 5-chloro-4-(3-cyano-4- 3-cyano-4-fluorophenol and 5-chloro-N- m/z 423
    fluorophenoxy)-2-fluoro- (2,4-dimethoxybenzyl)-2,4-difluoro-N- [M + H]+
    N-(pyrimidin-2- (pyrimidin-2-yl)benzenesulfonamide
    yl)benzenesulfonamide (WO2012004743)
    214 5-chloro-4-(3-cyano-4- 3-cyano-4-fluorophenol and 5-chloro-N- m/z 441
    fluorophenoxy)-2-fluoro- (2,4-dimethoxybenzyl)-2,4-difluoro-N-(5- [M + H]+
    N-(5-fluoropyrimidin-2- fluoropyrimidin-2-
    yl)benzenesulfonamide yl)benzenesulfonamide
    (WO2012004706)
    215 5-chloro-4-(4-cyano-3- 3-cyano-4-fluorophenol and 5-chloro-N- m/z 440
    fluorophenoxy)-2-fluoro- (2,4-dimethoxybenzyl)-2,4-difluoro-N-(5- [M + H]+
    N-(5-fluoropyridin-2- fluoro-2-pyridinyl)benzenesulfonamide
    yl)benzenesulfonamide (WO2012004743)
    • Library Protocol 4
  • Figure US20150259327A1-20150917-C00018
  • To a stock solution of the appropriate amine of formula (V) (1 mmol) in THF (5 mL) was added NMM (111 uL, 1 mmol).
  • An aliquot of this solution (50 uL, 10 umol) was added to a solution of 4-(3-chloro-2-cyanophenoxy)benzene-1-sulfonyl chloride (3.6 mg, 12 umol) in DCM (120 uL) and the reaction mixture stirred at room temperature for 24 hours. The reaction mixture was concentrated in vacuo to afford the desired compound of formula (Ib).
  • The compounds of the Reference Examples in the table below were prepared from 4-(3-chloro-2-cyanophenoxy)benzene-1-sulfonyl chloride (commercially available) and the appropriate amine of formula (V) according to Library Protocol 4. These compounds do not fall within the scope of formula (I).
  • Ref
    Ex Name Amine
    216 4-(3-chloro-2-cyanophenoxy)-N-(4- 4-methyl-2-
    methylpyridin-2-yl)benzenesulfonamide aminopyridine
    217 4-(3-chloro-2-cyanophenoxy)-N-(pyridin-4- 4-aminopyridine
    yl)benzenesulfonamide
    218 4-(3-chloro-2-cyanophenoxy)-N-(pyridin-2- 2-aminopyridine
    yl)benzenesulfonamide
    219 4-(3-chloro-2-cyanophenoxy)-N-(pyridin-3- 3-aminopyridine
    yl)benzenesulfonamide
    220 4-(3-chloro-2-cyanophenoxy)-N-(4- 4-methyl-2-
    methylpyrimidin-2-yl)benzenesulfonamide aminopyrimidine
    221 4-(3-chloro-2-cyanophenoxy)-N-(5- 5-methyl-2-
    methylpyridin-2-yl)benzenesulfonamide aminopyridine
    222 4-(3-chloro-2-cyanophenoxy)-N- 2-aminopyrimidine
    (pyrimidin-2-yl)benzenesulfonamide
    223 4-(3-chloro-2-cyanophenoxy)-N- 2-aminopyrazine
    (pyrazin-2-yl)benzenesulfonamide
    • Example 224 4-(4-aminophenoxy)-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide
  • Figure US20150259327A1-20150917-C00019
  • The title compound was prepared according to the method described for Library Protocol 2 using 3-cyano-4-fluoro-N-(5-fluoropyridin-2-yl)benzenesulfonamide (Preparation 2), 4-aminophenol.
  • MS m/z 385 [M+H]+
    • Example 225 5-chloro-4-(3-cyano-4-fluorophenoxy)-2-fluoro-N-(pyrimidin-2-yl)benzenesulfonamide
  • Figure US20150259327A1-20150917-C00020
  • The title compound was prepared according to the method described for Library Protocol 2 using 5-chloro-N-(2,4-dimethoxybenzyl)-2,4-difluoro-N-(pyrimidin-2-yl)benzenesulfonamide (WO2012004743) and 3-cyano-4-fluorophenol.
  • MS m/z 423 [M+H]+
  • The compounds of the Examples in the table below were prepared from appropriate compounds of formulae (II) and (IV) according to the specified Method Variation (MV) and, as necessary, purified according to the specified Purification Method (PM).
  • MS Data
    Ex Name Phenol and Sulfonamide (MV, PM)
    226 5-chloro-4-(3-chloro-4- 3-chloro-4-cyanophenol and 5-chloro- m/z 457
    cyanophenoxy)-2-fluoro-N- N-[(2,4-dimethoxyphenyl)methyl]-2,4- [M + H]+
    (5-fluoropyrimidin-2- difluoro-N-(5-fluoro-2-pyrimidinyl)- MV 5
    yl)benzenesulfonamide benzene sulphonamide PM A
    (WO 2012004706)
    227 5-chloro-4-(3-chloro-4- 3-chloro-4-cyanophenol and 5-chloro- m/z 439
    cyanophenoxy)-2-fluoro-N- N-(2,4-dimethoxybenzyl)-2,4-difluoro- [M + H]+
    (pyridazin-3- N-(pyridazin-3- MV 5
    yl)benzenesulfonamide yl)benzenesulfonamide (Prep 31). PM B, D.
    228 3-chloro-4-(4-cyano-3- 3-fluoro-4-cyanophenol and 3-chloro- m/z 422
    fluorophenoxy)-N-(5- N-(2,4-dimethoxybenzyl)-4-fluoro-N- [M + H]+
    fluoropyridin-2- (5-fluoropyridin-2- MV 5
    yl)benzenesulfonamide yl)benzenesulfonamide (Prep 32). PM A, B.
    229 4-(3-chloro-4- 3-chloro-4-fluorophenol and 3-cyano- m/z 429
    fluorophenoxy)-3-cyano-N- N-(4-cyanopyridin-2-yl)-N-(2,4- [M + H]+
    (4-cyanopyridin-2- dimethoxybenzyl)-4- MV 5
    yl)benzenesulfonamide fluorobenzenesulfonamide (Prep 36) PM A.
    230 4-(3-chloro-4- 3-chloro-4-fluorophenol and 3-cyano- m/z 429
    fluorophenoxy)-3-cyano-N- N-(5-cyanopyridin-2-yl)-N-(2,4- [M + H]+
    (5-cyanopyridin-2- dimethoxybenzyl)-4- MV 5
    yl)benzenesulfonamide fluorobenzenesulfonamide (Prep 38) PM A.
    231 4-((5-chloro-6- 5-chloro-6-(difluoromethoxy)-3- m/z 471
    (difluoromethoxy)pyridin-3- pyridinol (WO 2012007869) and 3- [M + H]+
    yl)oxy)-3-cyano-N-(5- cyano-4-fluoro-N-(5-fluoropyridin-2- MV 1
    fluoropyridin-2- yl)benzenesulfonamide PM E.
    yl)benzenesulfonamide (Preparation 2).
    232 4-(3-chloro-4- 3-chloro-4-cyanophenol and 3-cyano- m/z 445
    cyanophenoxy)-N-(5- 4-fluoro-N-(5-chloropyridin-2- [M + H]+
    chloropyridin-2-yl)-3- yl)benzenesulfonamide MV 1
    cyanobenzenesulfonamide (Preparation 39). PM E.
    233 4-(3-chloro-4- 3-chloro-4-cyanophenol and 3-cyano- m/z 425
    cyanophenoxy)-3-cyano-N- 4-fluoro-N-(5-methylpyridin-2- [M + H]+
    (5-methylpyridin-2- yl)benzenesulfonamide MV 1
    yl)benzenesulfonamide (Preparation 40). PM A.
    234 3-cyano-N-(5-fluoropyridin- 4-(hydroxypropan-2-yl)phenol m/z 428
    2-yl)-4-(4-(2- (Preparation 45) and 3-cyano-4- [M + H]+
    hydroxypropan-2- fluoro-N-(5-fluoropyridin-2- MV 1
    yl)phenoxy)benzenesulonamide yl)benzenesulfonamide PM A.
    (Preparation 2).
    235
    Figure US20150259327A1-20150917-C00021
         		4-hydroxy-2,6-bis(methyl- D3)-3,5-D2-benzonitrile (Journal of Labelled Compounds and Radiopharmaceuticals (2009), 52, 10, 435-442) and 3-cyano-4-fluoro-N-(5- fluoropyridin-2- yl)benzenesulfonamide (Preparation 2). m/z 431 [M + H]+ MV 1 PM B, C.
    236
    Figure US20150259327A1-20150917-C00022
         		4-hydroxy-2,6-bis(methyl- D3)-3,5-D2-benzonitrile (Journal of Labelled Compounds and Radiopharmaceuticals (2009), 52, 10, 435-442) and 5-bromo-N-(2,4- dimethoxybenzyl)-2,4- difluoro-N-(5-fluoropyridin-2- yl)benzenesulfonamide (Preparation 12). m/z 504 [M + H]+ MV 5 No PM.
    237 4-(3-chloro-4-cyano-5- 2-chloro-6-fluoro-4- m/z 445
    fluorophenoxy)-3-cyano-N- hydroxybenzonitrile (Prep 44) and 3- [M − H]−
    (5-fluoropyridin-2- cyano-N-(2,4-dimethoxybenzyl)-4- MV 5
    yl)benzenesulfonamide fluoro-N-(5-fluoropyridin-2- PM A.
    yl)benzenesulfonamide (Prep 18).
    238 4-((5-chloro-6- 5-chloro-6-methylpyridin-3-ol (J. Med. m/z 419
    methylpyridin-3-yl)oxy)-3- Chem. (1977), 17 (2), 172-81) and 3- [M + H]+
    cyano-N-(5-fluoropyridin-2- cyano-N-(2,4-dimethoxybenzyl)-4- MV 5
    yl)benzenesulfonamide fluoro-N-(5-fluoropyridin-2- PM A.
    yl)benzenesulfonamide (Prep 18).
    239 4-{[5-chloro-6- 3-chloro-4-(hydroxymethyl)phenol m/z 428
    (hydroxymethyl)pyridin-3- and N-(2,4-dimethoxybenzyl)-2,4- [M + H]+
    yl]oxy}-2-fluoro-N-(5- difluoro-N-(5-fluoropyridin-2- MV 5
    fluoropyridin-2- yl)benzenesulfonamide (Prep 34). PM B.
    yl)benzenesulfonamide
    240 4-(4-chloro-3- 4-chloro-3-(hydroxymethyl)phenol m/z 434
    (hydroxymethyl)phenoxy)- and 3-cyano-N-(2,4- [M + H]+
    3-cyano-N-(5-fluoropyridin- dimethoxybenzyl)-4-fluoro-N-(5- MV 5
    2-yl)benzenesulfonamide fluoropyridin-2- PM B.
    yl)benzenesulfonamide (Prep 18).
    • Example 241 3-cyano-4-(3,5-dichloro-4-cyanophenoxy)-N-(5-fluoropyridin-2-yl)benzenesulfonamide
  • Figure US20150259327A1-20150917-C00023
  • The title compound was prepared according to the method described for Method Variation 5 using 3-cyano-N-(2,4-dimethoxybenzyl)-4-fluoro-N-(5-fluoropyridin-2-yl)benzenesulfonamide (Preparation 18) and 2,6-dichloro-4-hydroxybenzonitrile, and then purified using preparative HPLC.
  • 1H NMR (400 MHz, DMSO-d6): δ ppm 6.58 (d, 1H), 7.13-7.21 (m, 2H), 7.58-7.59 (m, 2H), 7.78 (s, 1H), 7.94 (m, 1H), 8.12 (s, 1H).
  • LCMS Rt=3.29 minutes MS m/z no mass ion
    • Example 242 4-[(5-chloro-6-fluoropyridin-3-yl)oxy]-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide
  • Figure US20150259327A1-20150917-C00024
  • The title compound was prepared according to the method described for Method Variation 1 using 3-cyano-4-fluoro-N-(5-fluoropyridin-2-yl)benzenesulfonamide (Preparation 2) and 3-chloro-2-fluoro-5-hydroxypyridine and then purified using silica gel column chromatography eluting with 30-35% EtOAc in heptanes.
  • MS m/z 423 [M+H]+
    • Example 243 4-[(6-(azetidin-1-yl)-5-chloropyridin-3-yl)oxy]-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide
  • Figure US20150259327A1-20150917-C00025
  • To a solution of 4-((5-chloro-6-fluoropyridin-3-yl)oxy)-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide (Example 242, 200 mg, 0.47 mmol) in dimethylsulfoxide (2 mL) was added azetidine (54 mg, 0.94 mmol) followed by potassium carbonate (130 mg, 0.94 mmol) and the reaction was heated to 50° C. for 17 hours. The mixture was filtered and purified using preparative HPLC to afford the title compound.
  • 1H NMR (400 MHz, DMSO-d6): δ ppm 2.08 (quintet, 2H), 3.98 (t, 4H), 6.84 (d, 1H), 6.90 (dd, 1H), 7.49 (dd, 1H), 7.65 (d, 1H), 7.88 (dd, 1H), 7.93 (d, 1H), 8.01 (d, 1H), 8.15 (d, 1H), 11.08 (br s, 1H).
  • MS m/z 459 [M+H]+
    • Example 244 4-[(5-chloro-6-(methylamino)pyridin-3-yl)oxy]-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide
  • Figure US20150259327A1-20150917-C00026
  • The title compound was prepared according to the method described for Example 243 using methylamine.
  • 1H NMR (400 MHz, DMSO-d6): δ ppm 2.68 (d, 3H), 6.54 (q, 1H), 6.83 (d, 1H), 6.90 (dd, 1H), 7.49 (dt, 1H), 7.62 (d, 1H), 7.85-7.88 (m, 2H), 8.01 (d, 1H), 8.14 (d, 1H), 11.07 (br s, 1H).
  • MS m/z 433 [M+H]+
    • Example 245 4-{[5-chloro-6-(dimethylamino)pyridin-3-yl]oxy}-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide
  • Figure US20150259327A1-20150917-C00027
  • The title compound was prepared according to the method described for Example 243 using dimethylamine.
  • 1H NMR (400 MHz, d4-MeOH): δ ppm 3.00 (s, 6H), 6.99 (d, 1H), 7.16 (dd, 1H), 7.52 (dt, 1H), 7.68 (d, 1H), 8.06-8.11 (m, 3H), 8.31 (d, 1H).
  • MS m/z 447 [M+H]+
    • Example 246 4-[(6-amino-5-chloropyridin-3-yl)oxy]-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide
  • Figure US20150259327A1-20150917-C00028
  • The method described by Example 243 was followed, but using dimethoxybenzylamine instead of azetidine and with heating to 70° C. followed by stirring the residue in TFA (12 mL) for 1 hour. The resulting mixture was concentrated in vacuo and purified using reverse phase column chromatography eluting from 5% to 80% MeCN (0.1% HCO2H) in water (0.1% HCO2H) to afford the title compound.
  • 1H NMR (400 MHz, d4-MeOH): δ ppm 6.97 (d, 1H), 7.16 (dd, 1H), 7.50-7.55 (m, 1H), 7.61 (d, 1H), 7.86 (d, 1H), 8.07 (d, 1H), 8.09 (dd, 1H), 8.29 (d, 1H).
  • MS m/z 419 [M+H]+
    • Example 247 4-[3-chloro-4-(hydroxymethyl)phenoxy]-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide
  • Figure US20150259327A1-20150917-C00029
  • To a stirred solution of 3-chloro-4-(hydroxymethyl)phenol (120 mg, 0.54 mmol) and 3-cyano-N-(2,4-di methoxybenzyl)-4-fluoro-N-(5-fluoropyridin-2-yl)benzenesulfonamide (Preparation 18, 100 mg, 0.22 mmol) in DMSO (1.5 mL) was added potassium carbonate (78 mg, 0.56 mmol) and the reaction stirred at room temperature for 72 hours. Water (10 mL) and EtOAc (15 mL) were added and the layers separated. The aqueous phase was extracted with EtOAc. The combined organic extracts were washed with brine, dried over magnesium sulphate and concentrated in vacuo. The crude product was purified by silica gel column chromatography eluting with 3:2 EtOAc:heptanes. The residue (76 mg, 0.13 mmol) was dissolved in DCM (2 mL) and treated with TFA (2 mL). The reaction was stirred at room temperature for 18 hours. MeOH (1 mL) was added and the reaction concentrated in vacuo. The crude product was purified by silica gel column chromatography eluting with 10-30% EtOAc in DCM to afford the title compound (25 mg, 44%) as a colourless solid (25 mg, 44%).
  • 1H NMR (400 MHz, CDCl3): δ ppm 4.56 (d, 2H), 5.48 (t, 1H), 7.02 (d, 1H), 7.08 (dd, 1H), 7.28 (d, 1H), 7.46 (s, 1H), 7.62-7.72 (m, 2H), 8.08 (d, 1H), 8.20 (s, 1H), 8.36 (s, 1H), 11.24 (br s, 1H).
  • MS m/z 434 [M+H]+
    • Example 248 4-(3-chloro-4-cyanophenoxy)-3-cyano-5-fluoro-N-(5-fluoropyridin-2-yl)benzenesulfonamide
  • Figure US20150259327A1-20150917-C00030
  • To a solution of 3-cyano-4-(4-cyano-3-fluorophenoxy)-5-fluorobenzene-1-sulfonyl chloride (Preparation 43, 27 mg, 0.153 mmol) in DCM (5 mL) was added 5-fluoro-2-aminopyridine (26 mg, 0.230 mmol) followed by pyridine (36 mg, 0.459 mmol, 0.037 mL) and the reaction was stirred at room temperature for 18 hours. The reaction was diluted with DCM (20 mL) and water (30 mL). The organic layer was separated and the aqueous re-extracted with DCM (2×30 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated in vacuo. The residue was purified by reverse phase chromatography eluting with (acetonitrile/0.1% formic acid) and (water/0.1% formic acid), gradient 5% to 60% to afford the title compound as colourless solid (21 mg, 31%).
  • 1H NMR (400 MHz, Acetone-d6): δ ppm 7.29-7.34 (m, 2H), 7.53 (d, 1H), 7.60-7.65 (m, 1H), 7.95 (d, 1H), 8.18 (d, 1H), 8.29 (dd, 1H), 8.34 (m, 1H).
  • MS m/z 447 [M+H]+
    • Example 249 4-({4-cyano-3,5-bis[methyl-D3]-2,3D2-phenyl}oxy)-N-(5-fluoropyridin-2-yl)benzenesulfonamide
  • Figure US20150259327A1-20150917-C00031
  • To a degassed mixture of lithium chloride (42 mg, 1 mmol) in tetrahydrofuran (2 mL) was added tetrakis-(triphenylphosphine)palladium (0) (12 mg, 0.01 mmol) followed by a degassed solution of 5-bromo-4-({4-cyano-3,5-bis[methyl-D3]-2,3-D2-phenyl}oxy)-N-(5-fluoropyridin-2-yl)benzenesulfonamide (Example 236, 100 mg, 0.20 mmol) in tetrahydrofuran (2 mL) and triethylsilane (26 mg, 0.22 mmol). The reaction mixture was heated under reflux for 17 hours. An additional aliquot of tetrakis-(triphenylphosphine)palladium (0) (12 mg, 0.01 mmol), followed by another aliquot of triethylsilane (26 mg, 0.22 mmol), were added and the mixture heated under reflux for a further 24 hours. The reaction was cooled, diluted with ethyl acetate (20 mL), and washed with saturated aqueous ammonium chloride solution (20 mL), water (50 mL) and brine (10 mL). The organic layer was concentrated in vacuo and the residue purified using preparative HPLC to afford the title compound (21 mg, 25%).
  • 1H NMR (400 MHz, DMSO-d6): δ ppm 6.99 (dd, 1H), 7.05 (dd, 1H), 7.14 (dd, 1H), 7.67 (dt, 1H), 7.92 (t, 1H), 8.14 (d, 1H), 11.41 (br s, 1H).
  • MS m/z 424 [M+H]+
  • The compounds of formula (I) that follow may be prepared by procedures described in the aforementioned: Schemes; General Methods and Method Variations, as further illustrated by the Examples and corresponding Preparations; or by processes similar thereto.
    • 5-Chloro-4-(3-cyano-4-fluorophenoxy)-2-fluoro-N-(pyridazin-3-yl)benzenesulfonamide.
    • 5-Chloro-4-(3-chloro-4-cyanophenoxy)-2-fluoro-N-(pyrimidin-2-yl)benzenesulfonamide.
    • 4-(3-Chloro-4-cyanophenoxy)-3-cyano-N-(5-cyanopyridin-2-yl)benzenesulfonamide.
    • 4-(4-Cyano-3-fluorophenoxy)-N-(5-fluoropyridin-2-yl)-2-(trifluoromethyl)benzenesulfonamide.
    • 3-Cyano-4-[4-cyano-3-(trifluoromethoxy)phenoxy]-N-(5-fluoropyridin-2-yl)benzenesulfonamide.
    • 3-Cyano-4-[4-cyano-3-(difluoromethoxy)phenoxy]-N-(5-fluoropyridin-2-yl)benzenesulfonamide.
    • 3-Cyano-4-[4-cyano-3-(difluoromethyl)phenoxy]-N-(5-fluoropyridin-2-yl)benzenesulfonamide.
    • 3-Cyano-4-[4-cyano-3-(cyclopropyloxy)phenoxy]-N-(5-fluoropyridin-2-yl)benzenesulfonamide.
    • 3-Cyano-4-[3-cyano-4-(trifluoromethoxy)phenoxy]-N-(5-fluoropyridin-2-yl)benzenesulfonamide.
    • 3-Cyano-4-[3-cyano-4-(difluoromethoxy)phenoxy]-N-(5-fluoropyridin-2-yl)benzenesulfonamide.
    • 3-Cyano-4-[3-cyano-4-(trifluoromethyl)phenoxy]-N-(5-fluoropyridin-2-yl)benzenesulfonamide.
    • 3-Cyano-4-[3-cyano-4-(difluoromethyl)phenoxy]-N-(5-fluoropyridin-2-yl)benzenesulfonamide.
    • 3-Cyano-4-[3-cyano-4-(cyclopropyloxy)phenoxy]-N-(5-fluoropyridin-2-yl)benzenesulfonamide.
    • 3-Cyano-4-(3-cyano-5-fluorophenoxy)-N-(5-fluoropyridin-2-yl)benzenesulfonamide.
    • 3-Cyano-4-(2-cyano-3-fluorophenoxy)-N-(5-fluoropyridin-2-yl)benzenesulfonamide.
    • 3-Cyano-4-(2-cyano-5-fluorophenoxy)-N-(5-fluoropyridin-2-yl)benzenesulfonamide.
    • 3-Cyano-4-(2-cyano-6-fluorophenoxy)-N-(5-fluoropyridin-2-yl)benzenesulfonamide.
    • 3-Cyano-4-(4-cyano-3,5-difluorophenoxy)-N-(5-fluoropyridin-2-yl)benzenesulfonamide.
    • 3-Cyano-4-[4-cyano-3-(2,2,2-trifluoroethyl)phenoxy]-N-(5-fluoropyridin-2-yl)benzenesulfonamide.
    • 3-Cyano-4-(4-cyano-3-ethylphenoxy)-N-(5-fluoropyridin-2-yl)benzenesulfonamide.
    • 3-Cyano-4-[4-cyano-3-(propan-2-yl)phenoxy]-N-(5-fluoropyridin-2-yl)benzenesulfonamide.
    • 3-Cyano-4-[3-cyano-4-(hydroxymethyl)phenoxy]-N-(5-fluoropyridin-2-yl)benzenesulfonamide.
    • 3-Cyano-4-[4-cyano-3-(hydroxymethyl)phenoxy]-N-(5-fluoropyridin-2-yl)benzenesulfonamide.
    • 4-[4-Chloro-3-(hydroxymethyl)phenoxy]-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide.
    • 4-(3-Chloro-4-cyano-2-fluorophenoxy)-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide.
    • 4-(3-Chloro-4-cyano-2-methoxyphenoxy)-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide.
    • 4-(5-Chloro-4-cyano-2-fluorophenoxy)-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide.
    • 4-(5-Chloro-4-cyano-2-methoxyphenoxy)-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide.
    • 4-(4-Chloro-3-cyano-2-fluorophenoxy)-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide.
    • 4-(4-Chloro-3-cyano-2-methoxyphenoxy)-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide.
    • 4-(4-Chloro-5-cyano-2-fluorophenoxy)-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide.
    • 4-(4-Chloro-5-cyano-2-methoxyphenoxy)-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide.
    • 4-(3-Chloro-4-cyanophenoxy)-3-cyano-N-(5-fluoropyridin-2-yl)-5-methylbenzenesulfonamide.
    • 3-Chloro-4-(3-chloro-4-cyanophenoxy)-5-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide.
    Preparation 1 5-bromo-4-(4-cyano-3-fluorophenoxy)-N-(2,4-dimethoxybenzyl)-2-fluoro-N-(5-fluoropyridin-2-yl)benzenesulfonamide
  • Figure US20150259327A1-20150917-C00032
  • To a solution of 5-bromo-N-(2,4-dimethoxybenzyl)-2,4-difluoro-N-(5-fluoropyridin-2-yl)benzenesulfonamide (Preparation 12, 425 mg, 0.90 mmol) in DMSO (5 mL) was added K2CO3 (372 g, 2.70 mmol) followed by 2-fluoro-4-hydroxybenzonitrile (123 g, 0.90 mmol). The reaction mixture was left to stir at room temperature for 18 hours. To the reaction mixture was added water (20 mL) and saturated brine (20 mL) and the product was extracted with EtOAc (50 mL). The organic layer was retained and washed with saturated brine (3×40 mL), dried over MgSO4, and the solvent removed under vacuum. The residue was purified using silica gel column chromatography eluting with 15% EtOAc in heptanes followed by trituration with heptane to afford the title compound as a colourless solid (74 mg, 28%).
  • 1H NMR (400 MHz, CDCl3): δ ppm 3.68 (s, 3H), 3.76 (s, 3H), 5.00 (s, 2H), 6.34-6.38 (m, 2H), 6.82-6.86 (m, 3H), 7.17 (d, 1H), 7.30-7.35 (m, 2H), 7.66 (dd, 1H, 8.12 (d, 1H), 8.17 (d, 1H).
  • 19F NMR (376 MHz, CDCl3) δ ppm −101.9 (m, 1F), −104.1 (m, 1F), −128.5 (m, 1F).
    • Preparation 2 3-cyano-4-fluoro-N-(5-fluoropyridin-2-yl)benzenesulfonamide
  • Figure US20150259327A1-20150917-C00033
  • 3-Cyano-4-fluorobenzene-1-sulfonyl chloride (25 g, 114 mmol) was added to a solution of 5-fluoropyridin-2-amine (16.85 g, 150 mmol) and pyridine (23.7 g, 300 mmol) in dichloromethane (500 mL) at room temperature. The resulting mixture was stirred at room temperature for 3 hours. After evaporating the solvent the solid was stirred in diluted aqueous hydrochloric acid (2N, 400 mL) for 16 hours. The reaction mixture was filtered, washed with water (200 mL) and dried under high vacuum to afford the title compound as an orange solid (30.9 g, 98%).
  • 1H NMR (400 MHz, DMSO-d6): δ ppm 7.09 (dd, 1H), 7.65-7.77 (m, 2H), 8.18 (d, 1H), 8.22-8.29 (m, 1H), 8.44 (dd, 1H)), 10.82 (br s, 1H).
  • MS m/z 296 [M+H]+
    • Preparation 3 3-cyano-4-fluoro-N-(pyridin-2-yl)benzenesulfonamide
  • Figure US20150259327A1-20150917-C00034
  • The title compound was prepared according to the method described for Preparation 2 using 2-aminopyridine.
  • 1H NMR (400 MHz, DMSO-d6): δ ppm 6.85 (t, 1H), 7.25 (d, 1H), 7.65 (t, 1H), 7.75-7.83 (m, 1H), 7.93 (d, 1H), 8.19 (ddd, 1H), 8.35 (dd, 1H).
  • MS m/z 278 [M+H]+
    • Preparation 4 3-cyano-4-fluoro-N-(pyrazin-2-yl)benzenesulfonamide
  • Figure US20150259327A1-20150917-C00035
  • The title compound was prepared according to the method described for Preparation 2 using 2-aminopyrazine.
  • 1H NMR (400 MHz, DMSO-d6): δ ppm 7.75 (t, 1H), 8.23 (m, 1H), 8.26-8.27 (m, 1H), 8.32-8.36 (m, 2H), 8.53 (dd, 1H).
    • Preparation 5 3-cyano-4-fluoro-N-(pyridin-3-yl)benzenesulfonamide
  • Figure US20150259327A1-20150917-C00036
  • The title compound was prepared according to the method described for Preparation 2 using 2-aminopyrazine.
  • MS m/z 278 [M+H]+
    • Preparation 6 3-Cyano-4-fluoro-N-(pyridazin-3-yl)benzenesulfonamide
  • Figure US20150259327A1-20150917-C00037
  • To a solution of 3-cyano-4-fluorobenzenesulfonyl chloride (11.55 g, 52.63 mmol) in anhydrous acetonitrile (250 mL) was added pyridazin-3-amine (5 g, 52.63 mmol) followed by DABCO (5.9 g, 52.63 mmol) at 0° C. The reaction was stirred at room temperature for 18 hours, and then filtered. The filtrate was concentrated in vacuo and purified using silica gel column chromatography to afford the title compound (4.5 g, 30%)
  • 1H NMR (400 MHz, DMSO-d6): δ ppm 7.61-7.71 (m, 2H), 7.87-7.92 (m, 1H), 8.16 (m, 1H), 8.32-8.37 (m, 2H), 14.61 (s, 1H).
    • Preparation 7 3-Cyano-4-fluoro-N-(pyrimidin-5-yl)benzenesulfonamide
  • Figure US20150259327A1-20150917-C00038
  • The title compound was prepared according to the method described for Preparation 2 using 5-aminopyrimidine.
  • MS m/z 277 [M−H]−
    • Preparation 8 3-Cyano-4-fluoro-N-(pyridazin-4-yl)benzenesulfonamide
  • Figure US20150259327A1-20150917-C00039
  • The title compound was prepared according to the method described for Preparation 6 using 4-aminopyridazine.
  • 1H NMR (400 MHz, DMSO-d6): δ ppm 7.29 (dd, 1H), 7.66 (t, 1H), 8.19 (ddd, 1H), 8.34 (d, 1H), 8.39 (dd, 1H), 8.57 (d, 1H).
    • Preparation 9 3-cyano-4-fluoro-N-(pyridin-3-yl)benzenesulfonamide
  • Figure US20150259327A1-20150917-C00040
  • The title compound was prepared according to the method described for Preparation 2 using 4-aminopyridazine.
  • MS m/s 276 [M−H]−
    • Preparation 10 3-cyano-4-fluoro-N-(methoxymethyl)-N-(pyridazin-3-yl)benzenesulfonamide
  • Figure US20150259327A1-20150917-C00041
  • To a solution of 3-cyano-4-fluoro-N-(pyridazin-3-yl)benzenesulfonamide (Preparation 6, 6.70 g, 24.1 mmol) in DCM (150 mL) at 0° C. was added DIPEA (6.48 mL, 35.18 mmol) followed by chloromethoxymethane (1.46 mL, 25.54 mmol) and the reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was quenched by the addition of 1N NaOH (aq) solution, the organic layer was collected, washed with water, brine, and dried over Na2SO4 before concentrating in vacuo. The residue was purified using silica gel column chromatography eluting with EtOAc:Heptane 1:1 to afford the title compound as a mixture of isomers (3.85 g, 49%) that was used without further purification.
  • MS m/z 323 [M+H]+
    • Preparation 11 5-cyano-N-(2,4-dimethoxybenzyl)-2,4-difluoro-N-(pyrimidin-4-yl)benzenesulfonamide
  • Figure US20150259327A1-20150917-C00042
  • N-(2,4-Dimethoxybenzyl)pyrimidin-4-amine (WO2012004743, 0.70 g, 2.86 mmol), 3-cyano-4-fluorobenzene-1-sulfonyl chloride (0.75 g, 3.43 mmol) and 1,4-diazabicyclo[2.2.2]octane (0.39 g, 3.43 mmol) in acetonitrile (15 mL) were stirred at room temperature for 18 hours. The reaction mixture was diluted with dichloromethane (100 mL), washed with water (100 mL), the organic layer was dried over anhydrous magnesium sulphate and the filtrate was concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with 10% dichloromethane in ethyl acetate to afford the title compound as a yellow glass (0.69 g, 57%).
  • 1H NMR (400 MHz, CDCl3): δ ppm 3.59 (s, 3H), 3.80 (s, 3H), 5.15 (s, 2H), 6.35 (d, 1H), 6.45-6.43 (m, 1H), 7.17-7.10 (m, 2H), 7.30 (t, 1H), 8.00-7.98 (m, 1H), 8.23-8.19 (m, 1H), 8.55 (d, 1H), 8.87 (s, 1H).
  • 19F NMR (376 MHz, CDCl3): δ ppm −98.30
    • Preparation 12 5-bromo-N-(2,4-dimethoxybenzyl)-2,4-difluoro-N-(5-fluoropyridin-2-yl)benzenesulfonamide
  • Figure US20150259327A1-20150917-C00043
  • The title compound was prepared according to the method described for Preparation 11 using N-(2,4-dimethoxybenzyl)-5-fluoropyridin-2-amine (Preparation 20).
  • 1H NMR (400 MHz, CDCl3): δ ppm 3.65 (s, 3H), 3.76 (3, 3H), 4.99 (s, 2H), 6.32-6.36 (m, 2H), 6.97 (dd, 1H), 7.16 (dd, 1H), 7.28-7.38 (m, 2H), 8.02 (t, 1H), 8.17 (s, 1H). 19F NMR (376 MHz, CDCl3): δ ppm −128 (s, 1F), −104 (s, 1F), −94 (s, 1F).
    • Preparation 13 N-2,4-dimethoxybenzyl-2,4,5-trifluoro-N-(5-fluoropyridin-2-yl)benzenesulfonamide
  • Figure US20150259327A1-20150917-C00044
  • The title compound may be prepared according to the method described for Preparation 11 using 2,4,5-trifluorobenzenesulfonyl chloride and N-2,4-dimethoxybenzyl-5-fluoropyridin-2-amine (WO2012004743).
  • 1H NMR (400 MHz, CDCl3): δ ppm 3.65 (s, 3H), 3.76 (3, 3H), 4.99 (s, 2H), 6.32-6.36 (m, 2H), 6.97 (dd, 1H), 7.16 (dd, 1H), 7.28-7.38 (m, 2H), 8.02 (t, 1H), 8.17 (s, 1H).
    • Preparation 14 3-cyano-N-(2,4-dimethoxybenzyl)-4-fluoro-N-(pyridazin-3-yl)benzenesulfonamide
  • Figure US20150259327A1-20150917-C00045
  • To a suspension of N-(2,4-dimethoxybenzyl)pyridazin-3-amine (Preparation 19, 1.0 g, 4.00 mmol) in THF (15 mL) at −20° C. was slowly added LiHMDS (1M, 4.0 mL, 4.00 mmol). The reaction mixture was left to stir at −20° C. for 30 minutes and then cooled to −78° C. To the reaction mixture was slowly added 3-cyano-4-fluorobenzene-1-sulfonyl chloride (0.8 g, 3.64 mmol) suspended in THF (15 mL). The reaction mixture was slowly warmed to room temperature and left at room temperature for 18 hours. To the vessel was added saturated aqueous NH4Cl solution (30 mL) and the product was extracted with EtOAc (25 mL). The organic layer was washed with saturated brine (40 mL), dried over MgSO4, and the solvent removed under vacuum. The residue was purified using silica gel column chromatography eluting with 70% EtOAc in heptanes to afford the title compound as an orange oil (561 mg, 36%).
  • 1H NMR (400 MHz, CDCl3): δ ppm 3.54 (s, 3H), 3.76 (s, 3H), 5.01 (s, 2H), 6.28 (d, 1H), 6.36 (dd, 1H), 7.16 (d, 1H), 7.32 (t, 1H), 7.48 (m, 2H), 7.94 (dd, 1H), 8.09 (ddd, 1H), 9.03 (dd, 1H).
  • 19F NMR (376 MHz, MeOD): δ ppm −98.8
    • Preparation 15 3-cyano-N-(2,4-dimethoxybenzyl)-4-fluoro-N-(5-fluoropyrimidin-2-yl)benzenesulfonamide
  • Figure US20150259327A1-20150917-C00046
  • The title compound was prepared according to the method described for Preparation 14 using N-(2,4-dimethoxybenzyl)-5-fluoropyrimidin-2-amine (WO2012004706).
  • 1H NMR (400 MHz, CDCl3): δ ppm 3.30 (s, 3H), 3.81 (s, 3H), 5.38 (s, 2H), 6.23 (d, 1H), 6.46 (dd, 1H), 7.15-7.20 (m, 2H), 7.77 (dd, 1H), 8.14 (m, 1H), 8.23 (s, 2H).
    • Preparation 16 N-3,4-dimethoxybenzyl-3,4-di-fluoro-N-(5-fluoropyridin-2-yl)benzenesulfonamide
  • Figure US20150259327A1-20150917-C00047
  • The title compound was prepared according to the method described for Preparation using 3,4,-difluorobenzenesulfonyl chloride and N-2,4-dimethoxybenzyl-5-fluoropyridin-2-amine (WO2012004743).
  • 1H NMR (400 MHz, CDCl3): δ ppm 3.64 (s, 3H), 3.75 (s, 3H), 4.82 (s, 2H), 6.36 (m, 2H), 7.22 (d, 1H), 7.27 (m, 1H), 7.38 (m, 2H), 7.46 (m, 1H), 7.53 (m, 1H), 8.18 (d, 1H).
    • Preparation 17 3-cyano-N-(2,4-dimethoxybenzyl)-4-fluoro-N-(pyrimidin-2-yl)benzenesulfonamide
  • Figure US20150259327A1-20150917-C00048
  • The title compound was prepared according to the method described for Preparation 14 using NaHMDS and N-(2,4-dimethoxybenzyl)-2-pyrimidinamine (WO2012004743) at −50° C. The residue was triturated with EtOAc:Heptane 1:1 followed by acetone.
  • 1H NMR (400 MHz, CDCl3): δ ppm 3.28 (s, 3H), 3.82 (s, 3H), 4.42 (s, 2H), 6.23 (s, 1H), 6.44 (m, 1H), 6.99 (m, 1H), 7.18 (m, 2H), 7.82 (m, 1H), 8.15 (m, 1H), 8.57 (d, 2H).
    • Preparation 18 3-cyano-N-(2,4-dimethoxybenzyl)-4-fluoro-N-(5-fluoropyridin-2-yl)benzenesulfonamide
  • Figure US20150259327A1-20150917-C00049
  • To a −40° C. solution of N-(2,4-dimethoxybenzyl)-5-fluoropyridin-2-amine (Preparation 20, 2.32 g, 8.84 mmol) in THF (60 ml) was added LiHMDS (9.72 ml, 9.72 mmol, 1M in THF) keeping the temperature below −35° C. The reaction mixture was warmed to 0° C. for 40 minutes before re-cooling to −40° C. 3-Cyano-4-fluorobenzene-1-sulfonyl chloride (1.94 g, 8.84 mmol) was added to the reaction mixture as a solution in THF (10 mL) and the reaction mixture allowed to warm to room temperature for 18 hours. The reaction mixture was quenched with saturated ammonium chloride solution (100 mL) and extracted with EtOAc (2×100 mL). The organic layer was washed with saturated brine (100 mL), dried over MgSO4, filtered and the solvent removed under vacuum. The crude material was purified by silica gel column chromatography eluting with 20-40% EtOAc in heptane followed by reverse phase chromatography eluting with 0-100% MeCN in H2O to afford the title compound as a brown gum (2.48 g, 63%).
  • 1H NMR (400 MHz, CDCl3): δ ppm 3.62 (s, 3H), 3.76 (s, 3H), 4.82 (s, 2H), 6.31 (d, 1H), 6.35 (dd, 1H), 7.10 (d, 1H), 7.26-7.41 (m, 3H), 7.95-8.01 (m, 2H), 8.19 (d, 1H).
  • 19F NMR (376 MHz, CDCl3): δ ppm −99.36, −127.93
    • Preparation 19 N-[(2,4-dimethoxyphenyl)methyl]pyridazin-3-amine
  • Figure US20150259327A1-20150917-C00050
  • To a solution of 3,6-dichloropyridazine (1 g, 6.71 mmol) in nBuOH (25 mL) was added DIPEA (3.31 mL, 18.6 mmol) and 2,4-dimethoxybenzylamine (1.12 g, 6.71 mmol) and the reaction mixture was heated to 100° C. for 18 hours. The reaction mixture was concentrated in vacuo to afford 6-chloro-N-(2,4-dimethoxybenzyl)pyridazin-3-amine.
  • To a solution of 6-chloro-N-(2,4-dimethoxybenzyl)pyridazin-3-amine (7.5 g, 26.9 mmol) in ethanol (250 mL) was added ammonium formate (5.94 g, 94.15 mmol) and the mixture was degassed with nitrogen three times. Palladium on charcoal (10 wt %, 2.14 g) was added and the mixture was degassed and recharged with nitrogen and stirred at 80° C. for 90 minutes under a nitrogen atmosphere. The mixture was filtered, concentrated to 15 mL and partitioned between DCM (200 mL) and water (150 mL). The organic layer was washed with brine (150 mL) and concentrated in vacuo. The residue was recrystallised from EtOAc to afford the title compound as cream coloured solid (4.5 g, 68%).
  • 1H NMR (400 MHz, CDCl3): δ ppm 3.79 (s, 3H), 3.83 (s, 3H), 4.51 (d, 2H), 5.19 (b r s, 1H), 6.43 (dd, 1H), 6.47 (d, 1H), 6.62 (dd, 1H), 7.12 (dd, 1H), 7.24 (d, 1H), 8.52 (d, 1H).
    • Preparation 20 N-(2,4-dimethoxybenzyl)-5-fluoropyridin-2-amine
  • Figure US20150259327A1-20150917-C00051
  • Potassium carbonate (16.75 g, 128.1 mmol) was added to a solution of 2,5-difluoropyridine (4.91 g, 42.7 mmol) and 2,4-dimethoxybenzylamine (6.85 g, 42.7 mmol) in DMSO (30 mL). The mixture was heated to 110° C. for 16 hours, cooled to room temperature and poured into water (100 mL) and ethyl acetate (100 mL). The organic layer was separated and the aqueous layer was extracted with two further portions of ethyl acetate (25 mL). The combined organic extracts were washed with brine (50 mL), dried over MgSO4 and concentrated in vacuo. The residue was purified using silica gel column chromatography eluting with 10 to 30% ethyl acetate in heptanes to afford the title compound as a white solid (2.43 g, 22%).
  • 1H NMR (400 MHz, CDCl3): δ ppm 3.79 (s, 3H), 3.83 (s, 3H), 4.37 (m, 2H), 4.91 (br s, 1H), 6.34-6.44 (m, 3H), 7.17 (m, 2H) 7.94 (s, 1H).
    • Preparation 21 4-(3-chloro-4-cyanophenoxy)-3-cyanobenzene-1-sulfonyl chloride
  • Figure US20150259327A1-20150917-C00052
  • To a solution of trichloroisocyanuric acid (2.68 g, 11.55 mmol) in acetonitrile (25 ml) was added a solution of benzyltrimethylammonium chloride (6.56 g, 35.28 mmol) in water (11.7 ml) and the mixture was stirred at room temperature for 30 min, then cooled with an ice bath. The mixture was added to an ice cold solution of 4-(4-(benzylthio)-2-cyanophenoxy)-2-chlorobenzonitrile (Preparation 22, 4.61 g, 10.50 mmol) in acetonitrile (50 ml) with 1M sodium carbonate (10.5 ml, 10.5 mmol). The reaction mixture was stirred for 30 minutes at 0° C. The reaction mixture was doubled in volume using ethyl acetate and washed twice with dilute sodium hydrogen carbonate solution (2×200 mL). The organic layer was dried over MgSO4, filtered, and concentrated in vacuo. The residue was purified using silica gel column chromatography eluting with 0% to 20% ethyl acetate in heptanes to afford the title compound as a yellow solid (2.1 g, 46%).
  • 1H NMR (400 MHz, CDCl3): δ ppm 7.13 (d, 1H), 7.19 (d, 1H), 7.36 (s, 1H), 7.83 (d, 1H), 8.22 (d, 1H), 8.41 (s, 1H).
    • Preparation 22 4-(4-(benzylthio)-2-cyanophenoxy)-2-chlorobenzonitrile
  • Figure US20150259327A1-20150917-C00053
  • To a solution of 5-(benzylthio)-2-fluorobenzonitrile (Preparation 23, 6.18 g, 25.4 mmol) in dimethylsulfoxide (64 mL) was added potassium carbonate (10.92 g, 79 mmol) and 2-fluoro-4-hydroxybenzonitrile (6.07 g, 39.5 mmol). The reaction mixture was heated at 80° C. for 18 hours. The reaction mixture was diluted to 500 mL volume with diethyl ether and washed with dilute brine (250 mL), then 2N sodium hydroxide (aq) (2×250 mL) and finally dilute brine (250 mL). The combined organic layers were dried over MgSO4, filtered and the solvent removed in vacuo. The crude material was dissolved in 10% methanol in ethyl acetate, silica (25 g) was added and the mixture evaporated to dryness under vacuum. The resulting solid was purified using silica gel column chromatography eluting with 0% to 100% ethyl acetate in heptanes to furnish the title compound as light brown solid (5.61 g, 51%).
  • 1H NMR (400 MHz, CDCl3): δ ppm 4.14 (s, 2H), 6.98 (d, 2H), 7.17 (s, 1H), 7.22 to 7.38 (m, 5H), 7.46 (d, 1H), 7.58 (s, 1H), 7.65 (d, 1H).
    • Preparation 23 5-(benzylthio)-2-fluorobenzonitrile
  • Figure US20150259327A1-20150917-C00054
  • To a degassed solution of 5-bromo-2-fluorobenzonitrile (10 g, 50 mmol) in toluene (250 mL) was added N,N-diisopropylethylamine (26 mL, 150 mmol), benzyl mercaptan (5.87 mL, 52 mmol) and dichloro[1,1′ bis(di-tert-butylphosphino)]ferrocene palladium (II) (500 mg, 1 mmol). The reaction mixture was heated at 60° C. for 16 hours. The reaction mixture was diluted to 500 mL volume with ethyl acetate and washed with dilute brine (300 mL), then 2N HCl (2×300 mL) and finally dilute brine (300 mL). The combined organic layers were dried over MgSO4, filtered and the solvent removed in vacuo. The residue was purified using silica gel column chromatography eluting with 10% ethyl acetate in heptane to afford the title compound as light brown solid (6.18 g, 51%) 1H NMR (400 MHz, CDCl3): δ ppm 4.04 (s, 2H), 7.08 (t, 1H), 7.40 to 7.55 (m, 5H), 7.43 (m, 2H).
    • Preparation 24 4-chloro-2-D3-methoxyphenol
  • Figure US20150259327A1-20150917-C00055
  • To a solution of 3-D3-methoxy-4-acetylchlorobenzene (Preparation 25, 200 mg, 1.07 mmol) in DCM (10 mL) was added metachloroperbenzoic acid (276 mg, 1.6 mmol) and TFA (200 uL) and the reaction mixture was stirred at reflux for 18 hours. The cooled reaction mixture was poured onto 10% aqueous sodium metabisulphite (100 mL) and extracted with DCM (3×50 mL). The combined organic extracts were washed with saturated aqueous NaHCO3 (3×100 mL), dried over MgSO4 and concentrated in vacuo. The residue was dissolved in THF/water, sodium hydroxide (40 mg, 1 mmol) was added and the reaction stirred at room temperature for 18 hours. The reaction mixture was concentrated in vacuo then partitioned between EtOAc and water. The aqueous layer was collected and acidified with 2N HCl (aq). The compound was extracted from the aqueous phase with EtOAc, dried over MgSO4 and concentrated in vacuo to afford the title compound as an oil (125 mg, 78%), which was used without further purification.
    • Preparation 25 3-D3-methoxy-4-acetylchlorobenzene
  • Figure US20150259327A1-20150917-C00056
  • To a solution of 3-chloro-4-acetylphenol (5 g, 5.88 mmol) in DMF (5 mL) was added potassium carbonate (974 mg, 7.05 mmol) followed by CD3 l (1.02 g, 7.05 mmol) and the reaction mixture was stirred at 50° C. for 18 hours. The reaction mixture was poured into diethyl ether and washed with water, dried over MgSO4 and concentrated in vacuo to afford the title compound as a pale yellow solid (1.24 g, 94%).
  • MS m/z 188 [M+H]+
    • Preparation 26 4-chloro-2-(difluoromethoxy)phenol
  • Figure US20150259327A1-20150917-C00057
  • To a solution of 4-chloro-2-(difluoromethoxy)bromobenzene (Preparation 27, 200 mg, 0.63 mmol) in THF (6 mL) was added bis-neopentylglycolatodiboron (149 mg, 0.660 mmol), potassium acetate (191 mg, 1.88 mmol) and Pd(dppf)Cl2 (23 mg, 0.031 mmol). The reaction mixture was heated to reflux for 4 hours before cooling and diluting with EtOAc and water. The organic layer was collected, washed with brine, dried over Na2SO4 and concentrated in vacuo. The residue was dissolved in acetone (6 mL) and treated with a solution of oxone (1.64 g, 2.54 mmol) in water (6 mL). The reaction mixture was stirred at room temperature for 15 minutes. The reaction mixture was diluted with diethyl ether (10 mL) and water (5 mL). The organic layer was collected, washed with brine, dried over Na2SO4 and concentrated in vacuo. The residue was purified using silica gel column chromatography eluting with 0-15% diethyl ether in DCM to afford the title compound.
  • MS m/z 193 [M−H]−
    • Preparation 27 4-chloro-2-(difluoromethoxy)bromobenzene
  • Figure US20150259327A1-20150917-C00058
  • To a solution of 2-bromo-5-chlorophenol (1 g, 4.8 mmol) in DMF/water (45 mL/5 mL) was added sodium chlorodifluoroacetate (1.95 g, 12.0 mmol) and cesium carbonate (3.14 g, 9.64 mmol), and the reaction mixture was heated to 100° C. for 4 hours. The reaction mixture was cooled and diluted with TBME (20 mL) and water (20 mL). The organic layer was collected, washed with saturated aqueous NaHCO3 solution, brine, dried over Na2SO4 and concentrated in vacuo to afford the title compound (1.21 g, 98%), which was used without further purification.
    • Preparation 28 5-cyano-2-(difluoromethoxy)phenol
  • Figure US20150259327A1-20150917-C00059
  • To a solution of trimethylsilylethanol (0.953 mL, 6.68 mmol) in THF (20 mL) was added sodium hydride (267 mg, 6.68 mmol) at 0° C. The reaction mixture was stirred at this temperature for 30 minutes before the addition of 4-cyano-2-(difluoromethoxy)fluorobenzene (Preparation 29, 500 mg, 2.67 mmol). The reaction mixture was stirred at room temperature for 5 hours. The reaction mixture was quenched by the addition of methanol and concentrated in vacuo. The residue was purified using silica gel column chromatography eluting with 10-80% EtOAc in heptanes. The residue was dissolved in THF (6 mL) and TBAF (2 mL) was added. The reaction mixture was stirred at room temperature for 5 hours before the addition of silica gel and concentrating in vacuo. The residue was purified using silica gel column chromatography eluting with 10-100% EtOAc in heptanes to afford the title compound (260 mg, 41%).
  • MS m/z 184 [M−H]−
    • Preparation 29 4-cyano-2-(difluoromethoxy)fluorobenzene
  • Figure US20150259327A1-20150917-C00060
  • The title compound was prepared according to the method described for Preparation 27 using 2-fluoro-5-cyanophenol and was used without further purification.
    • Preparation 30 5-chloro-6-ethoxypyridin-3-ol
  • Figure US20150259327A1-20150917-C00061
  • The title compound was prepared according to the method described for the preparation of 5-chloro-6-(2-methylpropoxy)-3-pyridinol (WO2012007869), using 2-ethoxy-3-chloro-5-hydroxypyridine.
    • Preparation 31 5-chloro-N-(2,4-dimethoxybenzyl)-2,4-difluoro-N-(pyridazin-3-yl)benzenesulfonamide
  • Figure US20150259327A1-20150917-C00062
  • The title compound was prepared according to the method described for Preparation 14 using N-[(2,4-dimethoxyphenyl)methyl]pyridazin-3-amine (Preparation 19) and 2,4-difluoro-5-chlorobenzenesulfonyl chloride.
  • MS m/z 456 [M+H]+
    • Preparation 32 3-chloro-N-(2,4-dimethoxybenzyl)-4-fluoro-N-(5-fluoropyridin-2-yl)benzenesulfonamide
  • Figure US20150259327A1-20150917-C00063
  • The title compound was prepared according to the method described for Preparation 18 using N-(2,4-dimethoxybenzyl)-5-fluoropyridin-2-amine (Preparation 20) and 4-fluoro-5-chlorobenzenesulfonyl chloride.
  • 1H NMR (400 MHz, CDCl3): δ ppm 3.63 (s, 3H), 3.73 (s, 3H), 4.82 (s, 2H), 6.30-6.34 (m, 2H), 7.11 (d, 1H), 7.20 (t, 1H), 7.29-7.37 (m, 2H), 7.57 (ddd, 1H), 7.75 (dd, 1H), 8.16 (dd, 1H).
  • 19F NMR (400 MHz, CDCl3): δ ppm −128.61 (dd, ArF), −107.49 to −107.44 (m, ArF).
    • Preparation 33 3-bromo-N-(2,4-dimethoxybenzyl)-4-fluoro-N-(5-fluoropyridin-2-yl)benzenesulfonamide
  • Figure US20150259327A1-20150917-C00064
  • The title compound was prepared according to the method described for Preparation 11 using N-(2,4-dimethoxybenzyl)-5-fluoropyridin-2-amine (Preparation 20) and 4-fluoro-5-bromobenzenesulfonyl chloride at 40° C. The residue was purified by silica gel column chromatography eluting with 10% EtOAc in heptanes.
  • 1H NMR (400 MHz, CDCl3): δ ppm 3.63 (s, 3H), 3.73 (s, 3H), 4.82 (s, 2H), 6.30 (d, 1H), 6.32 (dd, 1H), 7.11 (d, 1H), 7.17 (t, 1H), 7.29-7.37 (m, 2H), 7.60-7.63 (m, 1H), 7.89 (dd, 1H), 8.16 (d, 1H).
  • 19F NMR (400 MHz, CDCl3): δ ppm −128.63 (dd, ArF), −99.49 to −99.44 (m, ArF).
    • Preparation 34 N-(2,4-dimethoxybenzyl)-2,4-difluoro-N-(5-fluoropyridin-2-yl)benzenesulfonamide
  • Figure US20150259327A1-20150917-C00065
  • The title compound was prepared according to the method described for Preparation 11 using N-(2,4-dimethoxybenzyl)-5-fluoropyridin-2-amine (Preparation 20) and 2,4-difluorobenzene-1-sulfonyl chloride.
  • 1H NMR (400 MHz, CDCl3): δ ppm 3.67 (s, 3H), 3.75 (s, 3H), 4.99 (s, 2H), 6.34 (s, 2H), 6.87-6.97 (m, 2H), 7.16 (d, 1H), 7.29-7.36 (m, 2H), 7.80-7.86 (m, 1H), 8.13 (d, 1H).
    • Preparation 35 2-((2,4-dimethoxybenzyl)amino)isonicotinonitrile
  • Figure US20150259327A1-20150917-C00066
  • The title compound was prepared according to the method described for Preparation 20 using 2,4-dimethoxybenzylamine and 2-fluoroisonicotinonitrile.
  • 1H NMR (400 MHz, CDCl3): δ ppm 3.80 (s, 3H), 3.84 (s, 3H), 4.41 (d, 2H), 5.26 (br s, 1H), 6.44 (dd, 1H), 6.48 (d, 1H), 6.70 (dd, 1H), 7.18 (d, 1H), 8.19 (d, 1H).
  • MS m/z 270 [M+H]+
    • Preparation 36 3-cyano-N-(4-cyanopyridin-2-yl)-N-(2,4-dimethoxybenzyl)-4-fluorobenzenesulfonamide
  • Figure US20150259327A1-20150917-C00067
  • The title compound was prepared according to the method described for Preparation 18 using 2-((2,4-dimethoxybenzyl)amino)isonicotinonitrile (Preparation 35) and 3-cyano-4-fluorobenzene-1-sulfonyl chloride. The residue was purified by reverse phase chromatography eluting with 0-100% MeCN in water/0.1% formic acid.
  • 1H NMR (400 MHz, CDCl3): δ ppm 3.60 (s, 3H), 3.78 (s, 3H), 4.96 (s, 2H), 6.32 (d, 1H), 6.39 (dd, 1H), 7.13 (d, 1H), 7.29-7.34 (m, 2H), 7.48 (s, 1H), 8.01 (dd, 1H), 8.05 (m, 1H), 8.50 (d, 1H).
  • 19F NMR (376 MHz, CDCl3): δ ppm −98.74.
    • Preparation 37 6-((2,4-dimethoxybenzyl)amino)nicotinonitrile
  • Figure US20150259327A1-20150917-C00068
  • The title compound was prepared according to the method described for Preparation 20 using 2,4-dimethoxybenzylamine and 6-fluororonicotinonitrile.
  • 1H NMR (400 MHz, CDCl3): δ ppm 3.80 (s, 3H), 3.84 (s, 3H), 4.47 (d, 2H), 5.47 (br s, 1H), 6.38 (d, 1H), 6.44 (dd, 1H), 6.48 (d, 1H), 7.53 (dd, 1H), 8.36 (d, 1H).
  • MS m/z 270 [M+H]+
    • Preparation 38 3-cyano-N-(5-cyanopyridin-2-yl)-N-(2,4-dimethoxybenzyl)-4-fluorobenzenesulfonamide
  • Figure US20150259327A1-20150917-C00069
  • The title compound was prepared according to the method described for Preparation 18 using 6-((2,4-dimethoxybenzyl)amino)nicotinonitrile (Preparation 37) and 3-cyano-4-fluorobenzene-1-sulfonyl chloride. The residue was purified by reverse phase chromatography eluting with 0-100% MeCN in water/0.1% formic acid.
  • 1H NMR (400 MHz, d4-MeOH): δ ppm 3.47 (s, 3H), 3.77 (s, 3H), 5.10 (s, 2H), 6.34 (d, 1H), 6.44 (dd, 1H), 7.14 (d, 1H), 7.45-7.51 (m, 2H), 7.98 (dd, 1H), 8.10 (dd, 1H), 8.24 (m, 1H), 8.68 (d, 1H).
  • 19F NMR (376 MHz, CDCl3): δ ppm −102.69.
    • Preparation 39 3-cyano-4-fluoro-N-(5-chloropyridin-2-yl)benzenesulfonamide
  • Figure US20150259327A1-20150917-C00070
  • The title compound was prepared according to the method described for Preparation 2 using 5-chloropyridin-2-amine.
  • MS m/z 310 [M−H]−
    • Preparation 40 3-cyano-4-fluoro-N-(5-methylpyridin-2-yl)benzenesulfonamide
  • Figure US20150259327A1-20150917-C00071
  • The title compound was prepared according to the method described for Preparation 2 using 5-methylpyridin-2-amine.
  • 1H NMR (400 MHz, DMSO-d6): δ ppm 2.12 (s, 3H), 5.73 (s, 1H), 7.17 (d, 1H), 7.62-7.66 (m, 2H), 7.79 (br s, 1H), 8.14-8.18 (m, 1H), 8.34 (dd, 1H).
  • MS m/z 292 [M+H]+
    • Preparation 41 5-bromo-2-(4-cyano-3-chlorophenoxy)-3-fluorobenzonitrile
  • Figure US20150259327A1-20150917-C00072
  • The title compound was prepared according to the method described for Preparation at 120° C. for 68 hours using 5-bromo-3-fluoro-2-hydroxybenzonitrile (WO 2006022374) and 2-chloro-4-fluorobenzonitrile.
  • 1H NMR (400 MHz, CDCl3): δ ppm 6.94 (dd, 1H), 7.06 (d, 1H), 7.65-7.70 (m, 3H).
    • Preparation 42 5-(benzylthio)-2-(4-cyano-3-chlorophenoxy)-3-fluorobenzonitrile
  • Figure US20150259327A1-20150917-C00073
  • The title compound was prepared according to the method described for Preparation at reflux using 5-bromo-2-(4-cyano-3-chlorophenoxy)-3-fluorobenzonitrile (Preparation 41) and benzyl mercaptan. The reaction was allowed to cool to room temperature and diluted with EtOAc (100 mL), water (50 mL) and saturated aqueous sodium hydrogen carbonate solution (100 mL). The organic was separated and the aqueous was re-extracted with EtOAc (2×100 mL). The combined organic layers were washed with brine (100 mL), dried over sodium sulfate, filtered and concentrated in vacuo. The residue was absorbed onto silica and purified by silica gel column chromatography eluting with 10% EtOAc in heptanes to afford the title compound as a yellow solid (115 mg, 28%).
  • 1H NMR (400 MHz, CDCl3): δ ppm 4.18 (s, 2H), 6.89 (dd, 1H), 7.00 (d, 1H), 7.29-7.35 (m, 7H), 7.63 (d, 1H).
    • Preparation 43 3-cyano-4-(4-cyano-3-chlorophenoxy)-5-fluorobenzene-1-sulfonyl chloride
  • Figure US20150259327A1-20150917-C00074
  • The title compound was prepared according to the method described for Preparation 21 using 5-(benzylthio)-2-(4-cyano-3-chlorophenoxy)-3-fluorobenznitrile (Preparation 42).
  • 1H NMR (400 MHz, CDCl3): δ ppm 7.01 (dd, 1H), 7.16 (d, 1H), 7.75 (m, 1H), 8.13 (dd, 1H), 8.23 (m, 1H).
    • Preparation 44 2-chloro-6-fluoro-4-hydroxybenzonitrile
  • Figure US20150259327A1-20150917-C00075
  • A solution of 2-chloro-6-fluoro-4-hydroxybenzaldehyde (WO 2008141249, 90 mg, 0.344 mmol) in formic acid (1 mL) was treated with hydroxylamine hydrochloride (23.9 mg, 0.344 mmol) and sodium formate (23.4 mg, 0.344 mmol) and stirred under nitrogen for 3.5 hours at 105° C. The mixture was concentrated in vacuo and the residue treated with saturated aqueous sodium bicarbonate solution (10 mL). The aqueous solution was extracted with ethyl acetate (2×10 mL), dried over sodium sulphate and concentrated in vacuo. The residue was purified using silica gel column chromatography eluting with 30-50% EtOAc in heptanes to afford the title compound as a beige solid (33 mg, 56%).
  • 1H NMR (400 MHz, MeOH-d4): δ ppm 6.70 (dd, 1H), 6.85 (d, 1H).
    • Preparation 45 4-(2-hydroxypropan-2-yl)phenol
  • Figure US20150259327A1-20150917-C00076
  • To a solution of 4-acetylphenyl acetate (250 mg, 1.4 mmol) in anhydrous THF (5 mL) cooled to −10° C. under nitrogen was added 3M methylmagnesium chloride solution in THF (2.81 mL, 8.42 mmol) over 10 minutes, keeping the internal temperature below −5° C. The resulting pale yellow solution was allowed to warm to room temperature for 5 hours. The reaction mixture was cooled in an ice bath and quenched with saturated aqueous ammonium chloride solution (20 mL). The resulting clear solution was extracted with EtOAc (2×50 mL). The combined organic extracts were washed with brine (50 mL), dried over MgSO4, filtered and concentrated in vacuo. The solid residue was purified by silica gel column chromatography eluting with 10-50% EtOAc in heptanes to afford the title compound as white solid (100 mg, 47%).
  • 1H NMR (400 MHz, DMSO-d6): δ ppm 1.34 (s, 6H), 4.75 (s, 1H), 6.62 (d, 2H), 7.21 (d, 2H), 9.08 (s, 1H).
    • Biological Assay 1. Generation of a Custom Clonal Cell Line for URAT1 Transporter Activity Assay
  • The nucleotide sequence for the long isoform of URAT1 (NM—144585) was C-terminally fused to that of enhanced green fluorescent protein (eGFP) (hereinafter referred to as URAT1(L)GFP). The combined sequence was codon-optimised and custom synthesized. The synthesized sequence was generated in pDONR221 Gateway entry vector (Invitrogen Life Technologies) prior to cloning in pLenti6.3/V5 Gateway destination vector (Invitrogen Life Technologies). A schematic of the URAT1(L)GFP construct is set forth in FIG. 1A. The nucleotide and amino acid sequence of the URAT1(L)GFP construct is set out in FIG. 1B, which also shows alignment of the nucleotide sequence with NM—144585.
  • Lentiviral particles were generated according to ViraPower HiPerform expression system procedure (Invitrogen Life Technologies) and used to transduce CHO cells. Blasticidin selection enabled the generation of a stable clonal pool of cells, confirmed by expression of GFP and V5 epitope. The clonal pools were sorted using fluorescence-activated cell sorting (FACS) on the basis of GFP expression with the gating set at the top 50% of expression into single cells which were subsequently expanded to generate clonal lines. One clone was identified with the best assay performance as determined by maximal separation between complete inhibition of uric acid transport (with 10 μM benzbromarone) and no inhibition (DMSO). This cell line was used for all screening activities and is referred to as CHO-URAT1(L)GFP#8 or CHO#8.
    • 2. URAT-1 Inhibitor Activity
  • The potency of the compounds of formula (I) as inhibitors of the URAT-1 transporter was determined as follows.
  • CHO#8 cells were cultured in cell line maintenance flasks in medium consisting of Dulbecco's modified Eagle medium (DMEM) with high glucose and sodium pyruvate (4.5 g of glucose per litre, Invitrogen Life Technologies), supplemented with heat-inactivated foetal bovine serum (FBC, 10% v/v), 1×NEAA (non-essential amino acids) and blasticidin (10 μg/ml). Cultures were grown in 175 cm2 tissue culture flasks in a humidified incubator at approximately 37° C. in approximately 95% air/5% CO2. Near confluent CHO#8 cell cultures were harvested by trypsinisation, re-suspended in culture medium and the process was repeated once or twice weekly to provide sufficient cells for use.
  • Assay ready flasks were generated by the same method, except the cells were not cultured in blasticidin.
  • Assay ready frozen cells were generated by freezing 40,000,000 cells in 1 ml of FBS (without blasticidin) containing 10% DMSO per vial. One vial was sufficient for 5 assay plates. Each vial was thawed rapidly to 37° C., washed and re-suspended in pre-warmed culture medium for seeding onto assay plates.
  • CHO#8 cells were seeded onto Cytostar™ 96-well plates at a density of 5×105 cells per well. The cells were cultured for 1 day at approximately 37° C. in a humidified incubator containing approximately 5% CO2 in air. After approximately 24 hours culture, cells were used for uptake experiments.
  • On the day of assay, culture medium was removed from the wells and the cells were washed once with 50 μL of chloride-containing buffer (136.7 mM NaCl, 5.36 mM KCl, 0.952 mM CaCl2, 0.441 mM KH2PO4, 0.812 mM MgSO4, 5.6 mM D-glucose, 0.383 mM Na2HPO4.2H2O, 10 mM HEPES, pH 7.4 with NaOH). The cells were pre-incubated with another 50 μL of chloride-containing buffer for one hour at approximately 37° C. in a humidified incubator containing approximately 5% CO2 in air.
  • Assay compound plates were prepared by diluting the compounds of formula (I) with chloride-free buffer (125 mM Na-gluconate, 4.8 mM K-gluconate, 1.3 mM Ca-gluconate, 1.2 mM KH2PO4, 1.2 mM MgSO4, 5.6 mM D-glucose, 25 mM HEPES, pH 7.4 with NaOH) in 100% DMSO to a final concentration of 1% DMSO. [14C]-Uric Uric acid working stock was made by addition of radiolabeled compound to a final concentration of 120 nM in chloride-free buffer. In all wells, the final assay concentration of solvent (DMSO) was 0.25%; the final assay concentration of [14C]-uric acid was 30 nM in chloride-free buffer and the final compound of formula (I) concentrations ranged from 0 to 10 μM. The vehicle comparator was DMSO (i.e. no inhibition of uric acid transport) and the pharmacological blockade (i.e. 100% inhibition of uric acid transport) was defined by benzbromarone at 10 μM final assay concentration.
  • After pre-incubation, cells were washed with 50 μL of chloride-free buffer and another 50 μL of chloride-free buffer was added. Thereafter, 25 μL of compound of formula (I) was added from the prepared compound plate and the cells were pre-incubated for 15 minutes prior to the addition of 25 mL of [14C] uric acid. The plate was incubated at room temperature and protected from light for three hours prior to measuring proximity-induced scintillation on a Wallac microbeta at 1 minute/well.
  • The accumulation of [14C]-uric acid into CHO#8 cells was calculated and the IC50 (μM) values, defined as the concentration of inhibitor required for 50% inhibition of transport, were determined from a 4 parameter logistic fit to generate sigmoid curves from dose response data.
  • Ex. IC50
    1 0.013
    2 >10.000
    3 0.141
    4 >10.000
    5 0.148
    6 0.267
    7 0.064
    8 0.119
    9 0.208
    10 0.074
    11 0.125
    12 0.047
    13 0.084
    14 0.206
    15 0.135
    16 0.218
    17 0.495
    18 >10.000
    19 0.057
    20 0.088
    21 0.084
    22 0.209
    23 >10.000
    24 0.135
    25 0.086
    26 0.057
    27 0.274
    28 0.092
    29 >10.000
    30 0.183
    31 0.078
    32 0.212
    33 0.117
    34 0.080
    35 >10.000
    36 0.241
    37 0.196
    38 0.055
    39 0.080
    40 0.988
    41 0.162
    42 0.383
    43 0.053
    44 0.167
    45 0.174
    46 0.107
    47 0.050
    48 0.683
    49 >1.382
    50 >10.000
    51 0.171
    52 0.259
    53 0.191
    54 >10.000
    55 0.129
    56 0.182
    57 >10.000
    58 0.287
    59 >10.000
    60 0.092
    61 0.039
    62 0.027
    63 0.321
    64 >1.127
    65 0.182
    66 0.135
    67 3.517
    68 0.155
    69 1.308
    70 0.025
    71 0.027
    72 0.077
    73 0.418
    74 >10.000
    75 2.209
    76 0.057
    77 0.043
    78 0.019
    79 0.007
    80 0.728
    81 >10.000
    82 0.409
    83 >5.966
    84 >8.866
    85 >10.000
    86 >5.332
    87 >7.674
    88 0.429
    89 0.105
    90 >3.578
    91 1.954
    92 0.414
    93 2.982
    94 >10.000
    95 >10.000
    96 >10.000
    97 >1.674
    98 3.868
    99 0.029
    100 >10.000
    101 0.594
    102 3.130
    103 0.145
    104 0.015
    105 >10.000
    106 >10.000
    107 0.058
    108 0.098
    109 0.892
    110 0.123
    111 0.074
    112 0.177
    113 >10.000
    114 0.069
    115 0.024
    116 >10.000
    117 >10.000
    118 >10.000
    119 0.090
    120 >10.000
    121 >10.000
    122 0.099
    123 0.091
    124 >10.000
    125 0.237
    126 >10.000
    127 >10.000
    128 >10.000
    129 >10.000
    130 0.119
    131 >10.000
    132 0.038
    133 0.793
    134 >10.000
    135 >10.000
    136 >10.000
    137 >10.000
    138 9.206
    139 >10.000
    140 >10.000
    141 0.043
    142 0.075
    143 0.079
    144 0.040
    145 0.096
    146 0.506
    147 0.187
    148 0.053
    149 0.095
    150 0.329
    151 >10.000
    152 0.050
    153 >10.000
    154 >10.000
    155 0.191
    156 >10.000
    157 0.051
    158 0.122
    159 0.514
    160 >10.000
    161 >10.000
    162 0.125
    163 >10.000
    164 6.163
    165 0.139
    166 0.116
    167 0.050
    168 0.612
    169 0.134
    170 0.570
    171 0.215
    172 0.502
    173 0.131
    174 >10.000
    175 0.455
    176 1.020
    177 0.246
    178 >10.000
    179 >0.728
    180 0.877
    181 >10.000
    182 0.175
    183 0.183
    184 0.385
    185 NT
    186 0.324
    187 >10.000
    188 3.743
    189 0.103
    190 >10.000
    191 1.993
    192 NT
    193 NT
    194 >10.000
    195 NT
    196 >10.000
    197 >10.000
    198 0.792
    199 0.129
    200 0.053
    201 0.074
    202 0.037
    203 >10.000
    204 2.628
    205 1.084
    206 1.084
    207 >10.000
    208 >10.000
    209 >10.000
    210 >10.000
    211 >2.998
    212 >10.000
    213
    214 >1.153
    215 >10.000
    216 >10.000
    217 >10.000
    218 >10.000
    219 >10.000
    220 >10.000
    221 >10.000
    222 >10.000
    223 >10.000
    224 >10.000
    225 2.331
    226 1.779
    227 >10.000
    228 0.244
    229 0.126
    230 0.062
    231 0.053
    232 0.012
    233 0.233
    234 1.150
    235 0.013
    236 NT
    237 0.008
    238 0.088
    239 0.002
    240 0.106
    241 0.003
    242 NT
    243 1.000
    244 0.258
    245 0.472
    246 0.087
    247 0.001
    248 0.324
    249 0.021
    NT = Not Tested

Claims (21)

1-16. (canceled)
17. A compound of formula (I)
Figure US20150259327A1-20150917-C00077
or a pharmaceutically acceptable salt thereof, wherein:
R1 is a ‘C-linked’ 6-membered heteroaryl containing one, two or three nitrogen atoms wherein said heteroaryl is optionally substituted by one, two or, valency permitting, three X1;
each X1 is independently selected from: F; Cl; CN; (C1-C4)alkyl optionally substituted by one, two or three F; and (C1-C4)alkyloxy optionally substituted by one two or three F;
one of R2, R3, R4 and R5 is either halogen or CN, and the remainder thereof are independently selected from: H; halogen; or CN;
R6 is phenyl substituted by one, two or three X2; or a ‘C-linked’ 6-membered heteroaryl containing one or two nitrogen atoms wherein said heteroaryl is optionally substituted by one, two or three X2;
each X2 is independently selected from: F; Cl; CN; —S(C1-C4)alkyl; —NR7R8; (C1-C6)alkyloxy optionally substituted by one, two or three F; (C3-C6)cycloalkyloxy; (C1-C6)alkyl optionally substituted by one, two or three F; and (C1-C6)alkyl substituted by OH; and
each R7 and R8 is independently H or (C1-C4)alkyl or, together with the nitrogen atom to which they are attached, form a saturated 4- to 6-membered nitrogen containing monocycle.
18. A compound according to claim 17, wherein R1 is a ‘C-linked’ 6-membered heteroaryl containing one or two nitrogen atoms, wherein said heteroaryl is optionally substituted by one or two X1.
19. A compound according to claim 17, wherein R1 is a ‘C-linked’ 6-membered heteroaryl containing one or two nitrogen atoms, wherein said heteroaryl is optionally substituted by X1.
20. A compound according to claim 17, wherein R1 is a ‘C-linked’ pyridinyl optionally substituted by X1.
21. A compound according to claim 17, wherein R1 is a ‘C-linked’ pyridinyl substituted by X1.
22. A compound according to claim 17, wherein X1 is F.
23. A compound according to claim 17, wherein R4 is either halogen or CN, and R2, R3 and R5 are independently selected from: H; halogen; or CN.
24. A compound according to claim 23, wherein R4 is CN; and each of R2, R3 and R5 are H.
25. A compound according to claim 17, wherein R6 is phenyl substituted by one, two or three X2.
26. A compound according to claim 25, wherein R6 is phenyl substituted by two or three X2.
27. A compound according to claim 17, wherein R6 is a ‘C-linked’ 6-membered heteroaryl containing one or two nitrogen atoms, wherein said heteroaryl is optionally substituted by one, two or three X2.
28. A compound according to claim 27, wherein R6 is a ‘C-linked’ 6-membered heteroaryl containing one or two nitrogen atoms, wherein said heteroaryl is substituted by one or two X2.
29. A compound according to claim 17, wherein each X2 is independently selected from: F; Cl; CN; —S(C1-C3)alkyl; (C1-C4)alkyloxy optionally substituted by one, two or three F; and (C1-C4)alkyl optionally substituted by one, two or three F.
30. A compound according to claim 29, wherein each X2 is independently selected from: F; Cl; CN; (C1-C3)alkyloxy; and (C1-C3)alkyl.
31. A compound according to claim 30, wherein each X2 is independently selected from: F: Cl; CN; methoxy; and methyl.
32. A compound according to claim 17, which is:
4-[3-chloro-4-(hydroxymethyl)phenoxy]-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
4-{[5-chloro-6-(hydroxymethyl)pyridin-3-yl]oxy}-2-fluoro-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
4-(3-chloro-4-cyanophenoxy)-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
4-[(5-chloropyridin-3-yl)oxy]-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
4-[(6-amino-5-chloropyridin-3-yl)oxy]-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
3-cyano-4-(3,5-dichloro-4-cyanophenoxy)-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
4-(3-chloro-4-cyanophenoxy)-3-cyano-N-(4-fluoropyridin-2-yl)benzenesulfonamide;
4-(3-chloro-4-cyano-5-fluorophenoxy)-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide;
4-(3-chloro-4-cyanophenoxy)-N-(5-chloropyridin-2-yl)-3-cyanobenzenesulfonamide; or
3-cyano-4-(4-cyano-3,5-dimethylphenoxy)-N-(5-fluoropyridin-2-yl)benzenesulfonamide; or a pharmaceutically acceptable salt thereof.
33. 4-[3-chloro-4-(hydroxymethyl)phenoxy]-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide, or a pharmaceutically acceptable salt thereof.
34. 4-(3-chloro-4-cyanophenoxy)-3-cyano-N-(4-fluoropyridin-2-yl)benzenesulfonamide, or a pharmaceutically acceptable salt thereof.
35. 4-(3-chloro-4-cyanophenoxy)-N-(5-chloropyridin-2-yl)-3-cyanobenzenesulfonamide, or a pharmaceutically acceptable salt thereof.
36. 3-cyano-4-(3,5-dichloro-4-cyanophenoxy)-N-(5-fluoropyridin-2-yl)benzenesulfonamide, or a pharmaceutically acceptable salt thereof.
US14/722,275 2013-04-19 2015-05-27 Chemical Compounds Abandoned US20150259327A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/722,275 US20150259327A1 (en) 2013-04-19 2015-05-27 Chemical Compounds

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361813809P 2013-04-19 2013-04-19
US201361917532P 2013-12-18 2013-12-18
US14/254,988 US9067922B2 (en) 2013-04-19 2014-04-17 Chemical compounds
US14/722,275 US20150259327A1 (en) 2013-04-19 2015-05-27 Chemical Compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US14/254,988 Continuation US9067922B2 (en) 2013-04-19 2014-04-17 Chemical compounds

Publications (1)

Publication Number Publication Date
US20150259327A1 true US20150259327A1 (en) 2015-09-17

Family

ID=50543278

Family Applications (2)

Application Number Title Priority Date Filing Date
US14/254,988 Expired - Fee Related US9067922B2 (en) 2013-04-19 2014-04-17 Chemical compounds
US14/722,275 Abandoned US20150259327A1 (en) 2013-04-19 2015-05-27 Chemical Compounds

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US14/254,988 Expired - Fee Related US9067922B2 (en) 2013-04-19 2014-04-17 Chemical compounds

Country Status (4)

Country Link
US (2) US9067922B2 (en)
TW (1) TW201512171A (en)
UY (1) UY35535A (en)
WO (1) WO2014170792A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201443025A (en) * 2013-04-19 2014-11-16 Pfizer Ltd Chemical compounds
TW201512171A (en) * 2013-04-19 2015-04-01 Pfizer Ltd Chemical compounds
KR20170110083A (en) 2014-12-23 2017-10-10 인털렉츄얼 프라퍼티 어쏘시에이츠, 엘엘씨 Methods and formulations for transdermal administration
CN107089955B (en) * 2016-02-18 2020-10-23 广东东阳光药业有限公司 Sulfonamide derivative and preparation method and application thereof
KR102366077B1 (en) 2016-05-20 2022-02-21 제논 파마슈티칼스 인크. Benzenesulfonamide compounds and their use as therapeutic agents
CN110325531B (en) * 2016-12-09 2022-05-27 泽农医药公司 Benzenesulfonamides and their use as therapeutic agents
CN109251184B (en) * 2017-07-13 2021-06-15 浙江海正药业股份有限公司 Medical application of 2-trifluoromethyl benzene sulfonamide derivative
US20190083527A1 (en) 2017-09-15 2019-03-21 Ampersand Biopharmaceuticals, Inc. Method of administration and treatment
US10745392B2 (en) 2018-06-13 2020-08-18 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
MX2021001380A (en) 2018-08-31 2021-05-27 Xenon Pharmaceuticals Inc Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents.
JP7383012B2 (en) 2018-08-31 2023-11-17 ゼノン・ファーマシューティカルズ・インコーポレイテッド Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9067922B2 (en) * 2013-04-19 2015-06-30 Pfizer Limited Chemical compounds

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58124758A (en) 1982-01-20 1983-07-25 Fujisawa Pharmaceut Co Ltd Benzenesulfonamide derivative
DE3232922A1 (en) * 1982-09-04 1984-03-08 Hoechst Ag, 6230 Frankfurt SULFAMOYLBENZOPHENONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AND PHARMACEUTICAL PREPARATIONS BASED ON THESE COMPOUNDS
US5591761A (en) 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5571821A (en) 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
DE3737748A1 (en) 1987-11-03 1989-05-18 Schering Ag 3-arylsulphonylamino-1H-1,2,4-triazoles, processes for their preparation, and their use as herbicides and growth regulators
JPH0264538A (en) 1988-08-31 1990-03-05 Fuji Photo Film Co Ltd Silver halide color photographic sensitive material
KR0166088B1 (en) 1990-01-23 1999-01-15 . Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
ATE167473T1 (en) 1990-08-20 1998-07-15 Eisai Co Ltd SULFONAMIDE DERIVATIVES
DE69206725T2 (en) 1991-09-10 1996-05-02 Zeneca Ltd Benzenesulfonamide derivatives as 5-lipoxygenase inhibitors
TW352384B (en) 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
NZ247440A (en) 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
DE4233124A1 (en) 1992-10-02 1994-04-07 Hoechst Ag Acylsulfonamido and sulfonamidopyridine-2-carboxylic acid esters and their pyridine N-oxides, processes for their preparation and their use as medicaments
GB9504854D0 (en) 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
GB9409618D0 (en) 1994-05-13 1994-07-06 Zeneca Ltd Pyridine derivatives
GB2295616A (en) 1994-12-01 1996-06-05 Zeneca Ltd N-Diazine-benzenesulphonamide derivatives as endothelin receptor antagonists
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
JPH09124620A (en) 1995-10-11 1997-05-13 Bristol Myers Squibb Co Substituted biphenylsulfonamide endothelin antagonist
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
AU759255B2 (en) 1998-01-29 2003-04-10 Amgen, Inc. PPAR-gamma modulators
JP2000159665A (en) 1998-11-27 2000-06-13 Nippon Kayaku Co Ltd Preventive or therapeutic agent of rheumatism
US6599942B1 (en) 1999-03-29 2003-07-29 Novartis Ag Thyromimetic organic compounds
CO5160290A1 (en) 1999-03-29 2002-05-30 Novartis Ag DERIVATIVES OF REPLACED PHENOXYPHENYLOXAMIC ACID.
US6790978B2 (en) 1999-03-29 2004-09-14 Novartis Ag Thyromimetic organic compounds
HN2000000137A (en) 1999-08-12 2001-02-02 Pfizer Prod Inc PYRIMIDINE-2,4,6-METALOPROTEINASE INHIBITING TRIONES
AU7404700A (en) 1999-09-29 2001-04-30 Novo Nordisk A/S Novel aromatic compounds
AU2456701A (en) 1999-12-31 2001-07-16 Texas Biotechnology Corporation Pharmaceutical and veterinary uses of endothelin antagonists
SE0001899D0 (en) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
AU2001268711A1 (en) 2000-06-23 2002-01-08 Bristol-Myers Squibb Pharma Company Heteroaryl-phenyl substituted factor xa inhibitors
SK4872003A3 (en) 2000-10-26 2004-08-03 Pfizer Prod Inc Metaloproteinase pyrimidine-2,4,6-trione inhibitors
KR20030064852A (en) 2000-12-22 2003-08-02 이시하라 산교 가부시끼가이샤 Aniline Derivatives or Salts Thereof and Cytokine Production Inhibitors Containing the Same
US7067539B2 (en) 2001-02-08 2006-06-27 Schering Corporation Cannabinoid receptor ligands
US7507767B2 (en) 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands
WO2002092606A1 (en) 2001-05-15 2002-11-21 Takeda Chemical Industries, Ltd. Fused imidazolidine derivatives, process for preparation of the same and use thereof
KR20050044517A (en) 2001-11-22 2005-05-12 바이오비트럼 에이비 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
PL370111A1 (en) 2001-11-22 2005-05-16 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
EP1461327A1 (en) 2001-11-22 2004-09-29 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
US7101883B2 (en) 2002-03-18 2006-09-05 Bristol-Myers Squibb Company Uracil derivatives as inhibitors of TNF-α converting enzyme (TACE) and matrix metalloproteinases
JP2003292485A (en) 2002-04-01 2003-10-15 Yamanouchi Pharmaceut Co Ltd Sulfonamide derivative
JPWO2004007472A1 (en) 2002-07-10 2005-11-17 小野薬品工業株式会社 CCR4 antagonist and pharmaceutical use thereof
GB0217431D0 (en) 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
WO2004021997A2 (en) 2002-09-06 2004-03-18 Microbia, Inc. Inhibitors of fungal invasion
AU2004224807A1 (en) 2003-03-24 2004-10-07 Axikin Pharmaceuticals, Inc. 2-phenoxy- and 2-phenylsulfomamide derivatives with CCR3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders
WO2004103980A1 (en) 2003-05-21 2004-12-02 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type i
US7915293B2 (en) 2003-05-30 2011-03-29 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
SE0301883D0 (en) 2003-06-25 2003-06-25 Biovitrum Ab New use II
SE0301882D0 (en) 2003-06-25 2003-06-25 Biovitrum Ab New use I
SE0301886D0 (en) 2003-06-25 2003-06-25 Biovitrum Ab New use V
WO2004113310A1 (en) 2003-06-25 2004-12-29 Biovitrum Ab Use of an inhibitor of 11-b-hydroxysteroid dehydrogenase type 1 compounds for promoting wound healing
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
CA2547212A1 (en) 2003-11-25 2005-06-16 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
JP2007514731A (en) 2003-12-19 2007-06-07 ファイザー インコーポレイテッド Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-β-hsd-1) for the treatment of diabetes and obesity
JP2007527918A (en) 2004-03-08 2007-10-04 アムジェン インコーポレイテッド Therapeutic modulation of PPAR gamma activity
JP2007261945A (en) 2004-04-07 2007-10-11 Taisho Pharmaceut Co Ltd Thiazole derivative
US7504431B2 (en) 2004-04-16 2009-03-17 Bristol-Myers Squibb Company Sulfonyl amide inhibitors of calcium channel function
ES2362884T3 (en) 2004-06-28 2011-07-14 F. Hoffmann-La Roche Ag PYRIMIDINE DERIVATIVES AS INHIBITORS OF 11BETA-HSD1.
JP4894517B2 (en) 2004-08-27 2012-03-14 アステラス製薬株式会社 2-Phenylpyridine derivative
SI1809624T1 (en) 2004-08-28 2014-02-28 Astrazeneca Ab Pyrimidine sulphonamide derivatives as chemokine receptor modulators
BRPI0516454A (en) 2004-10-04 2008-09-02 Hoffmann La Roche compound, process for preparing a compound, pharmaceutical composition comprising it, its use, method for treating and prophylaxis of diseases, and type II diabetes
DE102004050196A1 (en) 2004-10-15 2006-04-20 Sanofi-Aventis Deutschland Gmbh Substituted 2-pyridone derivatives, process for their preparation and their use as medicaments
EP1659113A1 (en) 2004-11-08 2006-05-24 Evotec AG Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1)
EP1666467A1 (en) 2004-11-08 2006-06-07 Evotec AG 11Beta-HSD1 Inhibitors
WO2006051662A1 (en) 2004-11-09 2006-05-18 Taisho Pharmaceutical Co., Ltd. Thiazole derivative
US20080015223A1 (en) 2004-12-03 2008-01-17 Arena Pharmaceuticals, Inc. Pyrazole Derivatives as Modulators of the 5-Ht2a Serotonin Receptor Useful for the Treatment of Disorders Related Thereto
WO2006066109A2 (en) 2004-12-17 2006-06-22 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
GB0513702D0 (en) 2005-07-04 2005-08-10 Sterix Ltd Compound
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
EA014329B1 (en) 2005-09-23 2010-10-29 Пфайзер Продактс Инк. Pyridinaminosulphonyl substituted benzamides as inhibitors of cytochrome p450 3a4 (cyp3a4)
US7754773B2 (en) 2005-10-06 2010-07-13 University Of Massachusetts Composition and synthesis of new reagents for inhibition of HIV replication
AR058296A1 (en) 2005-12-09 2008-01-30 Kalypsys Inc INHIBITORS OF HISTONA DEACETILASE AND PHARMACEUTICAL COMPOSITION
WO2007067993A1 (en) 2005-12-09 2007-06-14 Kalypsys, Inc. Inhibitors of histone deacetylase for the treatment of disease
GB0526255D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
EP2013179B1 (en) 2006-04-14 2011-01-19 Abbott GmbH & Co. KG Aryloxyethylamine compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
AU2007307990A1 (en) 2006-10-05 2008-04-17 Janssen Pharmaceutica, N.V. Heterocyclic derived metalloprotease inhibitors
WO2008118758A1 (en) 2007-03-23 2008-10-02 Icagen, Inc. Inhibitors of ion channels
WO2008141249A1 (en) 2007-05-10 2008-11-20 Acadia Pharmaceuticals Inc. Imidazol (1,2-a)pyridines and related compounds with activity at cannabinoid cb2 receptors
JP5460589B2 (en) 2007-07-13 2014-04-02 アイカジェン， インコーポレイテッド Sodium channel inhibitor
SG183667A1 (en) 2007-07-30 2012-09-27 Encysive Pharmaceuticals Inc Modulators of ccr9 receptor and methods of use thereof
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US20090281089A1 (en) 2008-04-11 2009-11-12 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
CA2721371C (en) 2008-04-14 2016-07-12 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of the pleckstrin homology domain and methods for using same
US8178699B2 (en) 2008-07-30 2012-05-15 Pfizer Inc. Modulators of CCR9 receptor and methods of use thereof
JP5580204B2 (en) * 2008-10-15 2014-08-27 キッセイ薬品工業株式会社 Biarylisonicotinic acid derivative and pharmaceutical use thereof
MX2011006332A (en) 2008-12-23 2011-06-27 Abbott Lab Anti-viral compounds.
GEP20135992B (en) 2009-01-12 2013-12-25 Icagen Inc Sulfonamide derivatives
US20120100609A1 (en) 2009-03-27 2012-04-26 Crawford Brett E N-linked glycan biosynthesis modulators
JP2012522013A (en) 2009-03-27 2012-09-20 ザ ユーエービー リサーチ ファウンデーション Regulated IRES-mediated translation
UY32799A (en) 2009-07-24 2011-02-28 Novartis Ag DERIVATIVES OF OXAZINE AND ITS USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS
CN102206172B (en) 2010-03-30 2015-02-25 中国医学科学院医药生物技术研究所 Substituted diaryl compound and preparation method and antiviral application thereof
JP5709146B2 (en) 2010-06-16 2015-04-30 アルデア バイオサイエンシーズ インク． Phenylthioacetic acid compounds, compositions and methods of use thereof
CA2803118C (en) 2010-07-09 2015-11-03 Pfizer Limited Sulfonamide derivatives as nav 1.7 inhibitors
EP2590972B1 (en) 2010-07-09 2015-01-21 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
JP5830534B2 (en) 2010-07-09 2015-12-09 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ Compound
ES2526981T3 (en) 2010-07-12 2015-01-19 Pfizer Limited N-sulfonylbenzamides as voltage dependent sodium channel inhibitors
US9749881B2 (en) 2010-07-21 2017-08-29 Telefonaktiebolaget L M Ericsson Technique for packet flow analysis
JP5363636B2 (en) * 2011-10-21 2013-12-11 ファイザー・リミテッド New salts and medical uses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9067922B2 (en) * 2013-04-19 2015-06-30 Pfizer Limited Chemical compounds

Also Published As

Publication number Publication date
WO2014170792A1 (en) 2014-10-23
UY35535A (en) 2014-11-28
US20140315878A1 (en) 2014-10-23
US9067922B2 (en) 2015-06-30
TW201512171A (en) 2015-04-01

Similar Documents

Publication Publication Date Title
US9067922B2 (en) Chemical compounds
US8772293B2 (en) Chemical compounds
US9102621B2 (en) Acyl sulfonamide compounds
US9096558B2 (en) N-sulfonylbenzamide compounds
US8772343B2 (en) Chemical compounds
US9096500B2 (en) Acyl sulfonamide compounds
US8592629B2 (en) Sulfonamide derivatives as Nav 1.7 inhibitors
US9145407B2 (en) Sulfonamide compounds
US20150291514A1 (en) N-Aminosulfonyl Benzamides
US20140315933A1 (en) Chemical compounds
US20230078764A1 (en) Compounds and uses thereof
WO2016034971A1 (en) Sulfonamides derivatives as urat1 inhibitors
US20170275275A1 (en) Benzenesulfonamides useful as sodium channel inhibitors

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION